Cost-effectiveness of innovations in pathology services in relation to cancer diagnosis and treatment management by El-Banna, Asmaa
 warwick.ac.uk/lib-publications  
 
 
 
 
 
 
A Thesis Submitted for the Degree of PhD at the University of Warwick 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/135018 
 
 
 
 
Copyright and reuse:                     
This thesis is made available online and is protected by original copyright.  
Please scroll down to view the document itself.  
Please refer to the repository record for this item for information to help you to cite it. 
Our policy information is available from the repository home page.  
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
i 
 
 Cost-effectiveness of innovations in pathology services in relation to 
cancer diagnosis and treatment management 
 
Asmaa El-Banna 
 
 
 
 
 
 
 
 
 
A thesis submitted in partial fulfilment of the requirements for the degree of 
Doctor of Philosophy 
 
University of Warwick  
June 2019 
ii 
 
Table of contents 
List of figures .......................................................................................................................... vi 
List of tables.......................................................................................................................... viii 
Acknowledgements ................................................................................................................ ix 
Declaration .............................................................................................................................. x 
Dedication............................................................................................................................... xi 
Abstract ................................................................................................................................. xii 
List of Abbreviations ............................................................................................................ xiii 
Chapter 1: Introduction ........................................................................................................... 1 
1.1 Cancer ............................................................................................................................ 1 
1.1.1 Cancer outcomes .................................................................................................... 1 
1.1.2 Cancer pathways .................................................................................................... 2 
1.1.3 Government policy ................................................................................................. 5 
1.2 Pathology ....................................................................................................................... 8 
1.2.1 Challenges in pathology ......................................................................................... 9 
1.2.2 Managing demand ............................................................................................... 10 
1.2.3 Pathology innovation ........................................................................................... 10 
1.3 Economic evaluations ................................................................................................. 12 
1.3.1 Challenges in the evaluation of pathology services ............................................ 13 
Chapter 2: Economic evaluations of pathology innovations - a systematic review ........... 15 
2.1 Introduction ................................................................................................................. 15 
2.1.1 Economic evaluations within pathology ............................................................. 15 
2.2 Aims ............................................................................................................................. 16 
2.3 Methods ....................................................................................................................... 17 
2.3.1 Information sources ............................................................................................. 17 
2.3.2 Eligibility criteria ................................................................................................... 18 
2.3.3 Data collection and analysis ................................................................................ 20 
2.3.4 Data synthesis ...................................................................................................... 21 
2.4 Results ......................................................................................................................... 22 
2.4.1 Search results ....................................................................................................... 22 
2.4.2 General study characteristics ............................................................................... 23 
2.4.3 Economic evaluation methods adopted .............................................................. 25 
2.4.4 Cost-effectiveness results reported ..................................................................... 31 
2.4.5 Quality assessment .............................................................................................. 33 
2.5 Discussion and conclusion .......................................................................................... 34 
Chapter 3: An introduction to digital pathology .................................................................. 37 
iii 
 
3.1 Speed ........................................................................................................................... 38 
3.1.1 The laboratory workflow ..................................................................................... 39 
3.1.2 MDT meetings ...................................................................................................... 43 
3.1.3 Reporting beyond the laboratory ........................................................................ 45 
3.1.4 The patient experience ........................................................................................ 46 
3.2 Accuracy ....................................................................................................................... 47 
3.2.1 Biomarker profile ................................................................................................. 50 
3.2.2 Lymph node status ............................................................................................... 52 
3.2.3 Tumour grade ....................................................................................................... 53 
3.2.4 Tumour size .......................................................................................................... 55 
3.3 Conclusion ................................................................................................................... 55 
Chapter 4: The breast cancer pathway ................................................................................. 57 
4.1 Introduction ................................................................................................................. 57 
4.1.1 Information sources ............................................................................................. 57 
4.2 Aims ............................................................................................................................. 59 
4.3 Methods ....................................................................................................................... 60 
4.3.1 Methods for the descriptions of the evidence-based pathway ......................... 60 
4.3.2 Methods for the description of the clinical-practice pathway ........................... 62 
4.3.3 Methods for the description of the network of digital pathology processes .... 63 
4.4 Results ......................................................................................................................... 64 
4.4.1 Evidence-based pathway ..................................................................................... 64 
4.4.2 Clinical practice pathway ..................................................................................... 74 
4.4.3 Relationship between digital pathology and breast cancer outcomes .............. 82 
4.5 Discussion and conclusion .......................................................................................... 84 
Chapter 5: Economic evaluation of digital pathology .......................................................... 87 
5.1 Introduction ................................................................................................................. 87 
5.1.1 Decision modelling for economic evaluation ...................................................... 88 
5.2 Aims ............................................................................................................................. 90 
5.3 Methods ....................................................................................................................... 91 
5.3.1 DES model development ...................................................................................... 91 
5.3.2 Economic evaluation .......................................................................................... 118 
5.4 Results ....................................................................................................................... 127 
5.4.1 Model validation ................................................................................................ 127 
5.4.2 Conventional microscope outputs ..................................................................... 128 
5.4.3 Digital pathology outputs .................................................................................. 131 
5.5 Discussion .................................................................................................................. 134 
iv 
 
5.6 Conclusion ................................................................................................................. 137 
Chapter 6: Systematic review and meta-analysis of HER2 testing accuracy ..................... 138 
6.1 Introduction ............................................................................................................... 138 
6.1.1 HER2 amplification and overexpression ............................................................ 138 
6.1.2 Anti-HER2 therapy .............................................................................................. 139 
6.1.3 Approaches to HER2 testing .............................................................................. 139 
6.1.4 HER2 testing algorithm ...................................................................................... 141 
6.1.5 Testing thresholds .............................................................................................. 142 
6.1.6 Accuracy of HER2 tests ....................................................................................... 143 
6.1.7 Quantifying accuracy .......................................................................................... 144 
6.2 Aims ........................................................................................................................... 147 
6.3 Methods ..................................................................................................................... 148 
6.3.1 Information sources ........................................................................................... 148 
6.3.2 Eligibility criteria ................................................................................................. 149 
6.3.3 Data collection and analysis .............................................................................. 151 
6.3.4 Data synthesis .................................................................................................... 152 
6.4 Results ....................................................................................................................... 154 
6.4.1 Study characteristics .......................................................................................... 155 
6.4.2 Quality assessment ............................................................................................ 159 
6.4.3 Accuracy data extraction ................................................................................... 161 
6.4.4 Base case analysis .............................................................................................. 166 
6.4.5 Sensitivity analysis ............................................................................................. 168 
6.5 Discussion .................................................................................................................. 174 
6.6 Conclusion ................................................................................................................. 179 
Chapter 7: Economic evaluation of digital HER2 testing .................................................... 180 
7.1 Introduction ............................................................................................................... 180 
7.1.1 Patient care ........................................................................................................ 180 
7.1.2 Economic evaluation .......................................................................................... 180 
7.2 Aims ........................................................................................................................... 181 
7.3 Methods ..................................................................................................................... 182 
7.3.1 Model structure .................................................................................................. 182 
7.3.2 Model costs ........................................................................................................ 184 
7.3.3 Model QALYs ...................................................................................................... 185 
7.3.4 UK prevalence .................................................................................................... 186 
7.3.5 Model probabilities ............................................................................................ 186 
7.3.6 Base case scenario .............................................................................................. 187 
v 
 
7.3.7 Scenario analysis 1: 2008 scoring thresholds .................................................... 189 
7.3.8 Scenario analysis 2: 12 month treatment period .............................................. 189 
7.3.9 Scenario analysis 3: Single study approach ....................................................... 189 
7.3.10 Cost-effectiveness analysis .............................................................................. 190 
7.3.11 Value of Information Analysis ......................................................................... 191 
7.4 Results ....................................................................................................................... 192 
7.4.1 Base case analysis results .................................................................................. 192 
7.4.2 Scenario analysis results .................................................................................... 194 
7.4.3 Value of Information Analysis ........................................................................... 196 
7.5 Discussion .................................................................................................................. 199 
7.6 Conclusion ................................................................................................................. 202 
Chapter 8: General discussion and conclusion ................................................................... 203 
8.1 Overview of thesis and main findings ...................................................................... 203 
8.1.1 The breast cancer pathway ................................................................................ 203 
8.1.2 Economic evaluation using DES modelling ........................................................ 204 
8.1.3 HER2 IHC accuracy with digital pathology ......................................................... 207 
8.1.4 Economic evaluation of digital pathology for HER2 scoring ............................. 208 
8.2 Strengths and limitations of research ...................................................................... 209 
8.3 Recommendations for policy .................................................................................... 209 
8.4 Recommendations for research ................................................................................ 210 
8.5 Conclusions ................................................................................................................ 210 
References ........................................................................................................................... 211 
Appendices .......................................................................................................................... 231 
Appendix A: Search strategies-systematic review of economic evaluations ................ 231 
Appendix B: Data extraction form - systematic review of economic evaluations ........ 235 
Appendix C: Simul8 building blocks ................................................................................ 236 
Appendix D: List of search terms .................................................................................... 237 
Appendix E: Search terms used in initial phase search strategy ................................... 238 
Appendix F: Search strategies - systematic review of HER2 accuracy ........................... 239 
Appendix G: Data extraction form - systematic review of HER2 accuracy ................... 242 
 
 
 
 
vi 
 
List of figures 
Figure 1-1 General cancer pathway ......................................................................................... 2 
Figure 1-2 Cancer waiting time targets .................................................................................... 7 
Figure 1-3 Relationship between pathology processes and patient outcomes..................... 14 
Figure 2-1 Study selection process ........................................................................................ 22 
Figure 2-2 Summary of cancer types investigated ................................................................. 24 
Figure 2-3 Summary of papers by country of origin .............................................................. 24 
Figure 2-4 Summary pathology interventions investigated ................................................... 25 
Figure 2-5 Summary modelling approaches adopted ............................................................ 26 
Figure 2-6 Distribution of CHEERS scores for all of the eligible studies ................................. 33 
Figure 3-1 Summary of the speed impacts of digital pathology ............................................ 38 
Figure 3-2 Conventional microscope versus digital pathology processes ............................. 40 
Figure 3-3 Overview of the patient cancer pathway ............................................................. 46 
Figure 3-4 Summary of the areas of potential accuracy gains with DP ................................. 49 
Figure 4-1 Steps in suspected breast cancer management based on published guidelines . 65 
Figure 4-2 Guidelines for triple assessment .......................................................................... 66 
Figure 4-3 Overview of surgery and radiotherapy guidelines for DCIS cases ........................ 67 
Figure 4-4 Summary of the recommended surgical pathway for IBC cases .......................... 69 
Figure 4-5 Overview of the radiotherapy guidelines for IBC cases ........................................ 70 
Figure 4-6 ER and HER2 therapy treatment guidelines ......................................................... 71 
Figure 4-7 Overview of the clinical practice breast cancer pathway ..................................... 75 
Figure 4-8 Outpatient clinic (symptomatic patients) ............................................................. 76 
Figure 4-9 Breast screening unit (symptomatic patients) ...................................................... 76 
Figure 4-10 Breast screening unit (asymptomatic patients) .................................................. 77 
Figure 4-11 Diagnostic MDT decision algorithm .................................................................... 79 
Figure 4-12 Neoadjuvant therapy .......................................................................................... 80 
Figure 4-13 Adjuvant therapy ................................................................................................ 81 
Figure 4-14 Post-surgery MDT ............................................................................................... 82 
Figure 4-15 Overview of process chain network for digital pathology .................................. 83 
Figure 5-1 Steps in DES model development ......................................................................... 92 
Figure 5-2 Summary breast cancer pathway through secondary care .................................. 94 
Figure 5-3 Overview of the conceptual model ...................................................................... 97 
Figure 5-4 DES model structure in Simul8 ........................................................................... 106 
Figure 5-5 Frequency of breast core arrivals at UHCW ....................................................... 113 
Figure 5-6 Experimental factors ........................................................................................... 120 
Figure 5-7 Days from CB arrival in pathology to adjuvant treatment plan .......................... 127 
Figure 5-8 Two sample t-test comparing data and model output ....................................... 127 
Figure 5-9 Histogram of the number of times an invasive breast cancer case is discussed at 
the MDT meeting ................................................................................................................. 128 
Figure 5-10 Histogram of the number of MDT discussions/IBC patient .............................. 132 
Figure 5-11 Mean number of MDT discussions/IBC patient ................................................ 132 
Figure 6-1 HER2 receptor expression in normal and cancerous cells .................................. 139 
Figure 6-2 HER2 testing algorithm ....................................................................................... 141 
Figure 6-3 Study identification and selection process ......................................................... 154 
Figure 6-4 Sensitivity and specificity of HER2 IHC using CM ................................................ 164 
Figure 6-5 Sensitivity and specificity of HER2 IHC using DP IA............................................. 165 
Figure 6-6 BCA comparison of CM and DP IA with SROC curves ......................................... 166 
vii 
 
Figure 6-7 BCA proportions of equivocal scores if HER2 positive: CM ................................ 167 
Figure 6-8 BCA proportion of equivocal scores if HER2 positive: DP IA............................... 167 
Figure 6-9 BCA Proportion of equivocal scores if HER2 negative: CM ................................. 168 
Figure 6-10 BCA proportion of equivocal scores if HER2 negative: DP IA ........................... 168 
Figure 6-11 SA1 Comparison of CM and DP IA with SROC curves ....................................... 169 
Figure 6-12 SA1 Proportion of equivocal cases if HER2 positive: CM .................................. 169 
Figure 6-13 SA1 Proportion of equivocal cases if HER2 positive: DP IA ............................... 170 
Figure 6-14 SA1 Proportion of equivocal cases if HER2 negative: CM ................................. 170 
Figure 6-15 SA1 Proportion of equivocal cases if HER2 negative: DP IA ............................. 170 
Figure 6-16 SA2 Comparison of CM and DP IA with SROC curves ....................................... 171 
Figure 6-17 SA2 Proportion of equivocal cases if HER2 positive: CM .................................. 171 
Figure 6-18 SA2 Proportion of equivocal cases if HER2 positive: DP IA ............................... 172 
Figure 6-19 SA2 Proportion of equivocal cases if HER2 negative: CM ................................. 172 
Figure 6-20 SA2 Proportion of equivocal cases if HER2 negative: DP IA ............................. 172 
Figure 6-21 Comparison of DP IA technologies with SROC curves ...................................... 173 
Figure 7-1 Illustration of the convention microscope arm of the decision tree .................. 183 
Figure 7-2 BCA cost-effectiveness plane .............................................................................. 193 
Figure 7-3 BCA CEAC ............................................................................................................ 193 
Figure 7-4 SA1 cost-effectiveness plane .............................................................................. 194 
Figure 7-5 SA2 cost-effectiveness plane .............................................................................. 194 
Figure 7-6 SA3 Cost-effectiveness plane .............................................................................. 195 
Figure 7-7 CEAC for all scenarios ......................................................................................... 195 
Figure 7-8 Patient level EVPI ................................................................................................ 197 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
List of tables 
Table 2-1 Summary inclusion criteria .................................................................................... 19 
Table 2-2 HER2 testing strategies compared by Dendukuri et al. (2007) .............................. 29 
Table 3-1 Agreement between DP and CM when grading breast cancers ............................ 54 
Table 4-1 List of publications to inform the evidence-based breast cancer pathway ........... 61 
Table 4-2 Summary of indications for chemotherapy in breast cancer ................................ 73 
Table 5-1 Summary of simplifications in DES model ............................................................. 95 
Table 5-2 Summary of pathology CB results ........................................................................ 100 
Table 5-3 Management of B3/B4 core biopsies in the dataset ........................................... 102 
Table 5-4 Number of breast tissue specimens per patient .................................................. 108 
Table 5-5 UHCW data collected ........................................................................................... 109 
Table 5-6 Model probabilities .............................................................................................. 110 
Table 5-7 Model time parameters in days ........................................................................... 112 
Table 5-8 Model cost parameters ........................................................................................ 114 
Table 5-9 Summary of chemotherapy regimens at UHCW .................................................. 117 
Table 5-10 Summary impacts of Digital Pathology .............................................................. 120 
Table 5-11 Accuracy of breast cancer grade reporting ........................................................ 122 
Table 5-12 Experimental scenarios ...................................................................................... 123 
Table 5-13 Patient groups to be analysed independently ................................................... 124 
Table 5-14 Simul8 trial calculator results ............................................................................. 125 
Table 5-15 Model outputs under each scenario .................................................................. 129 
Table 6-1 HER2 scoring thresholds, 2007 versus 2013 ........................................................ 143 
Table 6-2 Example 2x2 table ................................................................................................ 145 
Table 6-3 Systematic review of accuracy - summary inclusion criteria ............................... 151 
Table 6-4 Summary of included studies ............................................................................... 157 
Table 6-5 Summary digital pathology image analysis methods adopted in each study ...... 158 
Table 6-6 Quality assessment of included studies ............................................................... 160 
Table 6-7 Summary change in point estimates of sensitivity (SN), specificity (SP) and 
proportion of equivocal results reported in each study when comparing DP to CM .......... 163 
Table 6-8 Sensitivity and specificity estimates by DP IA technology ................................... 173 
Table 7-1 Decision tree endpoints ....................................................................................... 183 
Table 7-2 Cost of Herceptin treatment (Clarke et al., 2017) ............................................... 185 
Table 7-3 Example 9 week mean model costs input............................................................ 185 
Table 7-4 QALYs of Herceptin treatment ............................................................................. 186 
Table 7-5 List of test effects ................................................................................................. 187 
Table 7-6 Estimates of Log(OR) ............................................................................................ 187 
Table 7-7 BCA p1 distributions ............................................................................................. 188 
Table 7-8 SA1 p1 distributions ............................................................................................. 189 
Table 7-9 SA3 p1 distributions ............................................................................................. 190 
Table 7-10 Deterministic model outputs ............................................................................. 192 
Table 7-11 Probability of cost-effectiveness at NICE WTP thresholds ................................ 196 
Table 7-12 EVPI at NICE WTP thresholds ............................................................................. 197 
Table 7-13 Population level EVPI ......................................................................................... 198 
Table 7-14 EVPPI results ...................................................................................................... 198 
 
 
ix 
 
Acknowledgements 
First and foremost all praise and gratitude to God, the most gracious the most merciful, for 
providing me with the ability and the strength to complete this research. Without His 
constant presence, this research would not have been possible.  
I am deeply grateful to my supervisor Professor Jason Madan, who has supported and 
encouraged me extensively throughout this PhD journey in addition to continually sharing 
his invaluable expertise and knowledge. I would also like to thank my other supervisors, 
Professor Ian Cree and Professor Stavros Petrou.  
I am indebted to my colleagues at the University of Warwick. I am grateful to Peter Auguste 
who offered his insight into the options for meta-analysis of sensitivity and specificity. I 
would also like to thank Dr Felix Achana for his help and suggestions around the use of test 
performance measures in economic evaluations. 
This thesis would not have been possible without the support of my family and friends, who 
believed in me when I no longer believed in myself. In particular, I would like to express my 
gratitude to my parents, Dr Hany El-Banna and Mrs. Youseria Labib for their love and 
continued support and for always being the best of role models, I am forever indebted to 
them. To my siblings, Fatima, Hassan, Maryam and Omar for their continuous 
encouragement and to Ayman and Amara, for always making me smile. I am forever grateful 
to my friends Samantha and Bishal, we started this journey together six years ago and I hope 
our friendship lasts for many more years to come.  
Finally yet importantly, this research would not have been possible without the 
understanding and support of my husband Dr Usama Attia. Thank you for always believing 
in me.  
 
 
 
 
 
 
 
 
 
x 
 
Declaration 
This thesis is submitted to the University of Warwick in support of my application for the 
degree of Doctor of Philosophy. It has been composed by myself and has not been submitted 
in any previous application for any degree.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
Dedication 
 
To my husband Usama,  
for your unwavering love, patience and support throughout this PhD journey 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
Abstract 
Pathology plays an important role in cancer diagnosis and treatment management, results 
from the pathology lab guide clinicians’ diagnosis and inform patient care plans. Pathology 
digitisation is expected to maximise lab efficiency when handling tissue specimens, enhance 
speed, provide novel information to be used by clinicians when making treatment decisions 
and potentially improve test accuracy. Early cancer diagnosis and personalised treatment are 
key players in enhancing patients’ clinical outcomes and improving quality of life. Whilst 
research has shown digitisation of pathology labs to be an effective intervention for better 
management and reporting on tissue specimens, no evaluation has reported on the 
economic implications of the adoption of digital systems in an NHS with limited resources. 
Breast cancers are the most common cancer type in the UK so any advances in accuracy or 
time to diagnosis due to digital pathology are expected to have a large impact on this group 
of patients.  
This thesis investigates the cost-effectiveness of digital pathology through its impacts on 
breast cancer patients. A discrete event simulation model representing the breast cancer 
pathway was constructed and used to analyse the impacts of digitisation. There was evidence 
of both time and cost savings for breast cancer patients as a result of pathology digitisation.  
A systematic review and meta-analysis compared the diagnostic accuracy of the HER2 
biomarker pre- and post- the introduction of digital pathology. There was evidence of 
reporting precision but not of improved accuracy. Finally, a cost-effectiveness analysis 
comparing the two approaches found digital pathology not to be cost-effective when 
compared to conventional microscopes for scoring the HER2 biomarker.  
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Chapter 1: Introduction 
1.1 Cancer 
Cancer is classified as one of the five main causes of avoidable deaths in England 
(Department of Health, 2014), it accounted for 28% of UK deaths in 2016 (Cancer Research 
UK, 2016a), is related to over 25% of deaths in Europe (eurostat, 2018) and is the second 
leading cause of death worldwide (WHO, 2018). While cancer 5-year survival has increased 
steadily in England over the 40 years up to 2011, the number of new cases has more than 
doubled over this period (ONS, 2015), driven mostly by an ageing demographic. 
Cancer can come in many forms, subject to the part of the body affected and the cell types 
within these that show evidence of malignancy. Furthermore, cancer variants exist across an 
individual organ depending on the specific underlying characteristics of the disease. Some 
cancers are more common such as breast, lung and prostate cancer whilst others are 
categorised as rare (Cancer Research UK, 2018). Some cancers are associated with better 
chances of survival such as cervical and prostate cancer whilst others are associated with 
greater rates of mortality, for instance pancreatic cancer (Quaresma et al., 2015). The cancer 
type and the stage at diagnosis in part drive outcomes for cancer patients; however, health 
service systems and pathways in place to manage suspected cancer cases have an important 
role to play in maintaining and improving outcomes for cancer patients.   
1.1.1 Cancer outcomes 
Disparities in cancer outcomes exist between countries, owing to variations in healthcare 
systems (Starfield et al., 2005), patient’s access to tests and investigations of suspected 
cancer (Rose et al., 2015), patient’s awareness of the symptoms and risk of cancer (Forbes 
et al., 2013) and the primary research levels within countries to support evidence based 
practice (Are et al., 2018), to name but a few. Whilst perhaps greater differences in these 
contributory factors and others not listed are expected when comparing outcomes of low 
and middle-income countries to those of high-income countries, still disparities in cancer 
survival also exist among high-income countries.   
Cancer survival rates in England are inferior to those of similar countries (Foot and Harrison, 
2011), when compared to the rest of Europe, 5-year cancer survival for cancers diagnosed 
between 1991 and 1995 was generally below the European average (Coleman et al., 2003). 
This trend continued when estimating and comparing 5-year survival across Europe for 
cancers diagnosed between 1995 and 2007 (De Angelis et al., 2014). Approximately 7000 
cancer deaths would have been avoided each year between 1985 and 1999 if survival rates 
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Suspected 
cancer
Presentation 
in secondary 
care
Diagnosis Treatment Follow-up
in the UK were equal to the average European rates (Abdel-Rahman et al., 2009). Beyond 
Europe, UK survival for cancers diagnosed between the years 2000 and 2014 has repeatedly 
fallen behind that of Australia, Canada, New Zealand and the United States (Nuffield trust, 
2018).  
Several factors contribute to the poor survival outcomes reported in the UK, yet published 
research has continually shown delays in the time to diagnosis as a prominent issue, these 
can be delays in patient presentation in primary care with symptoms of suspected cancer, 
delays in referral from primary to secondary care or delays in investigation, diagnosis and 
treatment in secondary care (Majeed et al., 2018). No doubt an earlier diagnosis of cancer 
would result in fewer preventable deaths (Hiom, 2015). In addition to time delays, 
differences in the treatment received and care experienced by patients has been listed as a 
contributory factor to disparities in cancer outcomes that exist between the UK and similar 
high-income countries (O'dowd, 2015).  
1.1.2 Cancer pathways 
Patient cancer pathways are complex systems of events and activities beginning at the point 
of suspected cancer and ending with patient discharge and follow-up. They are designed not 
only to be specific to the cancer type diagnosed but also to the subtype determined, this 
ensures patients receive optimum care through their cancer pathway.   
The general cancer pathway itself can be broken down into several components, being made 
up of the referral, diagnostic and treatment pathways as illustrated in figure 1-1. Within each 
of these there can exist inherent weaknesses instigated by either the patient or the 
healthcare system itself that render the cancer pathway susceptible to delays. 
Understanding the points of delay and their primary stimuli within the context of the English 
healthcare system is the initial step in overcoming delays within cancer pathways and 
bringing outcomes in England on a par with those of the rest of Europe.  
Figure 1-1 General cancer pathway 
  
 
 
 Treatment 
pathway 
Diagnostic 
pathway 
Referral 
pathway 
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1.1.2.1 Primary care 
The referral component of the cancer pathway represents activities taking place in the 
community setting prior to patient presentation in secondary care. Patients present in 
secondary care for investigation of suspected cancer via more than one route, these can be 
divided into three categories: 
1. Symptomatic referrals through non-emergency routes such as those initiated by GPs  
2. Referrals made via the emergency route  
3. Non-symptomatic cases referred through screening programmes such as the 
National Health Service (NHS) breast or bowel screening programme (NCIN, 2013) 
Elliss-Brookes et al. (2012) analysed data on the route to diagnosis for cancer patients in 
England between 2006 and 2008, they found 76% of cancers to be referred through the non-
emergency route and 24% to present for further investigation in secondary care as an 
emergency case.  
Emergency presentations of suspected cancer cases are associated with poorer survival 
outcomes, 1-year survival is approximately 25% lower for these patients when compared to 
non-emergency presentations (McPhail et al., 2013). For example, oesophago-gastric cancer 
patients in England were given a curative treatment plan in 16%  of cases presenting through 
the emergency route compared to 36% of non-emergency cases and 1year survival stood at 
27% compared to 43% in non-emergency cases (Palser et al., 2013). Worsened outcomes are 
in large part due to the relationship between the referral route and stage at diagnosis, 
emergency presentations are associated with a more advanced cancer stage at diagnosis 
(Carneiro et al., 2016 ) indicating a delay in the patient arriving in secondary care for 
investigation.  Patients  that present with early stage cancer at grade 1 or 2 are more likely 
to survive since the cancer is less likely to have spread (Hiom, 2015), the chances of survival 
shrinks with each increase in stage especially for lung, ovarian  and bladder cancer (Public 
Health England, 2016). Furthermore, variances in stage at diagnosis partly explains 
international differences in survival for many cancers, including for lung cancer (Walters et 
al., 2013) colorectal cancer (Maringe et al., 2013) and breast cancer  (Muller et al., 2018).  
Several factors contribute to the occurrence of emergency presentations; patients delaying 
visiting their GP either due to lack of awareness of the signs and symptoms of cancer or 
barriers to access, where patients do make GP contact, many still arrive in secondary care 
through the emergency route while awaiting referral and others represent missed 
opportunities for referral by GPs (Murchie et al., 2017). Interventions designed to overcome 
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these and reduce the number of emergency presentations, thus the earlier diagnosis of 
cancers will inevitably have a positive impact on patient survival outcomes bringing them in-
line with their European counterparts.  Laudicella et al. (2018) explored the impacts of 
rerouting patients from emergency to non-emergency referral routes, they estimate over a 
5-year follow-up period from diagnosis, 1863 life years will be saved for colorectal cancer 
cases, 889 life years for breast cancers, 1195 life years for prostate cancers and 1011 life 
years saved for lung cancer patients. GPs are recommended to use cancer risk prediction 
tools to assist referral decisions made, to increase their awareness of recurrent symptoms in 
the cases of delayed cancer diagnosis (Morgan and Wilkes, 2017) and to improve their 
adherence to referral guidelines (Car et al., 2016), recognising and referring suspected cancer 
cases in a timely manner for investigation and treatment in secondary care will help 
overcome some of the delays  that generate poor cancer outcomes.  
1.1.2.2 Secondary care 
Once cancer patients are referred, the remainder of activities making up both the diagnostic 
and treatment pathways take place in secondary care.  Delays occur along the diagnostic 
pathway, mainly instigated by weaknesses in health service infrastructure rather than by 
patients themselves, since at this point patients are aware of their suspected cancer status 
and in general comply with the urgency of the tests and investigations being carried out. 
Delays in diagnosis in secondary care could be driven by: 
 Staff shortages within the medical departments involved in the cancer pathway  
 Unavailable equipment  
 Repeat investigation or examination owed to uncertain results or equipment failure  
 The need to seek external expert opinions for problematic cases where the 
appropriate expertise is not available onsite  
Delays in the diagnostic pathway from presentation in secondary care to diagnosis are 
however shorter than those manifesting in the primary care stage of the cancer pathway 
(Allgar and Neal, 2005). Delays in primary care occur at a stage where cancer may not yet be 
suspected or even considered, however in secondary care, cancer is evidently suspected and 
with it comes the urgency of confirmation and treatment initiation.  Nonetheless, secondary 
care delays contribute to overall diagnostic delay and their removal allows cancers to be 
diagnosed sooner and for patients to be set on their treatment pathway earlier.  
At the crossroads of the diagnostic and treatment pathway, decisions are made by clinicians 
on the treatment plans to follow for optimum patient care. These decisions are largely based 
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on the underlying characteristics of the disease reported, determined through investigation 
in the pathology lab within the diagnostic pathway.  The disease characteristics reported that 
inform decision-making must be reflective of the true disease state thus allowing clinicians 
to design treatment plans specific to the patient needs. Published guidance based on 
research evidence act as the stepping-stone between diagnosis and treatment, they help 
guide clinicians on the treatment to recommend based on the disease characteristics 
reported.  International variations exist in guidelines for cancer treatment but it is not known 
to what extent these contribute to the variations in cancer outcomes  (Norell et al., 2018). 
At best, hospitals in England must have systems in place to ensure compliance with UK 
standards. Patient, primary care, referral and secondary care delays can all contribute to 
overall diagnostic delay for cancer patients (Allgar and Neal, 2005). However the significance 
of each of these by cancer type is still not yet known (Neal et al., 2015), but it is established 
with certainty that delays should be avoided where possible (Hansen et al., 2011).  
1.1.3 Government policy 
Health service systems such as the NHS have an important role to play in eliminating delays 
in diagnosis and enhancing treatment management for cancer patients. At both the primary 
and secondary care level, clinicians must work to reduce unnecessary time delays by 
adhering to published cancer referral and cancer management guidelines. Interventions to 
overcome delays are certainly welcome but their impact must be measured against agreed 
benchmarks to determine if they are indeed of value in overcoming the delays existing in the 
cancer pathway. Universal standards are set and agreed upon at the governmental level, 
against these the time to diagnosis and treatment across different NHS providers in England 
can be measured and compared. Policy set by government ensures a minimum level of care 
is maintained across all English healthcare providers.   
Government strategies have continually kept early diagnosis at the core of their objectives 
for cancer care by setting minimum waiting time targets for cancer patients. These have 
evolved over the years as follows: 
1. NHS Cancer Plan 2000                                                                 (Department of Health, 2000) 
The following targets apply to symptomatic patients presenting via urgent GP referral  
a. Maximum 2 week wait for urgent outpatient appointment in secondary care 
b. Maximum 1 month (31 days) from diagnosis to treatment 
c. Maximum 2 months (62 days) from urgent referral to treatment 
2. Cancer Reform Strategy                                                              (Department of Health, 2007) 
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Identical targets to those outlined in the NHS Cancer plan remained in effect but they were 
updated as follows: 
a. The 62 day target was extended to also apply to patients arriving via the screening 
and the emergency route  
b. The 31 day target was extended to cover the second and third treatments in the 
cancer pathway where these are recommended 
3. Improving outcomes a strategy for cancer                             (Department of Health, 2011) 
No change from previous years  
4. Achieving world class cancer outcomes                   (Independent Cancer Taskforce, 2015) 
The waiting time targets of 31 and 62 days described in previous government strategies 
continue to stand, however additional recommendations were made for the waiting time to 
diagnosis, where cancer is either confirmed or excluded and the patient is discharged back 
into primary care. So far, government strategies have focused on time to treatment and time 
to referral but no specific target existed for time to diagnosis covering the investigative steps 
in secondary care, this phase is so far only covered by the 62- day target.  The Independent 
Cancer Taskforce (2015) go a step further than previous recommendations, they propose a 
four-week target in the investigative stages to be met for 95% of suspected cancer cases by 
2020, this is the period from GP referral to confirmed diagnosis or exclusion of cancer and 
within this time the result must be communicated to the patient. They go even further by 
suggesting that for 50% of cases, a diagnosis should be achieved within two weeks.  With 
these updated recommendations, the two-week target from referral to presentations in 
secondary care is no longer valid, since it is now encompassed within the new four-week 
target. Figure 1-2 summarises the current status of cancer waiting time targets as set by NHS 
England.   
The importance of early cancer diagnosis is unquestionable; cancers are more likely to be 
identified in their early stages of development with the possibility of treatment being 
initiated sooner. Patients have a greater chance of being recommended a curative treatment 
plan versus palliative care and thus survival outcomes for cancer patients are improved. 
Evidence of time savings in the cancer pathway have emerged since waiting time targets 
have come into effect. Neal et al. (2014) report a reduction of approximately five days in the 
time from the first symptom to diagnosis.   
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However early diagnosis alone is not sufficient, as patients are diagnosed they must receive 
the highest quality standard of treatment that is specific to their needs to maintain 
acceptable cancer survival outcomes. Early diagnosis is of little value if appropriate 
treatment management does not follow it. Cancer treatment plans are in most part governed 
by the diagnosis made during the investigative stages of the cancer pathway.  
Figure 1-2 Cancer waiting time targets 
 
 
 
 
 
 
Cancers that develop in the same part of the body can differ; appreciating the details of the 
cancer subtypes allows a targeted treatment approach to be taken by clinicians. Drugs are 
prescribed where there is a known likelihood of response and avoided together with their 
side effects where the feature of the cancer targeted by the drug is not present. Patients are 
given treatment that is expected to have an impact on their survival outcomes and avoid 
unnecessary treatment.  
‘The right treatment for the right patient at the right time’ (Jackson and Chester, 2015) 
defines personalised medicine. This is governed by the ongoing discovery of biomarkers with 
the simultaneous rapid development of diagnostic tests by pharmaceutical companies 
(Drucker and Krapfenbauer, 2013). Test results are used to guide the decision-making 
process. In addition to early cancer diagnosis, treatment and molecular diagnostics were at 
the heart of the recommendations for improving survival outcomes in the latest government 
strategy outlined by the Independent Cancer Taskforce (2015). Improving access to 
molecular diagnostic tests for all cancer types by 2020 was a target. 
While the existence of targets and recommendations is vital to measure against the 
performance of NHS care providers, systems must be in place to support clinicians in 
achieving these targets. Inputs into the cancer pathway through intervention or adaptation 
of the system will undoubtedly influence the performance output of NHS care providers. 
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Without these, government targets will only manifest as a burden, adding further pressure 
onto an already strained system.  
1.2 Pathology 
At the heart of all diagnosis lies pathology, a vital yet overlooked component of cancer 
pathways. Manipulation of pathology systems has the ability to contribute to improvements 
in both the time to diagnosis and treatment management. ‘Pathology is the bridge between 
science and medicine’ (RCPath, 2018c), it plays a role in all disease areas through the 
examination of an extensive range of bodily material including  tissue specimens, blood, bone 
marrow and other body fluids.  The material is analysed to understand the underlying cause 
and characteristics of disease. Clinicians use information from pathology to guide disease 
management including both diagnosis and treatment.  Pathology services are the backbone 
of patient care, 70-80% of decisions related to diagnosis and treatment are founded on 
results from the pathology lab (Beastall, 2008).  
Pathology itself covers a wide range of disciplines subject to the material being examined 
(Mahfouz, 2009). The Royal College of Pathologists list five main and nine smaller specialties 
of pathology. These are histopathology, medical microbiology, haematology, clinical 
biochemistry and immunology as the main branches of pathology in addition to the smaller 
specialties of genetics, neuropathology, cytology, clinical embryology, dermatopathology, 
forensic pathology, toxicology, veterinary pathology and virology (RCPath, 2018c). Each of 
these covers a wide range of tests and procedures carried out by doctors and scientists in 
the lab in order to study and understand disease.  
Histopathology is by far the most significant of all the pathology specialties, it involves the 
examination of tissue material under a microscope, making comparisons against healthy 
tissue to detect differences (Slaoui and Fiette, 2011). A specimen is removed from the patient 
in most cases through biopsy, it is gross examined, processed, embedded in paraffin, cut into 
thin sections and stained ready for microscopic examination by the histopathologist who 
deliver a diagnosis of the disease (Kapila et al., 2016). Histopathologists work closely with 
other clinicians with whom they share their findings (Masood and Horsfield, 2016). For most 
cancer cases, histopathologists are the primary pathology clinicians that tissue specimens 
are exposed to.  
Pathology services are the gold standard for cancer diagnosis  (Leong and Zhuang, 2011). 
Clinicians cannot plan or initiate treatment without the pathologists report on the clinical 
findings of the tissue removed from the suspected cancer by biopsy (Kufe et al., 2003). 
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Pathology services are located in the investigative stages of the cancer pathway in particular 
between the patient first presenting in secondary care and diagnosis of disease. Over recent 
years, with the advance of personalised medicine, the role of the pathologists in cancer 
diagnosis and treatment has changed dramatically (Misialek, 2014). They are often referred 
to as diagnostic oncologists due to the breadth and extent of diagnostic and prognostic 
molecular biomarkers (Srigley, 2009) they must test for to offer patients a care plan 
personalised to their specific disease characteristics.   
1.2.1 Challenges in pathology 
The continual discovery of cancer biomarkers and the introduction of their corresponding 
tests into patient cancer pathways requires the pathologist to first confirm the presence of 
malignancy as well as subtype the tumour and carry out molecular testing (Davidson et al., 
2013) for targeted therapies. This increases pathology workload when diagnosing cancers, in 
theory amplifying diagnostic delays as a result of the extent of information pathologists must 
now report prior to cancer treatment initiation. Simultaneously NHS cancer targets are 
continually being reviewed and updated to reflect more stringent criteria consequently 
adding further strain on laboratories when handling the changes in demand for cancer 
diagnostics.  
This comes at a time where pathology labs in general are being challenged due to the 
increasing pressure on their services. There has been an annual 4.5% increase in requests 
from pathology labs from a workforce that is growing at a much slower rate than for other 
specialities (Cancer Research UK, 2016b). Not enough medical trainees are starting pathology 
training and more than 30% of current pathology consultants are aged 55 or over (Cancer 
Research UK, 2016b), pathology labs are at the brink of a workforce crisis so that it becomes 
increasingly difficult to cope with the continual growth in demand for their services. 
Since 2010, there has been a 17% annual increase in patients waiting more than six weeks 
for  cancer diagnosis (Cancer Research UK, 2016b), falling behind on government targets. The 
rising demand for more complex specimen analysis, increased workload and a shortage of 
pathologists (Williams et al., 2017) have together created an environment predicted to 
hinder patient care through delays in diagnosis (Child and Gupta, 2009) if not confronted 
head on. Here we have a scenario of evident deficiencies in pathology labs further 
augmented by external pressures. 
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1.2.2 Managing demand 
Pathology labs must adapt to handle the additional diagnostic pressure without undermining 
the ability to adhere to cancer waiting time targets or quality standards. The appropriate 
infrastructure and procedures must be in place to support laboratory staff, including 
pathologists, in meeting the increasing demands for their services. Without intervention, 
pathology reporting on cancer specimens will become a lengthier process and cancer waiting 
time targets become difficult to attain, having a knock-on effect on patients’ treatment 
initiation and thus survival outcomes and reflecting negatively on NHS providers. 
In 1999 the Pathology Modernisation Programme was launched by the Department of Health 
at the time, with the aim of improving the quality and efficiency of pathology services 
(Beastall, 2008). One of the first policy documents, Modernising pathology services, resulting 
through consultation as part of the programme highlighted five key areas for the 
modernisation of pathology in order to meet increasing demands. These were:  
 Integrating pathology to support wider services 
 Re-designing the systems 
 The use of effective and appropriate testing 
 Decreasing inappropriate variation in pathology practice across the country 
 Taking advantage of new technology and IT           (Department of Health, 2004) 
The programme introduced the concept of new technologies and re-configuration of practice 
and systems in pathology to deliver high quality care for patients. The Pathology 
Modernisation Programme went on to commission two independent reviews into NHS 
pathology services in England. The first by Lord Carter (2006) recognised the importance of 
improving the quality of pathology services in the wider context of the patient pathways and 
recommended adapting systems and practice within pathology as well as the faster adoption 
of new technologies to achieve this. The second phase of the review also by Lord Carter 
(2008) once more recommended the adoption of innovation in both technology and practice 
to achieve clinical excellence in pathology. 
1.2.3 Pathology innovation 
Innovation in pathology is largely driven by the fundamental need to deliver high quality 
services efficiently within the lab to maximise the clinical benefits to the patient (RCPath, 
2019). There are currently two layers of innovation, the first is around the discovery of new 
tests to particularly focus and personalise treatment to the patient’s needs. The 
modernisation of practice through the availability of more accurate and novel diagnostic 
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information, adds to the oncologist’s ability to plan and target treatment appropriately, 
translating into better quality of care for the patient. This layer increases the workload of the 
pathology lab.  
The second layer of innovations are intended to counteract the workload impacts of the first. 
They are centred on the introduction of modifications in the way things are done in the lab. 
For this group of innovations, rather than introducing an intervention that provides more 
information about the characteristics of a disease, they are centred on maximising the 
capacity of the procedures already in place for example by enhancing existing systems 
through technology or re-configuring current pathology workflow to enhance efficiency 
within the lab or modifying strategies to testing rather than the introduction of a new test. 
Improvements in cancer outcomes will transpire as a result of productivity gains in the lab, 
shrinking the time to diagnosis and enabling a greater number of tissue specimens to be 
processed and analysed in the given time thus contributing to early diagnosis.  
Cancer Research UK (2016b) lay out a series of recommendations to address current issues 
within the pathology lab, one of which is digitisation. This is expected to upgrade workflows 
within the lab for a smoother transition from tissue specimen arrival to report ready by 
pathologist, in theory reducing the time taken to diagnosis and treatment initiation. 
Pathology activities comes under the new 28 day waiting time target, recommended by the 
Independent Cancer Taskforce (2015). Modernisation of pathology services that lead to time 
savings in this phase of the pathway are likely to have implications for overall cancer waiting 
times and thus improve survival outcomes. Furthermore, the digitisation of pathology is set 
to revolutionise the methods for analysis and reporting on tissue specimens through the 
introduction of computer software that allows more accurate quantification of the 
characteristics of disease.  
NHS England (2014b)’s report on the Digital First pathology programme described the ways 
in which pathology labs were already incorporating digital methods into their practice. These 
include: 
1. The use of a single laboratory system to consolidate pathology services across more 
than one site at Leicestershire Pathology Service 
2. The development of an electronic consultation service between primary and 
secondary care, including the electronic transfer of patient records  in Bradford 
3. An online portal for patients to access test results as well as advice for the 
management of their condition  
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4. Using business intelligence tools such as those adopted by Sandwell and West 
Birmingham Hospitals NHS Trust to analyse data and better manage  pathology 
services 
5. An automatic identification system between laboratory specimens and patients set 
up at Oxford University Hospitals NHS trust for safer sample management                                    
(NHS England, 2014b) 
Elsewhere the published literature has put forward other ideas for innovative pathology 
interventions that can contribute to improvements in patient pathways, including tele-
pathology, virtual microscopy and whole slide imaging (Weinstein et al., 2009). Tele-
pathology is the practice of pathology from a distance (Farahani and Pantanowitz, 2015), 
video imaging and telecommunications are used to aid diagnosis and decision-making 
(Weinstein et al., 2001). Virtual microscopy is the use of digital slides rather than glass slides 
to examine tissue specimens (Kumar et al., 2004). Glass slides are scanned to create digital 
files, resulting in larger digital images for the pathologist to view (Farahani et al., 2015). 
Whole slide imaging is the production of these digital images and viewing them using a virtual 
slide viewer (Weinstein et al., 2009).  
New tests and innovations around their application only impact on the specific patients they 
target. Whilst pathology modernisation in systems and processes are predicted to have 
positive effects for many patients, these types of pathology interventions are expected to 
cross multiple pathways of different disease areas so that many patients to various degrees 
will feel their benefits.  
1.3 Economic evaluations 
Interventions in pathology driven by modernisation and innovation are certainly welcome 
especially where they lead to enhanced outcomes for cancer patients and contribute to 
reducing delays in diagnosis. However, they no doubt come at an additional cost to the NHS 
since in most cases they may be designed to optimise rather than replace existing procedures 
or they may signify an additional step in the pathology workflow. In an NHS with limited 
resources it is essential that proposals for investment to improve pathology services are 
evaluated to quantify their economic implications alongside their clinical impacts. 
Economic evaluations support decision making in healthcare (Robinson, 1993e). The costs 
and outcomes of two interventions, in this case pathology innovation and pathology 
standard practice, are identified, measured, valued and compared against each other to 
place a value on the change in costs and benefits that will come with the implementation of 
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modernising interventions in pathology. There are five different approaches to economic 
evaluations. They all use similar methods to value the costs for comparison; the types of 
costs included in the evaluation must be relevant to the study perspective adopted.  
Economic evaluations differ in the methods they use to measure and value benefits. The 
different types of economic evaluations are listed: 
1. Cost utility analysis (CUA): outcomes are measured using preference-based or utility 
-based measures such as the quality-adjusted life year (QALY) (Robinson, 1993c) 
2. Cost-effectiveness analysis (CEA): outcomes are measured in natural units 
depending on the objective of the intervention, for example life years gained 
(Robinson, 1993b) 
3. Cost-benefit analysis (CBA): outcomes are assigned a monetary value (Robinson, 
1993a) 
4. Cost-consequence analysis (CCA): More than one outcome of the intervention, not 
necessarily in the same unit are listed in a disaggregated format (Hoomans and 
Severens, 2014) 
5. Cost-minimisation analysis (CMA): only costs are compared in this type of evaluation. 
This method is only used when it can be certain that the interventions being 
compared are equivalent (Robinson, 1993d)  
The differences between two interventions in a CUA and CEA are conveyed as a ratio of 
change in cost per unit change in outcome (Garber and Phelps, 1997) referred to as an 
Incremental Cost Effectiveness Ratio (ICER). The National Institute for Health and Care 
Excellence (NICE) has set a threshold of £20,000 to £30,000 per quality-adjusted life-year 
(QALY) to deem an intervention cost-effective and support its introduction (McCabe et al., 
2008). CBA results are expressed in Net Monetary Benefit (NMB), this is the monetary value 
of benefit less the cost of treatment, compared across the two interventions. Economic 
evaluations are central to investment decisions within a cash-strapped NHS system. Results 
from these support or challenge the case for the introduction of new technologies. 
1.3.1 Challenges in the evaluation of pathology services 
Carrying out economic evaluations of pathology interventions can be challenging owing to 
the relationship between pathology and the patient. Pathology interventions act through 
one or more intermediate processes before their impacts are experienced by the patient 
(Sutton et al., 2018). Unlike clinical interventions for example, where the effect of treatment 
impacts the patient directly so that clinical benefits are attributed to the intervention of 
interest, the output of a pathology intervention influences an intermediate process which in 
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turn impacts clinical outcomes. This applies to all pathology interventions whether they 
involve the introduction of new diagnostic tests or alterations in systems and processes.  An 
additional layer of complexity exists when evaluating the latter type of innovation, diagnostic 
tests are in most cases specific to a disease area whereas innovations in systems and 
processes can have many effects across a wide range of patient outcomes and care pathways 
(Sutton et al., 2018), the benefits of system changes can be substantial when measured 
appropriately.  
Lilford et al. (2010) summarised and presented a similar relationship between patient 
outcomes and policy and service interventions. Figure 1-3 adapts their description of the 
chain of events to pathology. To carry out an economic evaluation it is important to first 
understand how the pathology intervention fits into this chain of events, is it a targeted 
process such as a diagnostic test or a generic process such as modifications in workflow. 
There are no clinical processes within pathology.  
Figure 1-3 Relationship between pathology processes and patient outcomes 
 
 
 
 
 
 
Adapted from Lilford et al. (2010) 
The overall aim of the research presented in the following thesis is to establish the cost-
effectiveness of innovation in pathology, particularly focusing on generic processes and 
strategies introduced to modify current practice and systems or that introduce technology 
to support the pathology lab in handling greater demand whilst maintaining a high quality 
service. The thesis will focus on outcomes for cancer patients and explore how pathology 
innovation can play a role in early diagnosis and better treatment selection. The underlying 
objectives and methodology used to achieve this are detailed throughout this thesis at the 
start of each chapter.  
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Chapter 2: Economic evaluations of pathology innovations - a 
systematic review 
2.1 Introduction 
The motivation for innovation in pathology is largely driven by the increasing pressure on 
pathology services to meet increasing demand for more complex testing and diagnosis in an 
environment where workforces are shrinking and NHS services are subject to ever more 
stringent government waiting time targets. Pathology labs must modernise and adopt new 
ways for working in addition to introducing technologies into their systems to support 
pathologists’ in order to maximise efficiency, improve accuracy and cope with increased 
demand whilst allowing pathologists to maintain a high quality of care service.  
2.1.1 Economic evaluations within pathology 
There are two ongoing developments within pathology, the first is concerned with the 
discovery of new biomarker and genetic tests to achieve personalised treatment, the second 
is concerned with the modification of systems and processes to maximise efficiency, improve 
productivity and enhance accuracy within the lab. The extent of economic evaluations differs 
between these two groups. For the development of pathology tests there appears to be an 
abundance of research around the cost-effectiveness of these. Two systematic reviews of 
pathology tests are available. Fang et al. (2011) specifically reviewed the literature for CUAs 
of laboratory tests published up to 2008. Their study identified 141 published studies of 
which 42, the largest group were CUAs of haematology/oncology1 tests. A more recent 
review by Watts et al. (2017) identified 356 economic evaluations of pathology tests 
published between 2010 and 2015 of which 108 were tests used within 
haematology/oncology.  
When focusing on pathology tests that specifically target cancer patients, there are also a 
number of published studies that evaluate the cost-effectiveness of cancer tests, including 
both single studies and synthesised reviews. For example, Hornberger et al. (2012) carried 
out a systematic review of tests to determine risk of recurrence for early breast cancer 
patients, within this they analysed the economic data. Eleven out of the 56 studies eligible 
for inclusion in their review included an economic evaluation. Huxley et al. (2015) carry out 
an economic evaluation of a molecular test to identify malignancy in the lymph nodes of 
breast cancer patients. Havrilesky et al. (2013) carry out a CEA of a test to measure 
                                                          
1 Heamotology/oncology is a combined speciality within the US 
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metastases in endometrial cancer. D’Andrea et al. (2015) carry out a review of economic 
evaluations of genetic tests used in the cancer pathway.  
However the scope of economic evaluations of innovations in pathology that disrupt current 
processes, existing systems or strategies of work to introduce new ways of doing things in 
the pathology lab in order to cope with demand or improve the accuracy of existing 
procedures appear to be a lot more limited. These are important sources of information for 
decision makers. Process modifications are expected to be of considerable benefit due to the 
extended impact they can have for many disease areas, as a result, the cost per patient is 
likely to be minimal, but in most cases they will involve a considerable amount of upfront 
and on-going investment.   Economic evaluations can be used to justify and encourage the 
adoption of such processes. These are especially important within the cancer pathways as 
they can contribute to achieving waiting time targets and improving patient outcomes.  
PROSPERO, The Cochrane Database of systematic reviews, TRIP medical database and the 
ARIF reviews database were all searched, no completed or ongoing systematic reviews of 
economic evaluations of innovation in pathology were identified. 
2.2 Aims 
The aims of this chapter are as follows: 
1. To systematically review and summarise the methods applied when carrying out 
economic evaluations of histopathology process interventions through their impact 
on cancer outcomes.  
2. To summarise the cost-effectiveness evidence on innovations in pathology services 
for cancer patients  
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2.3 Methods 
The Centre for Reviews and Disseminations guidance for carrying out reviews in healthcare 
(CRD, 2009) were followed to guide the review process.  
2.3.1 Information sources 
A broad literature search was carried out to identify all the published economic evaluations 
of innovation in pathology. Both bibliographic database searches and forensic searching 
techniques were carried out to identify all the relevant literature.  
2.3.1.1 Electronic searches 
The following databases were searched for full economic evaluations: 
1. DARE 
2. Econlit 
3. Embase 
4. HTA 
5. Medline 
6. NHS EED 
7. Web of Science 
The search strategies used in the database searches combined three key concepts, in essence 
including key word and MESH search terms that describe cancer, pathology and economic 
evaluations. To maintain an inclusive approach to the types of patient outcomes that can be 
measured and the comparators used, no search terms related to either of these concepts 
were included in the search strategies so that the full breadth of economic evaluations are 
captured. Furthermore, whilst innovation is a clear criteria for inclusion of a publication, 
associated terms were not built-in so as not to restrict the search results, instead a year limit 
of 2000 was set, this ensures that the maximum number of studies are captured and those 
that were not relevant were excluded at the screening stage of the review. The search 
strategy was first developed in Medline and adapted for use in the remaining databases 
listed. The search strategies for each of the databases are given in appendix A.  
2.3.1.2 Other sources 
Forward and backward citation was carried out on all the included studies identified through 
the electronic searches to locate any further research not picked up in the initial database 
searches.  In addition to this, key word searches were carried out in Google (and Google 
Scholar) and the first three pages of search results screened against the eligibility criteria.  
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2.3.2 Eligibility criteria 
2.3.2.1 Types of studies 
All types of full economic evaluations that measure the difference in both costs and 
outcomes of two or more alternative strategies were eligible for inclusion in the review. 
These include cost-effectiveness analyses, cost-utility analyses, cost-consequence analyses, 
cost-minimisation analyses and cost-benefit analyses. They include economic evaluations 
that are carried out alongside randomised controlled trials (RCT) or those that use decision-
analytical modelling techniques as a vehicle for the analysis. Economic analyses that do not 
meet the requirements of a full economic evaluation were not eligible for inclusion in the 
review. All types of partial economic evaluations as listed in table 2-1 were excluded during 
the screening stages of the review but their total number and types of interventions that 
were evaluated was recorded.  
All conference proceedings were excluded, however they were initially screened against the 
eligibility criteria.  Where they referred to a full economic evaluation, the corresponding full 
paper was searched, for inclusion in the review if it had not already been identified through 
the electronic searches.  
2.3.2.2 Types of participants 
Since pathology services play a vital role in both the diagnosis and management of cancer 
cases, two groups of patients were eligible for inclusion in the review. All studies where 
patients with suspected cancer are the population of interest and secondly all studies where 
the population of interest had been previously diagnosed with cancer. There were no 
restrictions on the types of suspected or diagnosed cancers and no further criteria 
concerning the types of participants. Full economic evaluations that explore the cost-
effectiveness of pathology interventions targeting these groups of patients were eligible for 
inclusion in the review. 
2.3.2.3 Types of interventions 
Pathology interventions designed to disrupt current systems within the pathology lab either 
through the introduction of a new technology or the modification of current processes to 
support growing demand on pathology services or to improve the accuracy of existing tests 
were eligible for inclusion in the review. Due to the breadth of pathology, interventions had 
to particularly target the handling of tissue specimens (histopathology) to be included. 
Economic evaluations of newly discovered biomarkers and genetic tests that have not 
previously been adopted were excluded however, economic evaluations of strategies for 
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testing for molecular biomarkers that have already been approved and are in use were 
included. 
2.3.2.4 Types of comparators 
All studies that were eligible for inclusion in the review, had to include at least two arms in 
their economic evaluation. The first representing the pathology innovation being evaluated 
and the other(s) a suitable comparator. If an appropriate comparator could not be identified 
by the review authors they had to include a ‘do nothing’ arm for their study to be eligible for 
inclusion in the review. Studies that do not include a comparator arm were excluded from 
the review. 
2.3.2.5 Types of outcome measures 
Pathology services are classified as indirect interventions to patient care and their effects are 
not always measured in relation to patients. Economic evaluations had to explicitly keep 
cancer patients at the heart of the analysis and measure the effect of the intervention 
directly to them to be eligible for inclusion in the review. Beyond this requirement there 
were no restrictions on the types of outcomes that an economic evaluation could use to 
measure the effect of the pathology intervention. 
Table 2-1 Summary inclusion criteria 
 Include Exclude 
Population All patients that are suspected 
or have been diagnosed with 
any cancer 
Conditions other than cancer 
Intervention Histopathology interventions 
that include: 
 New technologies 
 Modifications in systems 
and processes 
 Alternative testing 
strategies 
Non-pathology interventions 
Pathology interventions that are 
not specific to histopathology 
Newly discovered molecular and 
genetic tests 
Comparator Any comparator No comparator 
Outcome Any outcome but must be 
related to cancer-patient 
Outcomes not related to cancer 
patient 
Study Design All types of full economic 
evaluations: 
 Cost-benefit analysis  
 Cost-consequence analysis 
All types of partial economic 
evaluations: 
 Cost analysis 
 Cost description 
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 Cost-effectiveness analysis 
 Cost-minimisation analysis 
 Cost-utility analysis 
 Outcomes analysis 
 Outcomes description 
Country of 
Research 
Europe and North America Countries outside of Europe and 
North America 
Language English only publications Non-English publications 
Publication Date 2000 Onwards Pre-2000 
 
2.3.3 Data collection and analysis 
Search results from the electronic databases as well as other sources were uploaded and 
managed in the reference manager EndNote. Duplicates were removed.  
2.3.3.1 Study selection 
Two reviewers were involved in deciding on the eligibility of studies for inclusion in the 
review. A two-step process was taken for study selection as recommended by CRD (2009) 
guidance. The first step involved the two reviewers independently screening the titles and 
abstracts of all search results against the pre-specified inclusion/exclusion criteria listed in 
table 2-1. An inclusive approach to study selection was taken at this stage of the screening 
process, only studies that were clearly irrelevant were excluded, all those where a decision 
could not be made with certainty were included at this stage and proceeded onto the second 
round of the screening process. Any disagreements between the two reviewers were 
mediated through consultation with a third reviewer.   
The second round of screening started with the retrieval of the full papers that passed the 
first stage of the two-step process. The full texts were screened one more time against the 
criteria listed in table 2-1 and the reasons for exclusion were recorded. Where more than 
one published study reported on the same economic evaluation these were regarded as one 
piece of research. Once again, any disagreements between the two reviewers on the 
inclusion or exclusion of a study were mediated through consultation with a third reviewer.   
Published research that passed through both stages of the screening process were included 
in the study. Their references were checked and citation searches carried out to identify 
further eligible research. All the stages of study selection were recorded in a PRISMA flow 
diagram.  
2.3.3.2 Data extraction and management 
Following the identification and retrieval of the eligible studies for inclusion in the review, 
the data points required from these to meet the study objectives were extracted using a pre-
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designed data extraction form. This can be found in appendix B. The data extracted was 
recorded in an excel spreadsheet, ready for analysis. The information documented included 
general study details, descriptions of both the pathology intervention and the comparator, 
economic evaluation approach taken and all details of the methods used, the thresholds 
applied by the study authors to determine cost-effectiveness and finally the cost-
effectiveness decision made concerning the intervention of interest.  
2.3.3.3 Reporting quality 
The reporting quality of the eligible studies was assessed against the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) checklist for reporting economic 
evaluations of healthcare interventions (Husereau et al., 2013). Each study was scored out 
of 24 and the results recorded in an excel spreadsheet.  
2.3.4 Data synthesis 
The cost effectiveness results including incremental costs and outcomes were summarised 
to establish the overall outcomes of economic evaluations of pathology interventions. 
Where possible studies were classified according to the population cancer and intervention 
type being evaluated to highlight the areas where economic evaluations were more 
prevalent and the different approaches used across each of these.  
A narrative synthesis of the data collected was undertaken, through the quality assessment 
scores it was possible to identify and highlight the common strengths and weaknesses across 
the studies including lessons that can be learnt when carrying out future economic 
evaluations of pathology interventions.  
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2.4 Results 
2.4.1 Search results 
The systematic review database searches identified 2483 publications, after de-duplication, 
2304 studies remained and were screened against the eligibility criteria. 2070 were discarded 
on the first round of screening, after retrieval and screening of the remaining full papers, 7 
studies met the systematic review criteria. Two further studies were identified through 
citation and reference searching. In total 9 studies met all the eligibility criteria for inclusion 
in the review. A summary of the study selection process is given in figure 2-1.  
Figure 2-1 Study selection process 
Records identified through 
database searching (n=2483)
Titles/Abstracts Screened
 (n=2306)
Records excluded
Duplicates removed: (n=179)
Records Excluded
(n=2070)
Full-text articles assessed for 
eligibility
 (n=236)
Full-text articles excluded:
 No access (n=2)
 Non English (n=2)
 Not cancer patients (n=7)
 Incorrect geography (n=10)
 Not an economic evaluation (n=135)
 Economic evaluation but not a pathology intervention (n=30)
 Economic evaluation of a cancer biomarker (n=28)
 Correct pathology but partial economic evaluation (n=13)
Studies Included
 (n=9)
Additional records identified 
(n=2)
 
 
227 studies were excluded on the second round of screening, on review of the full papers of 
each record, the reasons for exclusion are listed in figure 2-1. Of all the studies excluded, 28 
23 
 
studies were excluded because they were economic evaluations of new cancer biomarkers 
and 13 studies were excluded because they met the pathology intervention criteria but were 
not full economic evaluations. The types of interventions partially evaluated were recorded, 
they included: 
1. Intraoperative pathology procedures   
2. Alternative strategies for testing for cancer biomarkers 
3. Access to second opinion pathology 
4. Whole-mount processing and evaluation of specimens  
5. A feedback programme for pathologists 
The majority of these are targeted pathology processes that are specific to a cancer type. 
However, access to second opinion pathology and a feedback programme for pathologists 
are both generic pathology processes that will have a diffuse effect across many cancers and 
disease areas. Coblentz et al. (2001) compared the cost of seeking a second opinion to the 
cost of avoided surgery for patients with bladder carcinoma, they reported a cost saving as 
a result of their intervention. No patient outcomes were considered as their evaluation is a 
cost-cost offset analysis.  Torres et al. (2003) evaluated the impact of a feedback programme 
for pathologists involved in reporting on breast disease. The authors presented a cost 
description of the intervention and did not attempt to measure these against any benefits.  
2.4.2 General study characteristics 
9 studies were eligible for inclusion in the review. Figures 2-2, 2-3 and 2-4 describe the 
general characteristics of these. 8 out of the 9 published studies investigated pathology 
interventions in the breast cancer pathway. The remaining study evaluated a pathology 
intervention introduced into the thyroid cancer pathway. The majority of studies were from 
the US and Canada and only 2 were European based studies. Noticeably none of the studies 
were UK based.  
Of the pathology interventions evaluated, the majority were evaluations of alternative 
testing strategies for the detection of a particular biomarker. These were not evaluations of 
newly discovered biomarkers in the same way as for the 27 studies that were excluded from 
the review as described in figure 2-1. These were evaluations of biomarkers that were 
already proven cost-effective and were in use in the pathway. The motivation behind these 
evaluations was to determine the most appropriate test strategy to adopt to ensure patients 
receive the correct treatment. All studies in this group compared a range of testing strategies 
that can be used to determine the biomarker HER2 status in breast cancer. They included 
24 
 
Elkin et al. (2004), Garrison et al. (2013a), Blank et al. (2010), Morelle et al. (2006), Dendukuri 
et al. (2007) and Lee et al. (2011). 
Figure 2-2 Summary of cancer types investigated 
 
Figure 2-3 Summary of papers by country of origin 
 
Beyond the alternative testing strategies, Zanocco et al. (2013) evaluated the cost-
effectiveness of the use of intraoperative pathology examination (IPE) when investigating 
neoplasms in palpable thyroid nodules. Conventionally the tissue specimen is sent for 
pathological examination in the lab and the patient will return for second total 
thyroidectomy surgery if there is evidence of malignancy on pathological examination. With 
IPE the tissue specimen can be examined immediately within the first surgical time period so 
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that if second surgery is recommended it can be completed straightaway rather than 
delayed.  
Two papers by Look Hong et al. (2016b) and Look Hong et al. (2016a) report on the final 
pathology intervention identified in the list of eligible studies. They both evaluate the cost-
effectiveness of using whole-mount (WM) histopathology processing rather than 
conventional processing for the examination of breast specimens. Under the conventional 
pathology techniques tissue specimens are sampled onto small slides, because the whole 
specimen is not represented in the slides there is a risk of missing a diagnosis due to under 
sampling of the surgical tissue in the slides (Clarke et al., 2007). With WM histopathology 30 
times more tissue than with conventional methods is evaluated due to the preservation of 
the 3D conformity of the specimen (Look Hong et al., 2016b). Even though they both evaluate 
the cost-effectiveness of the same intervention, they were both included as they adopt a 
different approach to the economic evaluation in their published studies.  
Figure 2-4 Summary pathology interventions investigated 
 
2.4.3 Economic evaluation methods adopted 
The next section focuses on the methods adopted in the eligible studies to determine the 
cost-effectiveness of the pathology intervention of interest.  
All studies eligible for inclusion in the systematic review used a form of decision modelling 
as the base for the economic evaluation. The majority of authors constructed either a 
decision tree or Markov model. A summary of the types of models adopted is given in figure 
2-5. 
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Figure 2-5 Summary modelling approaches adopted 
 
6 studies evaluated the cost-effectiveness of alternative strategies to determine HER2 status 
to guide Herceptin treatment for breast cancer patients. There are two commonly used 
methods to determine HER2 status, Immunohistochemistry (IHC) or fluorescence in situ 
hybridisation (FISH). Many of the strategies explored in these studies include either one or a 
combination of these tests. IHC will generate one of the following three results, 0/+1 
(negative), +2 (equivocal) or +3 (positive). FISH results are either positive or negative.  
Approaches to testing is a targeted process intervention in the pathology lab, it is specific to 
a patient group and does not have a diffuse effect. Out of the 6 studies that evaluated the 
HER2 test strategy, 4 mapped the targeted process onto Herceptin treatment, the clinical 
process, to determine QALY gains as a result of treatment.  These were Blank et al. (2010), 
Elkin et al. (2004), Garrison et al. (2013a) and Lee et al. (2011). The remaining two studies 
did not measure QALYs by mapping the outcomes of testing onto Herceptin treatment. 
Morelle et al. (2006) worked out the cost per correctly managed breast cancer case and 
Dendukuri et al. (2007) measured the cost per correct determination of HER2 status.  
All of the HER2 testing strategy studies used decision-modelling techniques as a vehicle for 
their economic evaluation. Blank et al. (2010) and Elkin et al. (2004) used Markov models to 
estimate costs and QALYs over the breast cancer patient’s lifetime. Both studies reported all 
transition probabilities and cost and effectiveness parameters including their sources that 
were used to populate the model and provide illustrations of their model structures. Blank 
et al. (2010) compared 6 strategies: 
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1. Patients receive IHC test only 
2. Patients receive FISH testing only 
3. Parallel testing using both IHC and FISH tests  
4. FISH testing if IHC equivocal 
5. No testing and all patients receive Herceptin treatment.  
The sensitivity and specificity of each test strategy were based on the published literature. A 
strength of this evaluation is its use of 4 independent sets of transition probabilities for each 
type of breast cancer patient i.e. those that are true positive, false positive, true negative 
and false negative to ensure that the differences in accuracy across each strategy are 
modelled appropriately. Blank et al. (2010) follow their base case analysis with both 
deterministic and probabilistic sensitivity analyses.  
 Elkin et al. (2004) also use a Markov decision model as a vehicle for their economic 
evaluation. They compare 7 strategies for HER2 testing: 
1. No test and chemotherapy alone 
2. IHC test and Herceptin treatment if IHC +3 
3. IHC test and confirm +2 and +3 results with FISH 
4. IHC test and confirm +2 results with FISH 
5. IHC test and Herceptin treatment if +2 or +3 
6. FISH test only and Herceptin if positive 
7. No testing, Herceptin and chemotherapy treatment given 
To determine the sensitivity and specificity of the IHC test they identify 10 studies that 
compare IHC to FISH results and use these to work out the weighted average with confidence 
intervals for the probability of each test score. The main concern with this approach is the 
absence of consideration for the underlying scoring thresholds that are used to determine 
positive and negative status, these have changed over time due to updated guidelines. This 
issue is discussed extensively in chapter 6 later on in the thesis.  Furthermore, it is not clear 
from the study if the model transition probabilities reflect HER2 test results conditional on 
the true HER2 status. Unlike the transition probabilities reported by Blank et al. (2010), Elkin 
et al. (2004) report transition probabilities for HER2 and negative cases without subdivision 
by those that are false and those that are true. The results from this study may not be truly 
representative of the differences in accuracy with each test strategy. Elkin et al. (2004) carry 
out one-way and two-way sensitivity analyses to measure uncertainty around their base case 
analysis estimates. 
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Garrison et al. (2013a) and Morelle et al. (2006) also carry out economic evaluations of 
alternative HER2 testing strategies, they use decision tree models as the vehicle for their 
economic analysis. Garrison et al. (2013a) compare two testing strategies: 
1. Standard practice: IHC test as first-line with repeat test on +2 scores using FISH. 
2. Proposed expanded reflex testing strategy: IHC as first-line and retesting both +1 
and +2 scores using the FISH test.  
An illustration of their model structure is presented in their study. The model probabilities 
they use are based on a single study that estimates the probability of each score for the IHC 
and FISH test, however they do not reflect on accuracy in their model by separating out the 
false and true cases through the consideration of test sensitivity and specificity. This would 
reflect onto the cost and QALY values used, since undoubtedly the QALY gain of patient that 
is a true positive is expected to be greater than the QALY gain of a breast cancer patient that 
is false positive. Garrison et al. (2013a) carried out both deterministic and probabilistic 
sensitivity analysis to assess the robustness of their results. 
Morelle et al. (2006) also develop a decision tree model for their cost-effectiveness analysis 
however; they do not include an illustration of their model structure. They compare five 
strategies for the determination of HER2 status at metastatic relapse for breast cancer 
patients: 
1. IHC at first metastatic relapse (current practice) 
2. Systematic IHC at diagnosis 
3. FISH at first metastatic relapse 
4. IHC followed by FISH for +2 cases 
5. IHC followed by FISH for +2 and +3 cases 
The study authors estimated IHC sensitivity and specificity using data from a study that they 
have access to. They do not provide a description of the methods or primary data they use 
to estimate sensitivity and specificity.  They also do not provide estimates of the resultant 
sensitivity and specificity that they calculate and input into the model. They also do not 
provide a clear summary of the cost and effectiveness parameters used to populate the 
model. They do not link test results with treatment and present their results as the cost per 
number of correctly managed patients. Deterministic sensitivity analysis was also carried out. 
It is challenging to follow this study through and understand the methods they have adopted.  
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Lee et al. (2011) compared the costs and benefits of five strategies to determine HER2 status. 
These were: 
1. Primary FISH 
2. Primary SISH 
3. Primary CISH 
4. Primary IHC with FISH to confirm equivocal cases 
5. Primary IHC plus FISH to confirm equivocal and positive cases 
They did not compare the five against each other but carried out three different cross 
comparisons: 
 Compare strategies 1, 4 and 5 against each other 
 FISH versus CISH 
 FISH versus SISH 
They develop an algebraic model in excel but no description or illustration of this is presented 
in the published study. The study authors identified published literature that report HER2 
scores for each of the alternative tests and estimate sensitivity and specificity for each of 
these.  Interestingly they did not attempt to pool or summarise their estimates but run the 
model to reflect each study they have identified. The model is run more than once for each 
analysis, each time reflecting accuracy estimates from a separate study. The model is run 46 
times corresponding to 46 different studies that estimate sensitivity and specificity of IHC, to 
compare strategies 1, 4 and 5. For each version, estimates of cost-effectiveness are 
presented for each of the three strategies. To compare FISH and CISH the model is run 21 
times each based on estimates of sensitivity and specificity from 21 different studies. For 
each version, 21 cost-effectiveness estimates are presented. Finally, the model is run five 
times to compare SISH and FISH so that five estimates of cost-effectiveness are drawn.  
The final study, investigating the cost-effectiveness of alternative HER2 strategies is by 
Dendukuri et al. (2007). They compared 7 approaches for HER2 testing: 
Table 2-2 HER2 testing strategies compared by Dendukuri et al. (2007) 
Strategy Condition for Herceptin treatment 
Standard practice: IHC plus FISH if +2 +3 IHC OR positive FISH 
IHC only +2 OR +3 result 
IHC only +3 result 
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IHC plus FISH if +1 or +2 +3 IHC OR positive FISH 
IHC plus FISH if +2 or +3 Positive FISH test 
IHC plus FISH for all scores Positive FISH test 
FISH only Positive FISH test 
 
The study authors do not explicitly state that they used a model for their analysis however 
they refer to it in the description of their methods, the type of model used or a description 
of it is not given. They only consider the costs of diagnosis and report the ICER as the cost 
per accurately determined HER2 status. 
Look Hong et al. (2016b) and Look Hong et al. (2016a) are both economic evaluations of the 
use of WM histopathology in the processing of breast cancer surgical specimens. Even 
though they report on the same pathology intervention, both studies were included in the 
systematic review as they take a different approach to the economic evaluation. Look Hong 
et al. (2016b) constructed a decision tree model to measure the impact of WM 
histopathology processing to conventional processing. They presented four outcomes in 
their study: 
1. Proportion of patients with additional operation 
2. Total number of hours needed for tissue processing 
3. Total number of hours needed for pathologist reporting 
4. Total number of slides processed 
They modelled the sensitivity and specificity for each intervention onto repeat operation if 
malignancy is detected. Sensitivity and specificity estimates for both arms of the evaluation 
were taken from a single published study. Number of hours for tissue processing and 
pathologist reporting were based on observational data. Four ICERs were reported, one for 
each of the outcomes listed. Both deterministic and probabilistic sensitivity were carried out.  
The second study by Look Hong et al. (2016a) constructed a Markov model  to carry out a 
cost-effectiveness analysis comparing WM histopathology processing to conventional 
processing. Unlike the first, they estimated costs and QALYs over a 10-year time horizon. 
Model parameter estimates for sensitivity and specificity were identical across both studies. 
Both deterministic and probabilistic sensitivity analyses were carried out. 
In reality, the studies build on each other’s work, the first maps out the benefits of WM 
histopathology for intermediate endpoints such as the rate of re-operation and the second 
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study goes a step further by linking WM histopathology to the patient outcomes by 
measuring QALYs.  
Zanocco et al. (2013) is the final study that was eligible for inclusion in the review. They carry 
out a CEA of the use of intra-operative pathology examination (IPE) to report on diagnostic 
hemithyroidectomies over a lifetime horizon. The authors do not explicitly define the 
perspective of their evaluation, however, this can be inferred from the costs included. They 
take a societal perspective and measure effectiveness using QALYs. Zanocco et al. (2013) 
construct a Markov model for the economic evaluation. They compare three surgical 
procedures with or without intra-operative pathology as listed: 
1. Diagnostic hemithyroidectomy without IPE 
2. Diagnostic hemithyroidectomy with IPE 
3. Total thyroidectomy with IPE 
Clear diagrams were given for each version of the model that represented the three 
interventions of interest.  
2.4.4 Cost-effectiveness results reported 
Four studies compared more than two HER2 testing strategies, Blank et al. (2010), Elkin et 
al. (2004), Lee et al. (2011) and Dendukuri et al. (2007). All the studies listed and compared 
incremental costs and benefits for their included strategies in a tabular format. Blank et al. 
(2010) concluded that FISH testing alone was the most cost-effective strategy with an ICER 
of €12,245/QALY, two of the other strategies were dominated and the remaining two had 
ICERS of €400,154/QALY and €13,456,577/QALY. They conclude that both these ICERs are 
high but do not explicitly state what the cut-off threshold is to consider an intervention cost-
effective.  
In the Elkin et al. (2004) study four of the strategies were dominated compared to standard 
practice and so not considered cost-effective. Two strategies, FISH test only and IHC with 
FISH test for +2 and +3 cases were the only two strategies not dominated. However, they 
had ICERs of $125,100/QALY and $145,000/QALY respectively. The study authors do 
acknowledge that these ICERs are high compared to other breast cancer interventions but 
they do not explicitly state the cut-off threshold for cost-effectiveness.  
It is difficult to draw a cost effectiveness conclusion with the results presented by Lee et al. 
(2011) they present several tables with cost-effectiveness estimates that are based on 
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different values of sensitivity and specificity and do not explicitly conclude which strategy is 
cost-effective. 
Dendukuri et al. (2007) also present their incremental costs and QALYs for each strategy in a 
tabulated format. Three testing strategies are not dominated and have ICERs that range from 
$6175 to $8401 per accurately determined HER2 status. Once more they do not explicitly 
state their cut-off threshold for cost-effectiveness.  
Morelle et al. (2006) evaluated four strategies for scoring HER2 against standard practice. 
They presented ICERs in the form of cost per correctly managed case. However, they did not 
present an overall ICER but two ICERs per testing strategy. One ICER per correctly managed 
case where false negative results are avoided and a second ICER per correctly managed case 
where false positive results are avoided. For the false negative cases avoided, only one 
strategy was not dominated and for the false positive cases avoided, two strategies were not 
dominated. There was not a single strategy that was not dominated across both criteria. They 
conclude that standard practice is the efficient strategy when both criteria are considered. 
Garrison et al. (2013b) estimate their expanded reflex testing approach would generate an 
additional $39,745/QALY gain and $36,721 per life year gained and state that is clearly below 
the cost-effectiveness thresholds. They also carry out a probabilistic sensitivity analysis and 
present a probability cost-effectiveness curve. There is an 87% chance of cost-effectiveness 
at the $50,000 threshold and at the $100,000 threshold, cost-effectiveness of their proposed 
strategy to testing is certain.  
Zanocco et al. (2013) economic evaluation of IPE carried out alongside diagnostic 
hemithyroidectomies estimated that the intervention proposed was dominated by standard 
practice of conventional pathology. IPE was both cost increasing and QALY reducing.  
Look Hong et al. (2016b) and Look Hong et al. (2016a) both evaluated the cost-effectiveness 
of WM histopathology for the examination of breast specimens. The first study estimated 
four ICERs: 
1. $9495/additional surgery 
2. $122/each additional hour spent in processing 
3. $5306/each additional hour of pathologist time saved 
4. $133/slide avoided 
They used the results per additional surgery to construct a cost-effectiveness acceptability 
curve and demonstrate that their intervention is cost-effective at thresholds up to $15,000.  
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The second study, (Look Hong et al., 2016a) estimated the effectiveness of WM 
histopathology using QALYs. They calculated an ICER of $45414 per QALY gained. 
Deterministic and probabilistic sensitivity analysis supported their conclusion.  
2.4.5 Quality assessment  
The CHEERS checklist was used to assess the quality of all included studies. A summary of the 
distribution of scores for the included papers is given in figure 2-6. The average number of 
items that the eligible papers scored positively on was 18 and the scores ranged from 11 to 
22 items completed.  
Figure 2-6 Distribution of CHEERS scores for all of the eligible studies 
 
 
 
 
 
 
 
 
All except one of the eligible studies, Dendukuri et al. (2007), scored positively on over 50% 
of the CHEERS checklist items. All the eligible studies clearly stated that a CEA was carried 
out and included well-structured abstracts and summarised the broader context of the 
evaluation in their introductory section. The study perspective was clearly defined in all 
except two studies, 6 adopted a healthcare system perspective and one study adopted a 
societal perspective.  The comparators were clearly listed in all the eligible studies. The time 
horizon adopted was clearly defined in all except two studies, Dendukuri et al. (2007) and 
Elkin et al. (2004). Three studies adopted a life-time horizon, Blank et al. (2010), Garrison et 
al. (2013b) and Zanocco et al. (2013), three studies Lee et al. (2011), Look Hong et al. (2016a) 
and Morelle et al. (2006) each adopted a 15year or 20 year time horizon and finally Look 
Hong et al. (2016b)’s time horizon ends when the patient completes surgery. All of the 
studies presented their cost-effectiveness results as ICERs and carried out sensitivity analysis 
to confirm their findings. There is not a criterion in the CHEERs checklist that can be 
considered a weakness across all the studies. 
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2.5 Discussion and conclusion 
The systematic review emphasised the lack of economic evaluations of generic pathology 
processes. No economic evaluation was identified that analyses the impacts of changes in 
systems and processes or the introduction of new technology within pathology to manage 
the increasing challenges that are being faced. The testing strategies investigated are 
targeted pathology processes specific to breast cancer. The IPE and WM are also targeted 
processes but the same techniques can be adopted across other cancers or disease areas 
where a larger specimen than what is currently possible with conventional processing needs 
to be examined.  
The majority of the eligible studies carried out economic evaluations investigating 
interventions that are designed to improve the accuracy of pathology reporting. Alternative 
testing strategies are suggested to maximise the likelihood of patients being given the 
correct treatment as a result of their diagnosis and WM histopathology ensure that no 
malignancy on specimens is missed so that patients are considered for re-operation as 
appropriate. IPE is driven by its ability to reduce the number of second surgeries and patients 
having to return for re-operation. These types of interventions result in time savings in the 
management pathway to both the patient and clinicians, however these were not measured. 
Zanocco et al. (2013) used estimates of sensitivity and specificity and conclude that their 
intervention is not cost-effective.  
The use of decision modelling to model the costs and benefits of the pathology interventions 
onto treatment selection and thus onto patient outcomes was the most commonly used 
approach. None of the eligible studies were RCTs where patients are randomly assigned to 
the intervention and comparator arms.  
Pathology labs are involved in the diagnosis of disease so that the accuracy of the different 
pathology interventions that are being evaluated to guide treatment is at the heart of all the 
differences in costs and benefits measured between the intervention and its comparator. It 
is vital these are measured accurately and truly represent the underlying differences 
between the approaches under evaluation. All the eligible studies that reported accuracy, 
did so in the form of sensitivity and specificity estimates. Whilst most used a single pair of 
accuracy estimates taken from the published literature to inform their models, two studies 
used multiple estimates of sensitivity and specificity. Elkin et al. (2004) estimated a weighted 
average across more than one study for each accuracy parameter and Lee et al. (2011) rather 
than averaging or pooling accuracy estimates used each independent pair to inform their 
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model and so generated a range of cost-effectiveness results. No study used the 
recommended approach of meta-analysis to pool estimates from more than one study 
(Haidich, 2010) . 
A limitation of this systematic review is its inclusion of cancer patients only as the study 
population of interest. A broader approach to the systematic review beyond cancer could 
perhaps have identified a greater number of examples of pathology innovation that have 
been evaluated, since pathology interventions can have far-reaching consequences. 
However, this would have been a very broad study and would not meet the objectives of the 
thesis, which is focused on cancer patients and improvements in their management through 
pathology interventions.  
Even though the modernisation of pathology labs has been at the centre of policy 
recommendations since 1999, there were no UK based studies. Several pathology 
modernisation initiatives are currently being rolled out across England. Consolidation of 
pathology services through centralisation of the workforce and the use of large-capacity 
automated systems is a project that has been proposed and endorsed by the two Lord Carter 
reports  (Karakusevic et al., 2016). Satta and Edmonstone (2018) have identified cost savings 
in laboratories that have adopted consolidation methods when compared to labs that have 
not. They did not explore beyond the cost implications, to measure and value changes in 
accuracy and time when pathologists adopt a consolidated approach to working in the lab. 
A second initiative supported and endorsed by the UK government is the digitisation of 
pathology services. The UK government has recently invested in five new centres of 
excellence for digital pathology (DP) (Gov.UK, 2018) yet there are no economic evaluations 
of this intervention. DP is expected to have impacts on pathology workflow and accuracy 
especially when computer image analysis (IA) methods are used alongside. A recent survey 
of DP usage within the UK found approximately 60% of participating institutions to have 
access to a DP scanner but in most cases only applied its usage to teaching and research 
(Williams et al., 2018b). While many of the pathology departments agreed that the use of DP 
was priority within their institution, 82.5% of the respondents highlighted financial cost as a 
barrier to the use of DP. The institutions that responded identified data proving the 
intervention as cost-saving to be a strong enabler of its introduction (Williams et al., 2018b).  
DP is a generic pathology process that will have wide reaching impacts across many disease 
areas but in particular for cancer patients, enhancements in pathology workflow will 
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contribute to earlier diagnosis in secondary care and improvements in accuracy owing to IA 
can contribute to better management of disease.  
To start to put-together an economic case to justify the use of DP its impacts must be mapped 
onto patient outcomes through the use of economic evaluations that measure changes in 
both costs and benefits. Due to the scope of the impacts of DP, this can only be done within 
one disease area at a time. The focus of the thesis is on cancer patients, but even within 
cancer there are many management and treatment pathways that maybe influenced.  
The majority of the published research identified and included in the study was related to 
breast cancer treatment and diagnosis. Breast cancer accounts for 15% of cancers in the UK 
(Cancer Research UK, 2015).  It is the most common cancer and one of the most funded 
cancer research areas (Carter and Nguyen, 2012), it bears one of the largest burdens on 
society.  Any interventions such as DP that can contribute to improving outcomes for this 
group of patients is welcome.   
In conclusion, the systematic review highlighted the lack of economic evaluations that 
investigate the costs and benefit impacts of innovations in pathology. The remainder of this 
thesis is dedicated to exploring the cost-effectiveness impacts of digital pathology for breast 
cancer patients.  
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Chapter 3: An introduction to digital pathology 
The Royal College of Pathology defines Digital Pathology (DP) as “the use of whole slide 
imaging to create a digital image that can be used for diagnosis, education and research and 
will facilitate the development of pathology networks and the introduction of image analysis 
to assist pathologists in their work” (RCPath, 2018a). Digitisation is set to overhaul long 
established pathology systems and processes. Impacts of its implementation are anticipated 
to not only be felt in the day-to-day routine practice of the laboratory and in the approaches 
adopted by pathologists for reporting on  tissue specimens, but further beyond these, 
influencing how clinicians diagnose disease and in turn how patients’ treatment is managed.   
When analysing the impacts of DP, a holistic view of the patient pathway needs to be taken 
to ensure all effects are captured and measured. There are three angles to the logic behind 
supporting DP adoption; all keeping patient outcomes at the core of their reasoning. Firstly, 
DP has the potential to accelerate the availability of pathology reports by enhancing 
efficiency within the laboratory  (Griffin and Treanor, 2017), the time to diagnosis and 
treatment are cut-back and patients are discharged earlier. Secondly, diagnostic accuracy is 
central to the management of disease; it is essential digitisation of pathology systems does 
not undermine the current precision levels of a pathologists’ reporting.  DP systems should 
support and where necessary enhance the pathologists’ performance. Computerised image 
analysis (IA) algorithms have the potential to enhance diagnostic accuracy beyond 
equivalence; contributing to a quantifiable improvement in accuracy when used together 
with DP systems that are already in place.  The use of DP and IA allows the adoption of a 
quantitative measure rather than the current subjective approaches to measuring the 
underlying features and histological characteristics of tissue specimens (Webster and 
Dunstan, 2014). Clinicians use these results to plan treatment specific to each patients’ 
individual needs; laying the foundations for better management of disease and improved 
patient outcomes. Finally, DP can serve as a platform for the development of innovative 
approaches to the measurement and quantification of disease including the identification of 
novel biomarkers (Madabhushi, 2009); facilitating the illustration of a comprehensive 
overview of the individual patients’ underlying disease characteristics, beyond what is 
currently possible. Clinicians can use this information to further advance the concept of 
personalised treatment management thus improving patient health outcomes.   
While pathology has a significant role to play in the diagnosis, treatment and management 
of all diseases, the ripple effect of pathology digitisation will be experienced to variable 
38 
 
degrees across different disease areas. The scope of the impacts of DP are largely dependent 
on the inherent shortcomings of each disease pathway, these will differ from one to another. 
For example; if a specific biomarker is known to be associated with poor diagnostic accuracy 
on subjective microscope scoring, DP has the potential to contribute to the elimination of 
errors and improved treatment management for these patients. While for another disease 
the weakness in the pathway may be related to the speed at which the disease develops, so 
DP’s potential to contribute to laboratory efficiency, and a timelier reporting of results will 
have the greatest impact on patient outcomes here.  
The remainder of this chapter is divided into two sections. The first is dedicated to describing 
the fundamental features of digitisation that allow it to influence the time to the pathology 
report being ready. The second section summarises the accuracy implications of digitisation 
specifically from the breast cancer patients’ perspective.   
3.1 Speed 
Speed can be considered a universal effect of DP, efficient laboratory systems will feed into 
the tissue management processes of all arriving specimens regardless of the disease area. 
Differences in the effect size will arise when evaluating the consequent clinical impacts, for 
some disease areas these are likely to be more pronounced than others. Figure 3-1 provides 
an overview of the ways by which DP can influence speed in any pathway. 
Figure 3-1 Summary of the speed impacts of digital pathology  
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The effects can be split into 3 groups, through digital pathology’s impact on Multi-disciplinary 
Team (MDT) meetings that take place to discuss patient management, workflow within the 
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pathology lab and beyond the lab to the mechanisms of interaction with other pathologists 
and pathology departments. A detailed description of each of these follows.  
3.1.1 The laboratory workflow 
Currently tissue specimens arrive at pathology labs and glass slides are prepared for analysis 
by a pathologist using a conventional microscope (CM). The slide preparation phase will be 
identical for DP but will include an additional step to scan the glass slides prior to the 
pathologist viewing these on a computer screen rather than under a microscope, as 
illustrated in figure 3-2. The inclusion of a scanning step in theory is expected to extend the 
period from the point the glass slide is ready to the point results are reported, in essence 
delaying rather than speeding pathology processes. Together with the expected increase in 
cost these time delays will undoubtedly be seen as an obstacle to the adoption of DP; 
deeming it at outset an unjustifiable technology for investment. 
As tissue specimens move through the pathology lab they are subject to both diagnostic and 
non-diagnostic activities, before the final report with pathology results is available.  The non-
diagnostic phase encompasses all steps involved in the management and handling of the 
tissue specimen from the point it arrives at the pathology lab to the point a slide reaches the 
pathologist for reporting; whether as the original glass slide or in a digital format.  The 
subsequent diagnostic phase covers the steps from glass or digital slide arrival at the 
pathologist’s desk to the pathology report being ready. 
3.1.1.1 Non-Diagnostic Phase 
Pathologists play a vital role in diagnostic processes; based on their findings treatment 
decisions are made and implemented. Yet fundamentally, the diagnostic role of the 
pathologist follows the equally significant non-diagnostic steps that take place prior to the 
slides reaching their desks. Inclusion of a scanning step will affect the earlier non-diagnostic 
slide preparation phase of the tissue specimens’ pathway. Nonetheless, DP advocates 
deliberate extensively and are optimistic about the consequences of digitisation on non-
diagnostic activities in pathology labs..  
This non-diagnostic period will include all the events from specimen receipt to the point of 
slide arrival with pathologist. These tasks are generally related to a cases’ slide preparation, 
organisation and management, and are chiefly the responsibility of non-pathologist staff. 
Digitisation will influence this phase in two ways,  firstly the processes of preparation and 
organisation in the steps leading up to arrival at the pathologists’ desk for analysis are 
predicted to run more efficiently and secondly through the introduction of flexibility in the 
way the pathology workload is allocated when changing over from physical to digital slides.  
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Figure 3-2 Conventional microscope versus digital pathology processes 
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Focusing on case organisation and management, the literature describes several potential 
points in the pathology non-diagnostic workflow that can be advanced with DP. Once 
scanned, images are immediately available to be viewed at any computer screen in the lab, 
without these having to be picked up by or dropped off to the pathologist; saving time in the 
process (Griffin and Treanor, 2017). Most cases will have more than one associated glass 
slide; these are better organised when digital since they are now easily stored together 
reducing the possibility of misplacement and labelling errors (Williams et al., 2017). Images 
can eventually be attached to the corresponding pathology report on the hospital storage 
systems (Stathonikos et al., 2013). Both implications remove the anxiety and time loss in the 
laboratory when managing the consequences of loss and breakage since DP eliminates the 
risk of these occurring.  Staff will also have more control over the prioritisation of cases for 
reporting; when scanning glass slides with DP it is possible to fast track urgent cases using 
the methods adopted by Thorstenson et al. (2014). They loaded glass slides during the 
working day onto the scanner in smaller batches so that where necessary urgent cases can 
be incorporated in each batch leaving a large non-urgent batch to be loaded at the end of 
the day and scanned through the night ensuring these are ready for pathologists the 
following morning, thus utilising the non-working hours of the day.  
When focused on flexibility in the way the workload is allocated, developments will be seen 
through the ability of pathologists to access a central pool of digital cases. With CM, a 
pathologist receives a tray of glass slides for diagnosis (Griffin and Treanor, 2017), in some 
instances these sit on desks awaiting examination particularly when pathologists are 
involved with other tasks. This prevents other pathologists who may be free during this time 
from accessing these same slides and they too will receive a different tray of glass slides for 
analysis. Digitisation removes the spreading of glass slides across various desks pending 
pathologist attention (Stathonikos et al., 2013). DP will allow a pathologist who is ready to 
report to retrieve work from a pool of digital cases moving to a pull rather than a push system 
of workload allocation. Time is no longer wasted on cases awaiting a free pathologist and are 
reported on a first come first serve basis. Incidentally, it will be possible to monitor and 
review the time it takes from slide scanning to report ready, identifying the weak points in 
the system and so enabling the continual improvement of pathology workflow. Pathologists 
will also be able to promptly share slides with colleagues especially when seeking a second 
opinion on ambiguous cases, eliminating the need to move slides between desks and so 
saving time here also.  
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Vodovnik (2016)’s study did not formally measure the time differences in non-diagnostic 
pathology, but suggested based on their observations that they would expect at least a 10% 
time saving in the overall pathology specimen pathway due to the impact on the non-
diagnostic components of the specimen workflow. They equated this time saving to an 
additional 350 cases per year. Beyond this inference, no further research has been carried 
out to measure and quantify the difference, specifically in the non-diagnostic pathology time 
between DP and CM.  
Even though the positive impacts of DP on the non-diagnostic steps have not been officially 
measured, these will undoubtedly, together with the time saving outcomes seen in the 
diagnostic phase contribute to overall improved efficiency in the laboratory workflow.  
3.1.1.2 Diagnostic Phase 
Vodovnik (2016) measured the time from slide ready to pathologist report generation and 
found on average a 6% reduction in this diagnostic period when digital was compared to 
microscope. This outcome suggests that pathologists will in fact be able to give a diagnosis 
on a greater number of cases in the equivalent time.  Vodovnik (2016) predicted that each 
pathologist would report on at least an extra 250 cases per year when simply observing the 
impacts of DP on diagnostic time, as a result enhancing productivity and the overall efficiency 
of pathology labs. When combined with their projected outcomes for the non-diagnostic 
phase, in total each pathologist is expected to report on an extra 600 cases per year as a 
result of digitisation. Stratman et al. (2010) time and motion study further supported these 
conclusions; showing a 13.4% improvement in the pathologists’ diagnostic efficiency with DP 
apparatus in place. This is approximately an increase of 1.5 cases per day for every full time 
pathologist (Ho et al., 2014).  
The time saving inferences in these studies are attributable to a variety of factors as 
described by Williams et al. (2017); these include:  
(1) The ability of the pathologist to switch between the various slides of a case 
instantaneously without having to physically load these onto a microscope  
(2) All activities in the diagnostic process are carried out on a computer screen without 
having to alternate between this and a microscope  
(3) Slides can now be annotated on screen so any measurements are quicker to carry 
out  
(4) Pathologists no longer have to adjust the microscope when examining slides, saving 
time here  
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(5) Pathologists are able to immediately retrieve and view older slides digitally 
especially when dealing with recurrent cases  
(6) Pathologists can access and view molecular test slides concurrently with histology 
slides  
While these appear to be humble modifications; combined they make for an altogether 
smoother reporting experience for the pathologist and hence bring about the results 
described by both Vodovnik (2016) and Stratman et al. (2010)’s studies. It is already apparent 
digitisation can be a means for pathologists to manage a greater workload and potentially 
reduce the impact of staff shortages. DP can in principal contribute to improving the 
productivity of the pathologist. 
The measured time savings in the diagnostic period are promising for DP but they do not 
consider the additional scanning steps involved with DP during the non-diagnostic phase. 
While studies have measured the effect of digitisation on the diagnostic time, no literature 
was found exploring the overall time changes or the anticipated increase in capacity in 
pathology labs when taking into consideration the impact of DP on both diagnostic and non-
diagnostic activities. No formal analysis has compared the extra time needed for scanning 
with the time saved due to the overall improved workflow in pathology labs. Nonetheless 
based on the presented evidence it is safe to conclude that the time saving will outweigh the 
time gains seen with digitisation. On any given day, a pathologist will have a greater number 
of available slides to examine as well as have the capacity to analyse and diagnose a greater 
number of cases. Consequently, a larger number of patients are ready for discussion at the 
next available Multi-Disciplinary Team (MDT) meeting and so a care plan can be agreed 
sooner influencing patient outcomes.  
3.1.2 MDT meetings 
MDTs have brought many benefits to patient care due to clinician collaboration on diagnosis 
reducing the number of errors (Kane and Luz, 2013), as a result there is a growing demand 
for these meetings.  Hospitals are frequently setting up new MDTs as well as increasing the 
frequency of those existing (Kane et al., 2007), consequently clinicians are dedicating a 
greater amount of their limited time in attendance and preparation for these as well as 
reporting on a larger number of cases. The digitisation of pathology systems is reported to 
influence MDT meetings both directly and indirectly.  All improvements in the pathology lab 
workflow discussed previously are likely to have a knock on effect on this part of the patients 
care pathway.  Since evidence shows an increase in lab productivity this inevitably leads to a 
greater number of cases being ready and available at MDT for discussion sooner. 
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Simultaneously, instances where patients are due to be discussed but pathology reports are 
not ready are largely diminished. Clinicians save time in picking up a case only for it to be 
deferred to the following meeting due to missing pathology data.  These are indirect 
methods by which digitisation will influence MDT. An increase in the availability of cases to 
be discussed due to digitisation in pathology will further burden meetings, potentially 
causing a backlog especially when they are already at full capacity.  
Some of the ways in which to ensure MDT meetings run with greater efficiency in order to 
be able to accommodate the increased work load resulting from pathology digitisation and 
make better use of clinicians’ time will come as a direct consequence of digitisation itself. A 
survey by the National Cancer Action Team (Taylor and Ramirez, 2009) found less than 75% 
of MDTs had the technology in place to project images from glass slides. This no longer 
becomes an issue if slides are already on a digital platform since it is safe to assume all 
hospitals will have the apparatus in place to project images from a computer screen. The 
survey of MDT members also found over 98% of participants strongly agreed that they 
needed access to retrospective images and pathology reports (Taylor and Ramirez, 2009). 
With DP, all images and reports associated with the patient can be retrieved and viewed 
instantly; decreasing the number of MDT deferrals to give time for laboratory staff to locate 
the required information. The prompt accessibility of pathology images is of great benefit 
particularly when discussing recurrent cases and images related to a previous episode need 
to be brought up. DP will allow clinicians to view all slides for the case concurrently without 
loading slides individually onto a microscope (Stathonikos et al., 2013); an even greater 
benefit to teams without access to microscope projecting facilities who would normally 
group around a microscope to view more than one glass slide. Prior to the meeting glass 
slides are normally located and picked up by a staff member for cases due to be discussed at 
MDT, this takes less time with digitisation since physical slides are not collected and only 
digital images organised (Williams et al., 2017). All MDT members are able to view 
annotations made by the pathologist of clinically interesting findings they would like to 
highlight (Thorstenson et al., 2014) since these can now be made directly onto the slides with 
DP, supplementing the information available for treatment management. 
While it is difficult to quantify the direct influence on productivity with each projected use 
value to MDT, there is proof to support meetings running with greater efficiency with DP 
apparatus in place. A study exploring the experience of DP introduction at a Swedish hospital 
(Thorstenson et al., 2014) provided evidence MDT meetings were managed with greater 
effectiveness resulting in a 66% increase in productivity.  Each case was discussed in less time 
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and so in the 90 min allocated time for the meeting, 25 cases had agreements in place for 
next steps of action rather than the usual 15 cases complete in the same time slot.  
3.1.3 Reporting beyond the laboratory 
There are several circumstances under which pathologists have to send slides away for 
external reporting. A case may be difficult to interpret and so a second opinion is sought or 
the opinion of subspecialty pathologist is needed but not available on site and so the case 
needs to be sent away for assessment (Têtu and Evans, 2013). Currently glass slides are 
delivered at additional cost and time, with the risk of damage along the way. The same 
applies when pathology labs do not have the required facilities to carry out certain molecular 
tests and so the glass slides must be sent away for reporting. With DP, scanned slides can be 
sent electronically reducing the time it takes to get an external opinion from days to hours 
(Al‐Janabi et al., 2012) thus allowing for the swifter reporting of results while preserving the 
glass slides. 
Digitisation will allow a more malleable approach to work load allocation as described earlier, 
this is further augmented by the potential flexible management of pathologists. Offsite 
reporting with DP can be a way in which to overcome current staff shortages. Without the 
need for a microscope pathologists no longer have to be at a desk to report on a case but are 
able to examine and give a diagnosis from anywhere and at any time as long as a computer 
screen with the appropriate software is available, since glass slides are no longer needed and 
digital images are sufficient for diagnosis (Maras, 2015). This opens the door for more flexible 
working practices allowing pathologists to work from home or work part time or from 
different locations (Ho et al., 2014). DP will enable outsourcing of excessive work due to staff 
shortages since it is now possible to achieve a diagnosis  within a reasonable amount of time 
(Thorstenson et al., 2014). This has already to an extent been seen in Sweden where Kalmar 
hospital scan all their slides citing the need to work with other labs owing to the country wide 
shortage of pathologists (Pantanowitz et al., 2011). In future, the creation of central 
pathology hubs incorporating pathologists across all specialities will be the epitome of 
efficiency in pathology practice. Hospital labs are able to scan and send slides here for 
reporting ensuring the improved consolidation and management of workload across all 
hospitals in a trust.  
No study explored the effect of flexible pathology workforce management on productivity 
but a search of the literature found one investigation exploring DPs impact on external 
reporting time.  Vodovnik (2015) compared distance reporting with digital to onsite reporting 
using a microscope; they found DP reduced the average reporting time to 3.13 days 
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compared to the current 3.90 days with a microscope onsite. The proportion of cases 
reported in 3 days or less increased from 40.56% to 72.25% with external digital reporting. 
Pathologists can deliver a diagnosis sooner using DP remotely than when using a CM onsite. 
This study did not compare current distance reporting processes using CM and so did not 
take into account the current activities involved in the delivery of slides which include 
packing, delivery offsite, unpacking and delivery to second pathologist (Sectra, 2015).  
Preferably Vodovnik (2015) should have compared distance reporting using DP with current 
distance reporting practices; undoubtedly an even greater time saving would have been 
observed. 
3.1.4 The patient experience  
A patient with suspected cancer progresses through a series of appointments and tests in 
both primary and secondary care as illustrated in figure 3-3, before true disease status is 
confirmed and the appropriate treatment interventions are made.  
Figure 3-3 Overview of the patient cancer pathway 
 
 
 
 
 
 
Minimising the intervals between each point in the pathway guaranteeing diagnosis and 
treatment initiation as soon as possible is of immense importance both to the patient and to 
the NHS. UK cancer survival rates fall behind many other countries with delays in diagnosis 
and treatment as one of the causes for this discrepancy (Foot and Harrison, 2011). Even what 
may seem to be humble decreases in any unnecessarily prolonged period of the cancer 
pathway could result in cancer diagnosis treatment initiation before metastatic growth 
(Roope and AFOM). Evidence for time savings during both the diagnostic and non-diagnostic 
phases of the specimens’ pathology pathway, efficiency savings in MDT and time savings 
when reporting beyond the lab have all been reported with digitisation.  These factors affect 
the time period between presentation in secondary care and diagnosis. It is unlikely DP will 
influence any other phase of the patient pathway.  Secondary care delays up to point of 
diagnosis fluctuate between cancer type and vary dependent on source of referral (Allgar 
Presentation in 
primary care 
GP referral 
Presentation in 
secondary care Diagnosis 
Treatment 
DP Impacts 
47 
 
and Neal, 2005). GP referred cases experience greater delays in this period than those cases 
presenting through screening and colorectal cancers take nearly twice as long on average 
than suspected breast cancers to reach a diagnosis (Allgar and Neal, 2005).  Digitisation can 
be an avenue through which to explore levelling this period across all cancer types regardless 
of the point of referral.  With DP patients will benefit through having their pathology reports 
available earlier, thus a case can be discussed at MDT with a care plan agreed and treatment 
initiated sooner.   
Waiting for results can be an anxious period for many patients; a systematic review focusing 
on anxiety during the diagnostic phase of suspected breast cancer found overwhelming 
evidence to support this (Montgomery and McCrone, 2010). Any attempts to shorten this 
period will have positive impacts on patient wellbeing especially for those cases confirmed 
to be benign on diagnosis; patients can return to normal life no longer worrying about the 
prospects of undergoing further cancer treatment. As well as anxiety, prolonged periods at 
this point can be an inconvenience for patients especially if not managed appropriately. It is 
recommended patients are scheduled for outpatient appointments (OPA) on the same or 
following day of the MDT meeting where their case is discussed (National Cancer Action 
Team, 2010).  It is expected that all required reports including those from pathology will be 
available with the MDT to plan the course of action, enabling a clinician to communicate this 
to the patient during the upcoming OPA. Unfortunately, some cases are not discussed at 
MDT due to instances of missing pathology information.  These cases are inevitably 
postponed to the following meeting yet the patient is still due to come in for their scheduled 
OPA. In this scenario, patients are merely informed their results are not complete and so 
their OPA is rescheduled. This wastes both clinicians and patients’ time and enhances anxiety 
already experienced while awaiting confirmation of their disease status. For the patient, DP 
potentially signifies enhanced quality of life through reduced anxiety, inconveniences 
avoided and most importantly better survival outcomes.   
3.2 Accuracy 
Diagnostic accuracy measures express the nearness of the pathology result to its true value 
(Raab and Grzybicki, 2010), interpretations of pathology slides resulting in a diagnosis that 
does not reflect the underlying disease state (Raab et al., 2005) can influence a patients’ 
treatment therapy.  Improvements in diagnostic reporting accuracy lead to either prescribing 
treatment that previously would have been missed or avoiding treatment that would 
otherwise have been given incorrectly.  
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Unlike the speed implications of DP previously discussed which feed into all sorts of disease 
pathways, accuracy implications are specific to disease areas. Each disease area will have a 
unique set of histological features and disease characteristics that need to be measured for 
clinicians to make a diagnosis and to plan treatment. Dependent on the current reported 
accuracy with CM for each of these, DP systems have the potential to at least provide non-
inferior results by measuring diagnostic concordance and where possible enhance the 
pathologist’s reporting for those particular categories with recognised deficiencies by 
measuring diagnostic accuracy. These effects can only be quantified independently by 
disease area due to the breadth and scope of the influence pathology has within medicine. 
The remainder of this chapter will review the available research evidence for accuracy 
implications of DP from the perspective of the breast cancer patient.   
Numerous results are included in the pathology reports of breast cancer patients; 
pathologists grade the cancer, measure the tumour size and margins, determine lymph node 
(LN) involvement and score both the ER and HER2 biomarkers. Only when all this information 
is available can clinicians plan and design the treatment package appropriate for the patient. 
Khazai et al. (2015)’s study retrospectively reviewed 1970 breast cancer cases referred to 
their cancer centre for second review during 2010. They found 11.47% of all cases to have 
significant discrepancies between the original report results and those in the second review, 
corresponding to 225 patients diagnosed wrongly or given incorrect treatment. These 
discrepancies will undoubtedly affect patient care and outcomes. The quantitative rather 
than subjective approach to scoring taken with DP can in theory contribute to the reduction 
of inter-observer variability and enhance the precision of the pathology results reported.  
Numerous validation studies have compared the diagnostic accuracy of pathologists when 
examining and reporting on tissue specimens using digital slides to when this is done directly 
on the original glass slide using a microscope. Mills et al. (2017)’s evaluation examined 510 
surgical pathology cases across five different organs; accuracy levels were similar across both 
methods. Snead et al. (2016)’s validation study also proved digital accuracy to be non-inferior 
to microscope when they analysed the results for 3017 cases reported on by pathologists 
using both approaches. A systematic review by Goacher et al. (2016) reported a mean 
diagnostic concordance rate of 92.4% based on 38 studies comparing CM and DP that met 
its inclusion criteria.  
There are likewise several studies comparing CM and DP specifically focused on breast cases. 
A recent randomised study compared the accuracy of breast pathologist’s reporting on glass 
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slides to the digital set-up (Elmore et al., 2017), using a consensus reference standard. The 
study authors found the accuracy of the results observed using glass slides to be 3-5% 
superior, undermining the adoption of DP systems. However, they do acknowledge the 
pathologists’ lack of experience with using DP as a possible explanation for this discrepancy.   
A validation study that also focused on breast pathology reported 98.8% clinical concordance 
when comparing CM and DP (Williams et al., 2018a). All pathologists that were involved in 
studying the breast cases were initially provided with one-to-one training and were required 
to view and discuss a training set of twenty challenging cases before they proceeded onto 
live diagnoses using the digital platform (Williams et al., 2018a).  Three further studies 
compared CM to DP diagnoses on breast pathology cases.  Al-Janabi et al. (2012)’s study 
reported a 93% concordance level between both approaches. Of the discrepant cases, only 
1% would have clinical implications for the patients and their outcomes. Campbell et al. 
(2014) reported an overall concordance rate of 97% when comparing reporting on breast 
cases using DP to using CM. Finally, Reyes et al. (2014) included three pathologists, each 
examining the same slides under a microscope and on a screen. Their concordance rates 
were 99%, 99% and 96%.  
The evidence so far supports the non-inferiority of DP when compared to CM for diagnosing 
breast cases. However most studies did not focus on the accuracy implications of the 
individual histological features that are scored to make the overall diagnosis. These need to 
be measured for both conventional and digital slides independently and compared to a 
reference standard to highlight where DP will make the most difference to the pathology 
reports of breast cancer patients and thus their diagnosis and treatment.  
Figure 3-4 Summary of the areas of potential accuracy gains with DP 
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Figure 3-4 provides an overview of the potential accuracy gains reported in the literature for 
breast cancer patients when digital pathology systems are in place. They centre on 
improvements in tumour grading, determination of lymph node status, scoring molecular 
biomarkers and measuring tumour size.  The remainder of this section summarises the 
evidence for each of these.  
3.2.1 Biomarker profile 
There are three tissue based biomarkers that are routinely measured and analysed in order 
to plan breast cancer treatment, these are oestrogen receptor (ER), progesterone receptor 
(PR) and human epidermal growth factor 2 (HER2) (Ulaner et al., 2016).  
3.2.1.1 ER/PR 
The overexpression of ER/PR will guide hormonal treatment in breast cancer patients. 
Patients with low levels of these biomarkers will not benefit from hormonal therapy whereas 
patients with raised levels will respond to treatment. It is essential that these are scored 
accurately to avoid cases of over or under treatment and thus ensure the best possible 
outcomes for breast cancer patients.  
UK-NEQAS determined the frequency of ER/PR positivity by analysing data submitted by 200 
of its UK laboratories. According to this audit, in the UK 73.42% of breast cancer cases are ER 
positive and 58.1% of breast cancer cases are PR positive (Rhodes et al., 2000a), however 
high levels of variability in positivity rates exist between laboratories (Rhodes et al., 2000b). 
Hammond et al. (2010) set out a series of practice guidelines and recommendations to 
overcome these inconsistencies; these included the endorsement of the use of quantitative 
IA techniques for scoring ER/PR.   
Testing for ER/PR is carried out using immunohistochemistry (IHC) staining, considered the 
gold standard in scoring for breast cancer cases (Yaziji et al., 2008). In essence, this identical 
staining method is used across both approaches and the difference lies around the medium 
the pathologist uses to examine these identical slides. However with DP, pathologists have 
the opportunity to use IA algorithms to support their reporting, allowing for a more 
quantitative approach to biomarker scoring (Madabhushi and Lee, 2016). 
Nassar et al. (2011b) analysed inter-observer variability for six pathologists across two sites, 
each scored ER/PR using both conventional and digital IA. They found reproducibility of 
results with IA superior to that achieved with current microscopic examination. Lloyd et al. 
(2010) reported 100% equivalence in their study comparing pathologist’s subjective ER 
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scoring to results attained using quantitative IA. Turbin et al. (2008)’s study also presented 
evidence for consistent concordance between IA and microscopes for scoring ER.  
Many of the studies evaluating the impacts of digitisation on ER/PR results do not calculate 
diagnostic accuracy parameters such as sensitivity and specificity but rather examine 
concordance between and reproducibility levels across both approaches. Measuring the 
accuracy of IHC scoring for the ER/PR biomarkers, whether with CM or DP is challenging due 
to the lack of test that can be considered the reference standard against which comparisons 
can be made. Using pathologist’s subjective scoring as the reference standard in assessing 
the analytical validity of the quantitative scoring of newer IA algorithms is problematic 
(Aeffner et al., 2017), this assumes subjective scoring to represent the height of accuracy.  
Suggestions have been made for the use of pathologists’ consensus score or a combination 
of pathologist and IA scoring as the reference standard, since together they are expected to 
be superior to each alone, thus combining the strengths of both methods (Aeffner et al., 
2017).  
While there is perhaps evidence to support equivalent or enhanced precision with digital IA, 
it is not so obvious if there are advances in accuracy. 
3.2.1.2 HER2 
Herceptin treatment is recommended as part of the care plan for HER2 positive breast cancer 
patients, whereas negative cases will not respond to this treatment.  Herceptin is an 
expensive drug with an associated risk of cardio-toxicity, so it is essential results from 
pathology labs are accurate enough to guide treatment, limiting side effects to the patient 
and costs to the NHS. The guidelines for HER2 testing in breast cancer recommend the use 
of IHC staining as the first step in determining HER2 status, with FISH used where results are 
inconclusive (Rakha et al., 2014).  Unlike ER/PR testing, where no test exists that is thought 
of as the reference standard, for HER2 testing FISH has been correlated with superior 
accuracy and is more likely to generate reproducible results when compared to IHC (Ross, 
2011), for these reasons it is generally considered the gold standard in HER2 testing.  
DP systems have the potential to bring IHC HER2 results closer to those of FISH HER2, 
ensuring a greater number of breast cancer patients are prescribed Herceptin in line with 
their true HER2 status. Several studies have demonstrated greater accuracy of IHC when 
pathologists use IA with DP rather than conventional microscopes (Holten-Rossing et al. 
(2015), Dobson et al. (2010) and Skaland et al. (2008).  
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3.2.2 Lymph node status  
At some point in their pathway, all breast cancer patients will have their LNs examined for 
evidence of metastasis. If a palpable mass is detected in the axilla at the initial screening 
stage, a LN biopsy is taken alongside that from the breast. Otherwise, all patients with 
confirmed breast cancer in their CB will undergo a sentinel lymph node biopsy (SLN) with 
surgery to establish evidence of LN involvement. The SLN is where cancers cells are first likely 
to spread from the breast (Heerdt, 2018) and the presence of cancer cells here is an 
important prognostic indicator for breast cancer patients (Lyman et al., 2005).  
The SLN biopsy replaced the more invasive axillary lymph node dissection (ALND) procedure, 
fewer LNs are removed for analysis with evidence of enhanced identification of metastasis 
in SLN compared to ALND due to the focused nature of pathological examination (Giuliano 
et al., 1995). The accuracy of the SLN biopsy has been extensively researched and proven 
comparable to the gold standard ALND procedure. Miltenburg et al. (1999)’s meta-analysis 
showed a 98% concordance rate between SLN biopsy and ALND and a 5% false negative rate 
across all included studies. Pesek et al. (2012) much larger meta-analysis focused on studies 
only including SLN biopsies with a negative result, they estimated a 7% (6.1 to 7.9%) false 
negative rate using a random effects model for meta-analysis.   
The examination of fewer LNs with SLN biopsies promoted the adoption of more advanced 
techniques for the detection of cancer cells than those used with ALND , this made for a more 
intensive and time consuming pathological examination process (Maaskant-Braat et al., 
2011) increasing the work load on already strained pathology labs. Digital pathology systems 
can be used as a platform for the development of approaches to minimise the challenges 
presenting to pathology labs when examining and reporting on SLN biopsies (Holten‐Rossing 
et al., 2017).  
International researchers were asked to develop computer algorithms for the detection of 
metastases in SLN biopsies of breast cancer patients as part of the Cancer Metastases in 
Lymph Node challenge 2016 (CAMELYON16) (Bejnordi et al., 2017). 32 algorithms were 
submitted, the area under the receiver operating curve (AUC) for metastases classification 
ranged from 0.556 to 0.994 with four algorithms having AUCs that were statistically different 
to the AUC of pathologist scoring (Bejnordi et al., 2017), showing some evidence of increased 
accuracy with computer algorithms. Holten‐Rossing et al. (2017)  also developed a computer 
algorithm for SLN analysis and compared this to standard manual pathologist examination. 
They reported 100% sensitivity and 68.9% specificity i.e. no false negative cases but a risk of 
over treatment due to the false positive cases.  However, their sensitivity and specificity 
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values were calculated using conventional pathologist scoring as the reference standard so 
once again this is analysis of concordance rather than superior accuracy. Holten‐Rossing et 
al. (2017) propose the adoption of their algorithm as a screening tool to separate out the 
negative from the positive cases and use manual assessment on all positives cases which will 
include the false and the true positives. This alone will eliminate 58.2% of the work involved 
in SLN biopsy analysis, Holten‐Rossing et al. (2017) measured and compared the time spent 
on SLN examination using microscopy and using their algorithm. The average time was 
reduced from 6.88 to 2.88 minutes. Due to the already advanced accuracy of SLN evaluation, 
the greater benefit of digital systems to measuring this feature of breast cancers may come 
with the minimisation of the time-consuming analysis process.  
3.2.3 Tumour grade 
Breast cancers are divided into three groups when assigning their grade; grade 1 cancers look 
most similar to normal cells and are slow growing, grade 3 look most unlike normal cells and 
are fast growing and in between are grade 2 breast cancers (Breast Cancer Care, 2018). 
Oncologists consider the breast cancer grade when planning a patient’s neoadjuvant and 
adjuvant treatment; especially when deciding on the administration of chemotherapy. 
However, there are concerns around the lack of reproducibility when grading breast tumours 
(Elston and Ellis, 1991) due to the subjective techniques used by pathologists when assigning 
a grade (Rakha et al., 2018b).   
Boiesen et al. (2000) examined the reproducibility of grade results across seven pathology 
laboratories in Sweden; concordance ranged from 57% to 77% providing evidence for only 
moderate levels of reproducibility between laboratories. Longacre et al. (2006) reviewed 
pathologist’s scoring for each of the individual breast cancer features, including grade. They 
showed evidence of both inter-observer variability; ranging from 12.2% to 38.6% and intra-
observer variability ranging from 0% to 13%. The highest level of disagreements in both 
analyses corresponded to grade 2 tumours. Longacre et al. (2006) also analysed the accuracy 
of the grade classification by comparing the study pathologists’ scoring to that of the study 
chair, which they regarded as the reference standard. The following results were reported 
on the mean and range of accuracy for each grade: 
 Grade 1: 83.3% (75 to 100%) 
 Grade 2: 64.6% (50 to 83.3%) 
 Grade 3: 92.3% (79 to 100%) 
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The highest levels of discrepancy are once more associated with the scoring of grade 2 
tumours. Approximately 17% of cases scored as grade 1 could in fact be grade 2 and thus are 
potentially missing out on chemotherapy treatment. Over 35% of grade 2 tumours are scored 
incorrectly, some of these are likely to be grade 1 and so not considered for chemotherapy 
treatment, while others are expected to be grade 3 and would be routinely given 
chemotherapy treatment. Approximately 8% of grade 3 tumours could in reality be grade 2, 
these patients are not routinely prescribed chemotherapy but their grade is considered 
alongside other characteristics of the breast cancer when deciding on the treatment plan.  
Rakha et al. (2018a) compared the grading of breast cancers when using DP to when 
pathologists use CM techniques. The results reported in their study are adapted to give the 
percentage agreement levels in table 3-1. 
Table 3-1 Agreement between DP and CM when grading breast cancers 
Discrepancies in grading breast cancers 
exist between CM and DP, with the highest 
levels of discordance around grade 2 
cancers. However, the authors have not 
measured the accuracy of each method by 
comparing the results to a ‘gold standard’. From these results alone, it is not possible to 
ascertain whether DP represents a more superior approach to grading or is in essence 
equivalent or maybe even inferior. Rakha et al. (2018b) analysed intra-observer variability 
when pathologists grade each of the digital images a second time after a three-month 
interval. They reported overall a 77% level of agreement when grading breast cancers; 
specifically 77% for grade 1, 70% for grade 2 and 86% for grade 3 cases. These fall below the 
intra-observer agreement rates  described by Longacre et al. (2006) when grading breast 
cancers using conventional techniques, suggesting lower levels of precision with DP 
compared to CM. Nonetheless, it is difficult to make robust conclusions regarding the non-
inferiority of DP to grade breast cancers when very limited primary research is available on 
which decisions can be made.   
Beyond digitisation, computer algorithms that quantify the underlying scores that together 
makeup the assigned grade are anticipated to become available (Madabhushi, 2009). No 
study so far has compared and reported on the grading of breast cancers using computer-
aided quantification to conventional subjective grading.  
Digital  
Microscope 
Grade 1 Grade 2 Grade 3 
Grade 1 85% 31% 3% 
Grade 2 14% 62% 30% 
Grade 3 1% 7% 67% 
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3.2.4 Tumour size 
The size of the breast tumour influences the patient’s treatment plan. It is measured using 
imaging techniques such as mammography or ultrasound prior to surgery. Together with 
clinical examination, clinicians will use the tumour size to decide whether a patient 
undergoes a mastectomy or a wide local excision. DP is not likely to influence the surgery 
recommended but it can play a role in the assessment of tumour margins post-surgery and 
thus the decision for further re-excision. IA algorithms can be used alongside DP systems to 
differentiate between invasive and uninvolved cells within the excision margins (Cruz-Roa et 
al., 2017). While the theory underpinning the use of algorithms with DP is understood, the 
primary research comparing the results of margin analysis using CM with results from digital 
techniques and the consequent impact on re-section rates is limited.  A significant 
fundamental issue in tumour margin analysis is the lack of consensus on the definition of a 
positive margin (Emmadi and Wiley, 2012) and while there are guidelines set by the 
Association of Breast Surgery there is considerable variation in current practice across 
hospitals in the UK and Ireland (Tang et al., 2017). Before the DP impacts on margin 
assessment and the consequent re-excision rate can be determined, breast pathologists 
need to be clear on the underlying thresholds. Validation studies for the measurement of 
this feature of breast pathology reporting are non-existent and further primary research is 
needed before any conclusive decisions can be made on the value of DP with or without IA 
when examining breast margins.  
3.3 Conclusion 
Throughout the current literature it is clear the generation of digital images of glass slides 
alone will not bring about accuracy improvements when measuring the features of breast 
cancer that are required to make decisions around treatment and disease management. DP 
slides are identical to CM slides but they are in principal viewed using different mediums; it 
is only with supplementary technology such as quantitative image analysis and computerised 
scoring techniques that DP can really begin to make a difference to the accuracy of results 
and allow the development of novel diagnostic approaches. Digitisation alone has its greatest 
impact on workflow and laboratory systems, as long as DP systems are proven to have 
equivalent diagnostic concordance without undermining current diagnostic accuracy when 
compared to conventional microscopic techniques, there is an argument to support the 
adoption of digital systems based on efficiency implications alone.  
Knowledge of the individual effects seen with digital pathology are of limited value unless 
the clinical impacts to the patient are known. The time and accuracy consequences of 
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digitisation need to be measured by quantifying the implications they will have for the 
patient, whether digitisation influences their time to diagnosis or time to treatment or 
changes patient care plans as a result of changes to diagnoses. Further research and 
evaluation is needed to give value to the digitisation of pathology through the perspective of 
breast cancer patients by determining the clinical utility of this pathology innovation.  
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Chapter 4: The breast cancer pathway 
4.1 Introduction 
Chapter 3 highlighted the ways by which the digitisation of glass slides can influence the 
examination and the analysis of breast cancer tissue specimens in the pathology lab. 
Whether through its accuracy or time implications; these effects must be measured and 
evaluated whilst keeping the breast cancer patients at the centre of all decision making. The 
differences in pathology results observed when moving from CM to DP are only of true value 
if there is a concomitant measured benefit for the patient. Likewise, efficiency in pathology 
labs as a result of digitisation should be assessed in relation to their effects on the patient. 
Outputs of pathology labs are not directly linked to patients in the same way, as for example 
treatment interventions; pathology results and their availability will guide surgery and 
systemic treatment plans, which will in turn influence patient outcomes. 
In order to be able to identify, measure and give value to the effects of digitisation for the 
patient, it is important to first clearly understand the breast cancer pathway and the 
underlying relationships between pathology and the different events that take place within 
the patient’s course of management in secondary care. An appreciation of this network of 
activities will highlight how modifications and innovations in pathology through digitisation 
will influence patient outcomes. Further to this, mapping the pathway will identify any 
shortcomings in the system that could perhaps be overcome through advances in pathology; 
setting the scene for further research of novel technologies to overcome these shortfalls.   
4.1.1 Information sources 
There are two sources of information that can be drawn from to clearly illustrate the breast 
cancer pathway. Firstly, evidence-based guidelines such as those published by the National 
Institute for Health and Care Excellence (NICE) and secondly, the experiences of clinicians in 
the management of patients under their care. Ideally, clinicians should comply with 
published recommendations so that clinical practice reflects guidelines and all patients are 
offered identical opportunities in the diagnosis, management and treatment of their disease, 
creating an environment of high quality care across all NHS services.  In reality this is not 
always the case and disparities exist in the management of breast cancer patients in the UK 
(Purushotham et al., 2001).  
Guidelines represent tools that can be used by NHS services to ensure consistency in clinical 
practice and management of disease. They are “systematically developed statements to 
assist practitioner and patient decisions about appropriate healthcare for specific clinical 
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circumstances” (Lohr and Field, 1990). They are developed following a meticulous process of 
activities that involve the identification of the best available research evidence through 
systematic review of the literature, consultation with experts and piloting of guidelines to 
establish the feasibility of adhering to them in practice (Thomas, 1999). Guidelines are 
regularly reviewed and updated to reflect the most up to date findings; bridging the gap 
between research and practice.  
While numerous guidelines are available in healthcare for different disease areas including 
breast cancer, avoidable variations in clinical practice are still evident indicating 
inconsistencies in the implementation of evidence-based recommendations. Irregularities in 
care and survival outcomes for breast cancer patients continue to exist across England (All-
Party Parliamentary Group, 2018). This is in spite of previous recognition of this concern and 
the proposal of general health service recommendations in the ‘Five Year Forward View’ 
report by NHS England (2014a) as well as recommendations specific to cancer in the 
‘Achieving World Class Cancer Outcomes’ report by the Independent Cancer Taskforce 
(2015) to overcome variation in care.  Development of guidelines alone is not sufficient, 
systems need to be in place to ensure these are disseminated and implemented 
appropriately (Kennedy et al., 2010).  
The key motivation behind the development of evidence based guidelines is the 
enhancement of quality of care to patients as well as the maximisation of patient health 
outcomes (Woolf et al., 1999). There is evidence that patients managed in accordance with 
guidelines score better on outcomes than those managed based on clinician’s experience 
alone. Sacerdote et al. (2013) recognised the presence of improved quality of care for breast 
cancer patients post implementation of clinical practice guidelines. Furthermore, Andreano 
et al. (2017) demonstrated an increased probability of 5year survival for breast cancer 
patients whose management followed an evidence based care pathway compared to those 
that did not.   
The impacts of interventions in pathology can only be evaluated when there is a clear 
understanding of the relationship between pathology services and other activities in the 
breast cancer care pathway. It is important to first conceptualise the breast cancer pathway 
structure to appreciate the role pathology has to play within the grander scheme of breast 
cancer patient care. Following this, a network of the chain of events starting with pathology 
digitisation as the generic process can be illustrated to depict the transformation of outputs 
from here into target processes, followed by clinical processes and finally patient outcomes. 
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The measurement of patient outcomes must be done within the framework of a pathway 
that is based on both guidelines and practice to ensure precision in the evaluations of 
pathology interventions. When interventions are evaluated within an evidence based 
pathway that may not represent clinical care, this may lead to misleading results especially 
where inconsistencies exist between both. A breast cancer pathway modelled on both 
guidance and practice represents a more realistic depiction of care, based on which 
pathology impacts can be evaluated. Besides an understanding of both versions of the breast 
cancer pathway will identify and highlight the differences between both.  Gaps as well as 
barriers to the application of guidance in practice are recognised and recommendations 
made to remove these.  
4.2 Aims 
There are four aims to this chapter: 
1. To develop an understanding of the breast cancer pathway that is based on both 
guidelines and clinical practice at University Hospitals Coventry and Warwickshire 
(UHCW) 
2. To identify the discrepancies in clinicians’ adherence to published recommendations 
and where possible provide explanations and appreciate the challenges for 
implementation 
3. To visually summarise the activities in the breast cancer pathway and the decisions 
that control the interaction between them to be used as the foundation for 
evaluations of any interventions along the pathway 
4. To depict the network of the chain of events that connect pathology digitisation as 
an intervention to patient outcomes 
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4.3 Methods 
There were two stages to the development of the breast cancer pathway. Firstly, UK 
guidelines and recommendations were used to develop a pathway that reflects evidence-
based guidelines. Secondly, the expert opinion of the clinicians at UHCW involved in the 
management and treatment of breast cancer patients was sought. Two breast cancer care 
pathways were developed so that comparisons could be made between them. Each pathway 
represents the course of activities and the underlying decisions made from the point a 
patient with suspected breast cancer is referred to secondary care to the point of treatment 
planning and initiation.  
4.3.1 Methods for the descriptions of the evidence-based pathway 
An online literature search was carried out to identify all available UK guidelines that are 
designed to be used by clinicians during the diagnosis, treatment and management of breast 
cancer cases. A list of key words was compiled and used in the website searches:  
Breast AND (cancer or HER2 or ER or oestrogen or grade or chemotherapy or radiology or 
pathology or surgery or lymph nodes or Herceptin or invasive or in situ or malignant or early 
or primary) 
 In particular, searches were carried out for NICE guidance, pathways and technology 
appraisals as well as Public Health England (PHE) professional guidance for their NHS Breast 
Screening Programme (NHSBSP). In addition, searches for breast cancer related guidance 
was carried out in the websites of the Royal College of Pathologists, Royal College of 
Surgeons and the Royal College of Radiologists. The websites of the various charities that 
provide information and support to breast cancer patients were also searched. These 
included Breast Cancer Care, Macmillan Cancer Support, Breast Cancer UK and Cancer 
Research UK. Any material circulated by these organisations is based on research findings 
and UK recommendations.  A list of all the publications identified are listed in table 4-1. A 
large degree of overlap was expected between the sources listed, where disparate 
recommendations are made in more than one publication but related to the same step in 
breast cancer management, information from the most recent will be incorporated into the 
pathway. 
All publications were reviewed and information from these extracted to inform the evidence-
based breast cancer pathway. This pathway models the epitome of care quality that NHS 
trusts are expected to adopt in order to maximise patient health outcomes.  
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Table 4-1 List of publications to inform the evidence-based breast cancer pathway 
Source Publication Reference 
NICE Breast Cancer (Quality Standard 12) (NICE, 2011a) 
Early and locally advanced breast cancer: adjuvant 
therapy 
(NICE, 2014) 
Early and locally advanced breast cancer: diagnosis 
and treatment (Clinical Guidance 80) 
(NICE, 2009) 
Early and locally advanced breast cancer overview  (NICE, 2011b) 
Hormonal therapies for the adjuvant treatment of 
early oestrogen receptor positive breast cancer 
(Technology Appraisal Guidance 112) 
(NICE, 2006a) 
Improving outcomes in breast cancer (Cancer 
Service Guideline 1) 
(NICE, 2002) 
Trastuzumab for the adjuvant treatment of early-
stage HER2-positive breast cancer (Technology 
Appraisal Guidance 107) 
(NICE, 2006b) 
PHE NHS Breast Screening Programme: Consolidated 
standards 
(PHE, 2017) 
Quality assurance guidelines for surgeons in breast 
cancer screening 
(NHS BSP, 2009) 
Clinical guidance for breast cancer screening 
assessment 
(Borrelli et al., 2016) 
 
Quality assurance guidelines for breast cancer 
screening radiology 
(NHS BSP, 2011a) 
Quality assurance guidelines for breast pathology 
services 
(NHS BSP, 2011b) 
 
Reporting, recording and auditing B5 core biopsies 
with normal/benign surgery  
(NHS BSP, 2007) 
Royal 
Colleges 
Appendix D : TNM classification of tumours of the 
breast (UICC TNM 8) 
(RCPath, 2018b) 
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Pathology reporting of breast disease in surgical 
excision specimens incorporating the dataset for 
histological reporting of breast cancer 
(Ellis et al., 2016) 
Guidelines for non-operative diagnostic procedures 
and reporting in breast cancer screening 
(Lee et al., 2016) 
Best practice diagnostic guidelines for patients 
presenting with breast symptoms 
(Willett et al., 2010) 
Surgical guidelines for the management of breast 
cancer 
(ABS, 2009) 
Postoperative radiotherapy for breast cancer: UK 
consensus statements 
(RCR, 2016) 
Patient 
Information 
Breast Cancer Care: Understanding your pathology 
results 
(Breast Cancer Care, 
2013) 
 
Breast Cancer Care: Primary breast cancer (Breast Cancer Care, 
2016) 
Understanding breast cancer (Macmillan, 2016) 
Breast Cancer (Cancer Research 
UK, 2017) 
Other Updated UK recommendations for HER2 
assessment in breast cancer 
(Rakha et al., 2014) 
 
4.3.2 Methods for the description of the clinical-practice pathway 
From the evidence-based pathway, it was possible to identify the medical specialities within 
secondary care that breast cancer patients are exposed to. Contact with both a consultant 
and trainee pathologist at UHCW had already been established early on in the study, details 
for the remaining clinicians that are responsible for breast cases at UHCW were requested 
from the pathologists. The clinicians were contacted for interview to seek their expert 
opinion on breast cancer care.  The following clinicians were interviewed to inform the 
clinical-practice pathway: 
 Breast care nurse (surgical) 
 Breast care nurse (oncological) 
 Consultant breast pathologist 
 Consultant breast radiologist 
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 Consultant breast surgeon 
 Consultant pathologist 
 Medical oncologist 
 MDT lead clinician  
 Trainee pathologist 
Semi-structured interviews were carried out with each of the clinicians listed; these 
comprised general questions around breast cancer care in addition to speciality specific 
questions about the section of the pathway relevant to each clinicians’ training area. 
Clinicians were given the opportunity to highlight inconsistencies between guidelines and 
their practice. If any conflicts were identified between guidelines and clinical practice, 
rationalisations for their presence were explored with the clinician through further 
questioning. Where there was ambiguity around steps in the evidence-based pathway, 
perhaps due to absent guidance, these points were also discussed.  
All interviews were recorded and transcribed. As each member of the breast cancer care 
team was interviewed, the evidence-based pathway was updated to reflect the practice of 
clinicians at UHCW. On completion of interviews, the clinical practice breast pathway 
describes current breast cancer care at a large teaching hospital.   
In summary two pathways were depicted in Microsoft Visio, the first representing the breast 
cancer pathway based on guidelines alone and the second on clinical practice. 
4.3.3 Methods for the description of the network of digital pathology processes 
Chapter 3 summarised the published literature exploring the evidence of the impacts of 
pathology digitisation for breast cancer patients, this information was merged with the 
breast cancer pathway that is described later in this chapter. 
The two sources of information were used to design a process pathway portraying digital 
pathology and the processes within the breast cancer pathway it is expected to connect to 
in order to indirectly influence patient outcomes. The resultant pathway is a chain of events 
starting with digital pathology as a generic process and ending with appropriate patient 
outcomes. From the breast cancer pathway, the targeted and clinical processes that sit 
between were identified.  
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4.4 Results 
4.4.1 Evidence-based pathway 
The published guidelines and recommendations for breast cancer management were 
reviewed; these were used to inform the evidence-based pathway. The following section 
describes this. Based on guidelines the patient pathway through secondary care can be 
broken down into several phases as outlined in figure 4-1. Guidelines acknowledge that 
patients with suspected breast cancer can be referred for assessment in secondary care via 
two sources, either through their general practitioner if they present in practice with signs 
or symptoms of breast disease or they can be asymptomatic cases that are referred through 
routine breast screening. First patients should be assessed to determine the nature of their 
disease; this should be followed by a discussion of the case at MDT where management plans 
should be agreed. There are two types of breast cancers, ductal carcinoma in situ (DCIS), 
where cancers cells have not spread beyond the lining of the ducts to surrounding tissue and 
invasive breast cancer (IBC), where cancer cells have spread to the surrounding tissue 
(Cancer Research UK, 2017).  For DCIS cases, the recommendations for management include 
surgical intervention only and for IBC they involve a combination of both surgery and 
systemic therapy.  The guidelines were explicit in defining that each breast cancer type 
should be treated differently. The phases in figure 4-1 can each be further broken down for 
a more granular understanding of the published recommendations that fall under each of 
the assessment and treatment phases of the breast cancer pathway.    
4.4.1.1 Triple assessment 
Assessment of suspected breast cancer cases referred to secondary care for investigation 
should be carried out in the breast clinic during a single hospital visit.  Figure 4-2 summarises 
the three recommended interventions that together make-up the assessment carried out to 
verify breast cancer status. At this stage of the breast pathway all suspected cases are 
expected to be managed in the same way regardless of their source of referral, since it will 
not yet be known if a tumour is IBC or DCIS or whether it is even cancerous.   
Published guidelines divide triple assessment between clinical examination, imaging and 
biopsy. In the first step, the clinician should examine the breast and axilla of the patient for 
any obvious palpable lumps. This should be followed by imaging of the breast to identify the 
location and provide initial indications of the size and multi-focality of the breast tumour. 
Where discrepancy exists between clinical assessment and imaging, guidelines recommend 
an MRI scan is carried out in addition to the initial imaging procedure. If there is obvious 
evidence of malignancy on clinical examination due to the presence of a palpable lump in 
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the axilla, the patient is also recommended to undergo an ultrasound of the axilla. The final 
recommended step in triple assessment involves the removal of a tissue sample from the 
breast by biopsy and only if there is evidence of malignancy on ultrasound of the axilla, a 
biopsy should be taken from the lymph nodes. Decisions at MDT are made based on the 
results of this assessment process.  
Figure 4-1 Steps in suspected breast cancer management based on published guidelines 
Mammographic 
abnormality
Symptoms or signs
Assessment
Figure 4-2
Routine screeningDiagnostic MDT
Normal or definitively 
benign result
Treatment
Significant abnormality
Indeterminate result
Neoadjuvant 
therapy
Surgery
Figure 4-4
Adjuvant therapy
Figure 4-5 & 4-6
Surgery
Follow-up
Invasive breast cancer
Surgery
Figure 4-3
Ductal carcinoma 
insitu
Referral
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Figure 4-2 Guidelines for triple assessment 
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Lymph node 
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No lymph node 
sampling
Normal Abnormal
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4.4.1.2 Breast cancer treatment 
The breast cancer by this stage has been confirmed as either DCIS or IBC and the guidelines 
recommend the commencement of treatment as appropriate. Guidelines for the 
management of invasive and DCIS cases are reported separately. DCIS should be considered 
for surgical and radiotherapy interventions as part of their treatment plan whereas IBC cases 
are recommended a combination of surgical, radiotherapy and systemic interventions 
dependent on various pathology results.  
4.4.1.3 Surgery and radiotherapy  
For DCIS and IBC tumours, surgery is the first-line recommendation followed by other 
therapies where appropriate. Radiotherapy and surgery are closely linked; the decision to 
offer radiotherapy is largely associated with the surgical intervention undergone by the 
patient. Figure 4-3 outlines the surgical and radiotherapy guidelines for DCIS cases and figure 
4-4Error! Reference source not found. and figure 4-5 do the same for IBC cases.  
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Figure 4-3 Overview of surgery and radiotherapy guidelines for DCIS cases 
DCIS patient
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ALND
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Re-excision
Margins <2mm
Margins ≥2mm
High risk of 
invasive disease
No high risk of 
invasive disease
Breast 
Radiotherapy
End of pathway
WLEMastectomy
Area of DCIS too large >40mm
OR
Small breasts
OR
Several areas of DCIS
The surgery recommended for DCIS cases is largely dependent on the size and extent of the 
tumour, mastectomies should be carried out where the ratio of tumour to breast is large 
otherwise patients should undergo wide local excisions (WLE).  On pathological analysis of 
the WLE surgical specimen, a clear margin of at least 2mm is recommended in NICE 
guidelines, if less than this the patient should return to surgery for re-excision until a clear 
margin of greater than or equal to 2mm is achieved.  
68 
 
The guidelines do not endorse axillary staging as routine practice for DCIS patients unless 
they undergo a mastectomy or at high risk of invasive disease where a WLE is recommended. 
The axillary staging should take place alongside their main surgical interventions. High risk 
DCIS patients are defined as patients with a palpable lump in the axilla on clinical 
examination (NICE, 2009). As outlined in figure 4-3, only DCIS patients undergoing a WLE 
procedure are recommended radiotherapy post-surgical intervention.  
The surgical and radiotherapy recommendations for IBC cases are discussed in greater detail 
in the guidelines than for DCIS cases, this is largely due to the underlying nature of this breast 
cancer type. IBC have already spread into the breast tissue when compared to DCIS cases, 
they are treated with greater urgency and as a result these patients are exposed to a greater 
number of tests and examinations and have a more complex treatment and management 
pathway. 
Similarly to DCIS cases, the choice between mastectomy and WLE is based on the size and 
extent of the tumour but no further guidelines are given. Throughout the literature, the 
terms ‘informed decision making’ are used but no threshold on the size of the tumour are 
explicitly stated. It is clear the choice of surgery should be made based on MDT experience 
and informed discussion with the patient. Where WLE has been carried out, consistent with 
DCIS cases, the surgical specimen margins are measured and a cut off of 2mm is 
recommended to determine the need for further re-excision.  
Unlike DCIS cases, axillary staging is recommended routine practice for IBC cases. All patients 
should undergo an axillary surgical intervention alongside their breast surgery, dependent 
on pre-operative assessment and results. Patients with a previous positive lymph node 
biopsy are accordingly recommended an ALND, whereas those with a negative lymph node 
biopsy or no previous lymph node sampling should be considered for a SLN biopsy. Where 
LNs are positive on pathological examination of the SLN, an ALND is recommended as a 
second surgical intervention. The surgical guidelines for IBC patients are summarised in 
figure 4-4. The radiotherapy published recommendations are also extensive for IBC patients 
as summarised in figure 4-5. 
Treatment with radiotherapy is dependent on both the breast surgery undertaken and the 
nodal status of the patient. The guidelines recommend breast radiotherapy following all 
WLEs whereas patients undergoing a mastectomy are only considered for radiotherapy 
subject to their risk of recurrence. Low risk cases are not recommended radiotherapy at all 
and high risk cases are recommended chest wall but not breast radiotherapy, in between 
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patients with intermediate risk are not normally recommended radiotherapy intervention 
but the SUPREMO trial investigates the use of chest wall radiotherapy in this group of 
patients (Kunkler et al., 2008) and so they should be offered the choice to take part in the 
trial.    
Figure 4-4 Summary of the recommended surgical pathway for IBC cases 
IBC patient
WLE Mastectomy
Re-excision
Surgery end
Margins <2mm
Margins ≥ 2mm
Pre-operative 
assessment of size 
and extent of tumour
Pre-operative axillary 
assessment
Axillary staging
SLNB
Axillary treatment
ALND
LNB -ve or No LNB LNB +ve
LN +ve 
(Macro- or micro-metastases)
LN -ve 
(None or isolated tumour cells)
  
Radiotherapy to the axilla is mentioned only when LNs are positive on SLN biopsy but an 
ALND is not possible.  Post ALND, radiotherapy to the axilla is not considered but 
radiotherapy to the supraclavicular fossa is recommended dependent on the number of 
positive lymph nodes after pathological examination of the ALND. 
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Figure 4-5 Overview of the radiotherapy guidelines for IBC cases 
IBC patient
Breast Nodal
Breast 
radiotherapy
WLE
Mastectomy 
high risk of 
recurrence
No breast 
radiotherapy
Mastectomy
low risk of 
recurrence
Chest wall 
radiotherapy
SUPREMO trial
Mastectomy
Intermediate risk 
of recurrence
No axilla 
radiotherapy
LN -ve
Axilla 
radiotherapy
SLNB
LN +ve 
ALND not possible
No axilla 
radiotherapy
ALND
Supraclavicular 
fossa radiotherapy
1-3 +ve LNs
and poor 
performance status
4 +ve LNs
 
. 
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4.4.1.4 Systemic therapy 
Figure 4-6 ER and HER2 therapy treatment guidelines 
 
 
 
 
 
 
 
 
Systemic interventions should be offered to IBC patients only; these are a combination of hormone therapy, Trastuzumab (Herceptin) and chemotherapy. 
The decision to prescribe the first two is relatively straightforward as outlined in figure 4-6. However, recommendations on the chemotherapy regimens to 
be given to IBC patients was not as clear-cut to learn from the guidelines alone. 
 
 
IBC patient only
Pre-menopausal Post-menopausal
ER +ve
Tamoxifen
Aromatase 
Inhibitor
Assess cardiac 
function
HER2 +ve
Trastuzumab 
therapy
No Trastuzumab 
therapy
High risk of 
cardiotoxicity
Low risk of
cardiotoxicity
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Chemotherapy 
Chemotherapy is prescribed by oncologists to reduce the risk of recurrence and improve 
overall survival in women that are being treated for breast cancer (Early Breast Cancer 
Trialists' Collaborative Group, 1998). Whilst Herceptin and hormone therapy are included in 
breast cancer treatment plans in response to the result of a given biomarker test, the 
decision to administer chemotherapy is not as prescriptive as it is for the other systemic 
therapies. Chemotherapy is clearly recommended and discussed throughout the published 
guidelines ((Breast Cancer Care, 2016), (NICE, 2014), (NICE, 2011a), (ABS, 2009), (NICE, 2009) 
and (NICE, 2002)) however the circumstances under which chemotherapy should be 
prescribed and the regimens and dosages to be given were not so clear.  
The most concise summary of the types of patients that should be recommended 
chemotherapy came from Breast Cancer Care (2016)’s patient information leaflet on primary 
breast cancer. Breast Cancer care is a specialist UK charity providing information and support 
to those affected by breast cancer. In the leaflet they list the features of a patient’s breast 
cancer that are most likely to predispose them to chemotherapy treatment: 
 Tumour larger than 2cm 
 Grade 3 IBC 
 LN positive  
 HER2 positive  
Further to this, NICE (2002)’s Improving outcomes in breast cancer publication recommends 
chemotherapy for all women assessed as being at intermediate or high risk of recurrence. 
The risk of recurrence is closely related to the presence of the cancer features listed in Breast 
Cancer Care’s information leaflet.  
Three publications NICE (2014), NICE (2011a) and Breast Cancer Care (2016) reference the 
use of Oncotype DX, a tool that predicts the likelihood of cancer recurrence (Carlson et al., 
2013) in patients with intermediate risk, defined as those with ER positive, HER2 negative 
and LN negative breast cancers (NICE, 2011a). Results of this assay are used to support 
chemotherapy decisions. Overall, it can be deciphered from the published guidelines that 
breast cancer patients with low risk of recurrence should not be routinely prescribed 
chemotherapy since this group is not mentioned in the chemotherapy sections of guidelines. 
Patients with intermediate risk may or may not be prescribed chemotherapy and the 
guidelines recommend the use of prediction tools such as Onctype DX to support clinician 
decision making. Patients with high risk of recurrence are likely to be prescribed 
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chemotherapy. Beyond these relations between risk of recurrence and chemotherapy 
treatment a few other recommendations can also be taken from the guidelines. These are 
summarised in the table below. 
Table 4-2 Summary of indications for chemotherapy in breast cancer 
Hormone status 
Both ER positive and negative breast cancers can be considered for 
chemotherapy. If status is positive and hormone therapy is given 
clinicians need to measure whether there is any benefit to chemotherapy 
especially in the following cases: 
 Patient has a low risk of recurrence 
 ER expression is high 
 Other existent causes of mortality e.g. old age 
(ABS, 2009) 
HER2 status 
Chemotherapy given alongside Herceptin treatment if HER2 status is 
positive.  
(Breast Cancer 
Care, 2016) 
Triple negative 
Triple negative breast cancers i.e. HER2, ER and PR negative can be 
treated with chemotherapy 
(Breast Cancer 
Care, 2016) 
LN status 
Patients with LN positive breast cancers should be offered docetaxel 
Patients with LN positive breast cancers should not be offered Paclitaxel 
(NICE, 2009) 
Patients with LN positive breast cancers can be given a combined 
regimen of docetaxel, doxorubicin and cyclophosphamide 
Patients with LN positive breast cancers are not recommended paclitaxel 
(NICE, 2014) 
Risk of recurrence 
4-8 cycles of chemotherapy are recommended for women with 
intermediate or high risk of recurrence.  
(NICE, 2002) 
 
There are no further chemotherapy recommendations in the reviewed guidelines beyond 
those listed in table 4-2. It is not possible to put together a chemotherapy decision algorithm 
giving details of the regimen and dosages to be prescribed and under which circumstances. 
Chemotherapy treatment decisions appear to be complex; clinicians must consider overall 
breast disease rather than simply one biomarker suggesting that clinician experience plays a 
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key role in treatment planning rather than the use of clearly defined chemotherapy 
treatment decision algorithms.  
Neoadjuvant treatment 
The final consideration in breast cancer treatment is the use of neoadjuvant therapy, the 
administration of systemic therapy prior to surgery rather than the usual vice versa methods. 
The guidelines are ambiguous about the circumstances under which such an approach would 
be recommended, there is no clear indication in any of the publications. Only NICE (2014) 
mention patient preference suggesting that choices around the organisation of breast cancer 
treatment are left to the clinicians and discussion with their patients.  
However, it is clear that the underlying motivation behind this format is the evasion of a 
mastectomy procedure. Initial systemic therapy is expected to reduce tumour size, allowing 
the patient to undergo a WLE rather than a mastectomy on surgery. The same combination 
of drugs that would be used in the adjuvant setting would be recommended in the neo-
adjuvant (NICE, 2002).  
4.4.2 Clinical practice pathway 
The evidence-based pathway described so far was further modified to reflect clinical practice 
at UHCW, a large teaching hospital. The foremost clinicians involved in breast cancer 
management and treatment were identified, contacted and interviewed and their interviews 
transcribed. As each clinician was questioned, the pathway was updated.  
It was possible with the information gathered to develop a more detailed sense of the 
pathway from patient arrival in secondary care through to treatment initiation and 
management. To some extent, some clarity was gained around the elements of the evidence-
based pathway with associated ambiguity, particularly the neoadjuvant and chemotherapy 
sections. In general the findings taken from the clinician interviews supplemented the 
evidence based pathway and allowed a deeper understanding of the breast cancer patient 
experience.  
Figure 4-7 provides an illustrative overview of the clinical practice pathway, the basic frame 
of this is very similar to the illustrative summary of the evidence-based pathway given in 
figure 4-1. However, through clinician discussion it was possible to precisely identify the 
points of pathological examination and assessment as well as to deduce the frequency and 
positions of both surgical and oncological patient consultation to really understand how the 
activities in the breast cancer pathway are interconnected. 
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Figure 4-7 Overview of the clinical practice breast cancer pathway 
Out Patient Clinic
Figure 4-8
Symptomatic patient
Breast Screening 
Unit
Figures 4-9 & 4-10
Asymptomatic patient
Pathology
Diagnostic MDT
Figure 4-11
Patient Consultation
Arden Oncology Centre 
Neo-adjuvant therapy
Figure 4-12
Pre-operative 
Assessment Clinic
Day Surgery Unit
TheatrePathology
Post-Surgery MDT
Figure 4-14
Patient Consultation 
(Surgeon)
Patient Consultation 
(Oncology)
Arden Oncology Centre
Adjuvant therapy
Figure 4-13
Follow Up
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Figure 4-8 Outpatient clinic (symptomatic patients) 
Symptomatic GP 
referral
Physical examination
Further 
investigation 
needed?
No Yes
This is carried out by a suitably 
trained member of the team. It 
can be a surgeon, breast 
clinician, radiologist, 
radiographer or advanced nurse 
practitioner
Breast 
screening unit
 
Figure 4-9 Breast screening unit (symptomatic patients) 
Patient aged 
over 40yrs?
Mammogram
Ultrasound of 
breast lesion
Yes No
Evidence of 
abnormality
Clinical core 
biopsy
No
Mammogram
Yes
Discrepancy 
between US and 
Mammogram?
MRI
Yes
Category?
Ultrasound of 
breast and 
axilla
Evidence of LN 
involvement?
US guided needle 
sampling of the 
axilla
Yes
R1
No
No further axilla 
sampling at this stage
No
Ultrasound of 
breast 
R2/R3
R4/R5
If radiologist judges 
the lesion to be 
cancerous the 
patient will go on to 
have mammogram 
if  it is a benign 
looking lesion on 
ultrasound they 
won t have a 
mammogram 
Radiology Results
R1 – Negative
R2 – Benign
R3 – Equivocal
R4 – Suspected
R5 - Malignant
Core Biopsy 
under image 
guidance
Almost all patients will get an image 
guided core biopsy if they can see it. 
The only people that get a clinical core 
biopsy is when the lesion can be felt 
but is not seen on imaging
Other indications for MRI scan:
-High risk of breast cancer
-Monitoring response to chemotherapy
-Clinical/radiological/pathological discordance
-Tumours which are occult on imaging
-Implant evaluations because ultrasound and 
mammogram will not be sensitive enough
Specimen to 
pathology lab
Specimen to 
pathology lab
Symptomatic patients from outpatient clinic
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Figure 4-10 Breast screening unit (asymptomatic patients) 
Asymptomatic 
patients
Mammogram
Category?
Ultrasound of 
breast and 
axilla
Evidence of LN 
involvement?
Yes
US guided needle 
sampling of the 
axilla
No further axilla 
sampling at this stage
No
Core Biopsy 
under image 
guidance
R4/R5
Ultrasound of 
breast 
R2/R3
R1
Physical examination
Specimen to 
pathology lab
 
Figures 4-8, 4-9 and 4-10 summarise the steps in the assessment of symptomatic and 
asymptomatic breast cases on their arrival in secondary care. Both groups undergo triple 
assessment, encompassing physical examination, imaging and biopsy, consistent to what is 
already learnt by reviewing the guidelines. Physical examination is a standard procedure 
carried out in the outpatient clinic for symptomatic patients and in the breast-screening unit 
for asymptomatic patients. Asymptomatic and symptomatic patients over 40 years follow 
identical pathways through the breast-screening unit, post physical examination. The 
guidelines stipulate mammography and/or ultrasound of the breast as the imaging 
modalities of choice. Conversations with clinicians clarified the circumstances under which 
each or both would be recommended. Asymptomatic patients and symptomatic patients 
over 40 years will undergo a mammogram as their first-line imaging procedure, the breast 
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lesion category reported at this stage will dictate subsequent imaging. Negative lesions will 
undergo no further imaging, benign and equivocal lesions will have an ultrasound of the 
breast only and suspected or malignant lesions will have an ultrasound of both the breast 
and axilla. Post imaging all breast cases, from normal to malignant lesions will have a tissue 
sample removed through core biopsy of the breast in addition to biopsy of the lymph nodes 
where there is evidence of involvement on the ultrasound image.  Symptomatic patients 
under 40 years follow a slightly different pathway through the breast-screening unit. Their 
initial imaging procedure is an ultrasound of the breast with a mammogram undertaken if 
the radiologist suspects breast cancer on ultrasound. This will be followed by a core biopsy. 
In essence, there were no contradictions between the evidence base recommendations 
outlined earlier and clinical practice, the guidelines permitted a general depiction of triple 
assessment which was supplemented by clinician interviews to provide a more 
comprehensive understanding of the underlying activities and decisions that are involved in 
this section of the breast pathway. 
The majority of decisions around the subsequent steps in breast management are made at 
the diagnostic MDT. The outcomes of the triple assessment are discussed and clinicians make 
collective recommendations that can be discussed with patients. All decisions and possible 
outcomes at this stage of the pathway are presented in figure 4-11. The MDT decision 
algorithm overlaps with the surgical pathways for DCIS and IBC developed from reviewing 
the guidelines, given in figure 4-3 and figure 4-4 respectively. Once again, there were no 
contradictions between the evidence base and clinical practice except that clinician interview 
allowed a slightly more detailed illustration of the pathway. A greater amount of material 
was available on the handling of benign (B2) and inconclusive (B3/B4) cases. B2 cases were 
not covered by the guidelines, however this can be expected as they are not cancerous cases. 
B3/B4 cases are referred for repeat biopsy in order to collect a larger sample of breast tissue, 
the clinicians did not specify the type of breast biopsy but recommend a larger surgical 
excision if atypia is present to remove all the affected cells. Once more, this was not 
discussed in the guidelines.  The guidelines focus on confirmed cancerous cases, both DCIS 
and IBC but do not extensively discuss the lower reported breast pathology categories. While 
guidelines and clinical practice matched for DCIS, for IBC there was greater detail gained from 
the clinician interviews.  In particular, the clinician interviews gave a clearer understanding 
of the circumstances under which neoadjuvant therapy was recommended since these 
decisions were identified as an evidence gap when mapping out the evidence based 
pathway. 
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Benign or 
malignant?
Medication
Evidence of 
metastases?
Are the breast 
small and too 
much area 
affected?
Multi-focality?
Neoadjuvant 
Chemotherapy
Is an ALND 
possible?
Is treatment 
required?
Benign
No
Drainage
Surgery
Yes
Type
Malignant
Large lesion?
Possible to 
reduce the size 
and have WLE?
Is the patient 
suitable for 
surgery?
Palliative 
Care
Advanced 
metastatic 
disease
Close to 
margins?
Yes
Yes
Yes
No
No
Yes
No
Yes
WLE +/- LN 
treatment
Yes
LN treatment
No
Yes
Yes
Radiotherapy 
to the axilla
No
Large area of 
DCIS, 
multicentric 
disease, 
palpable mass, 
radiotherapy 
contraindicated
Atypia present?
SLNB
Mastectomy +/- 
LN treatment
ALND
DCIS
(Surgery only)
B3 lesion
No
Vacuum 
assisted 
biopsy
No
Surgical 
excision
Yes
Mastectomy 
+ SLNB
Yes
WLE
No
Inconclusive 
biopsy
No
Primary 
lifelong 
Endocrine 
Treatment
Successful?Yes No
Any IBC post 
WLE?
SLNB
No Yes
The vast majority of patients with a benign lesion won t have treatment. Medication (antibiotics) and 
drainage will most likely have already taken place prior to MDT n the breast screening unit.  The lesion would 
have been identified as an abscess at this stage and the clinician started the necessary steps for management .  
Surgery (removal) is carried out if there is some diagnostic doubt. 
Treatment of choice 
in majority of cases
Elderly/
frail
No
Re-biopsy
Yes
Breast case arrival at MDT 
post pathological 
examination and reporting
No
OR
OR
IBC
(Surgery & 
systemic therapy)
Breast treatment
Figure 4-11 Diagnostic MDT decision algorithm 
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As well as understanding the circumstances under which neoadjuvant therapy is 
recommended, clinicians were able to give an indication of the commonly prescribed 
chemotherapy regimens included in breast cancer treatment plans at both the neo-adjuvant 
and adjuvant phase of treatment.  Figures 4-12 and 4-13 highlight the use of FEC 
chemotherapy unless it is contradicted and so cyclophosphamides are recommended.  
Figure 4-12 Neoadjuvant therapy 
MRI 
FEC*6 cycles
FEC-T (+/- 
Trastuzumab)* 
6 cycles
TC (+/- 
Trastuzumab) 
*6 cycles
MRI
Arden 
oncology centre
Infusion 3-4 
week interval 
over 6 months
MRI is used to monitor the size of the 
tumour. A scan is taken before initiation of 
therapy, interim and post. If at the interim 
stage (3-4 cycles given) there is no shrinkage 
of the tumour, treatment is stopped
Many of the decisions taking place here are 
made by clinicians depending on the well 
being of the patient and cardiac function
 
 
However, FEC is administered with or without Docetaxel (T) and at both a 75mg and 100mg 
dose; it was not possible to draw out a decision algorithm at a more granular level, describing 
when each of these regimens is recommended. The breast oncologist emphasized the 
challenges in adopting a universal approach but rather each patient must be considered 
independently taking into account breast cancer features, age, presence of co-morbidities, 
previous cancer management and the treatment response before deciding the regimen to 
recommend. Chemotherapy decisions are made by clinical oncologists in the oncology centre 
and treatment involves close monitoring of patient function and response to treatment, the 
appropriate regimen is continually assessed and modified to reflect the condition of the 
patient being treated.  
The remaining decision and activities around ER, HER2 and radiotherapy in figure 4-13 and 
the pathway in figure 4-14 for post-surgery MDT decision making are identical to those 
recommended in the guidelines. 
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Breast 
radiotherapy
IBC + WLE OR
High grade DCIS + WLE
Chest wall 
radiotherapy
IBC + mastectomy +
high recurrence risk
SUPREMO trial
IBC + mastectomy +
Intermediate 
recurrence risk
Axilla 
radiotherapy
Positive SLNB but 
ALND declined Supraclavicular 
fossa radiotherapy
≥4 involved 
LNs on SLNB
Menopausal 
status
5yrs of 
Tamoxifen 
20mg od
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Figure 4-13 Adjuvant therapy 
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Figure 4-14 Post-surgery MDT 
 
 
 
 
 
 
 
 
 
 
 
4.4.3 Relationship between digital pathology and breast cancer outcomes 
The points of impact of pathology digitisation within the breast cancer pathway learnt by 
reviewing the literature were presented in chapter 3. These were mapped onto the clinical 
practice pathway to generate the network of processes from pathology digitisation through 
to patient outcomes; this is illustrated in figure 4-15. Digital pathology can potentially impact 
the cancer pathway in two ways, first through gains in accuracy and secondly through gains 
in speed. The processes for the accuracy gains were straightforward to map onto outcomes 
for breast cancer patients. Digital pathology can contribute to improving accuracy for a range 
of targeted processes such as testing or pathological examination of slides which in turn 
influence clinical processes such as the treatment or surgical intervention recommended 
which have a direct relation with the patient. To measure the full extent of the impacts of 
accuracy enhancements within the breast cancer pathway with digitisation, changes in 
outcomes for HER2 and ER scoring and the examination of lymph nodes, tumour margins and 
tumour grade would need to be explored. The value of change in accuracy for example by 
measuring test performance can be mapped onto the appropriate clinical processes as 
illustrated in figure 4-15 to measure outcomes of these for the patient. The combined 
benefits of each of the clinical processes can be measured to understand the total benefits 
for the breast cancer patient due to the digitisation of pathology.  
Further Surgery 
needed?
ALND
Delayed Breast 
Reconstruction
Further Resection
SLNB involved Margins involved
Patient preference
Adjuvant 
therapy 
needed?
No
No
Yes
Oncology 
consultation
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Figure 4-15 Overview of process chain network for digital pathology 
 
 
 
 
 
 
 
 
 
 
 
 
Unlike the accuracy gains, the speed gains through digitisation do not feed directly into targeted processes that can be mapped onto a clinical process to 
measure patient outcomes. Digitisation enhances the efficiency of pathology workflow, external pathology reporting and MDT meetings. These are all within 
themselves generic processes that each have a diffuse effect across many disease areas. 
84 
 
4.5 Discussion and conclusion 
Adherence to evidence based guidelines that translate scientific research into 
recommendations to support clinicians’ decision-making is key to improvements in patient 
care. Lugtenberg et al. (2009) systematic review evaluated the effectiveness of clinical 
guidelines; they reported evidence of improvements in both the structure of care and patient 
outcomes with their implementation. However, in reality guidelines can be over ambitious 
and difficult to put into practice especially when the appropriate facilities are not in place to 
support adherence. In addition, clinicians may not always diligently adopt and follow 
recommendations for numerous reasons including; lack of familiarity, awareness, agreement 
and motivation (Cabana et al., 1999). As a result, some level of disparity was expected 
between published breast cancer guidelines and clinical practice but the opposite was found 
to be true.  
The information gained from UHCW clinicians supplemented rather than contradicted the 
published breast cancer management recommendations. There were no discrepancies 
between the first version of the pathway based on guidelines alone and the second based 
on clinical practice. From the standpoint of clinical decision-making, patients at UHCW 
appear to be receiving good practice evidence based care in the management of their cancer 
diagnosis and treatment.  There is more than one possible justification for this observation: 
 UHCW is a large teaching hospital with in-house breast cancer management 
guidelines that are based on published recommendations. It is evident that they 
have systems in place for the update, dissemination and implementation of these. 
 The nature of the disease area and the continual emphasis on the improvement of 
cancer outcomes through government targets may influence clinicians’ uptake of 
new research that may not be seen with other disease areas 
Even though the findings made on adherence to evidence based practice are positive they 
may not be generalisable beyond UHCW to smaller hospitals or perhaps even beyond the 
group of clinicians interviewed, to more junior staff members or clinicians that do not sit on 
MDT meetings. Furthermore, it is perhaps vital to recognise that the similarities between 
guidance and practice are based on what clinicians say they would do under certain 
circumstances rather than what they in fact do which can only be learnt by collecting and 
analysing individual patient level data, discrepancies between guidance and practice may 
have arisen if this approach was taken.    
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The resultant breast pathways highlighted the importance of both guidance and clinician 
experience when making decisions around the management of disease, this was especially 
evident in the choices around chemotherapy recommendations. It is difficult to adopt a 
single approach to disease management for all patients in practice and it is impossible for 
guidance to cover all types of individual patients with their specific characteristics. Guidelines 
will provide recommendations for the most typical cases and are not intended to be followed 
dogmatically without consideration for the patients’ wider needs (Green and Piehl, 2003). 
Thus, it is vital that guidelines are implemented appropriately, together with clinicians’ 
judgements through MDT discussions, especially when more complex and rarer cases are 
being managed.  
Nonetheless, an accurate and comprehensive understanding and depiction of the breast 
cancer pathways’ details from referral to secondary care through to treatment planning 
based on both evidence and clinical practice is now available for use.  Decision analytical 
models based on part or all of the breast cancer pathway can be developed and used in the 
evaluation of interventions at any point along the pathway since the basic processes and the 
relationship between the various activities and the underlying decisions involved have now 
been summarised in one document. Furthermore, the pathway can be periodically updated 
to reflect new recommendations but only after confirming feasibility of their application with 
UHCW clinicians. 
The clinical practice pathway can in particular be used to assess the impacts of digital 
pathology on the overall breast cancer pathway. As described in chapter 3, DP is expected to 
make multiple improvements in time and accuracy at several points through the breast 
patients’ management pathway.  Evaluating each of these independently will not enable the 
appreciation of all the impacts of digitisation. Through mapping of the information learnt in 
chapter 3 onto the breast cancer pathway it was possible to summarise the chain of events 
connecting pathology digitisation to the other activities in the pathway and eventually 
patient outcomes. 
This is the first step in identifying the elements of the pathway that are relevant and should 
be considered when evaluated the combined impacts of pathology digitisation. While 
pathology outputs influence some activities within the breast cancer pathway, they do not 
have a relationship with all of them; these can be eliminated in the evaluation of pathology 
services allowing simplifications to be made to future modelling exercises. The development 
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of a decision analytical model that captures and measures the combined impacts of DP is an 
iterative activity and this is the first step in that process.   
In conclusion, the breast cancer pathway has been developed based on evidence and clinical 
practice for use in the evaluation of interventions along the breast cancer pathway. The 
pathway allows a clear understanding of events together with interactions between them 
through decision-making. It is possible to appreciate how modifications in certain activities 
will influence others and eventually overall patient outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
Chapter 5: Economic evaluation of digital pathology 
5.1 Introduction 
The breast cancer pathway informed by published recommended guidelines and current 
clinical practice at UHCW was illustrated and described in chapter 4. This mapping activity 
provided insight into the relationships between processes within the pathway that cross 
multiple medical specialities. This useful tool can be used in the initial steps of the evaluation 
of any intervention along the pathway by first understanding the chain of events that link 
interventions to patient outcomes.  
A combination of general time savings for the pathology lab and accuracy gains for breast 
pathology examinations have been reported in the published literature and were described 
in chapter 3. It is important to understand how each of these can contribute to time to 
diagnosis and treatment selection for cancer patients to achieve government waiting time 
targets on early diagnosis and improved disease management.  
The evolution of cancer waiting time targets set by the Department of Health in England has 
previously been outlined in chapter 1. Digital pathology activities fall in the period between 
arrival in secondary care and diagnosis, currently there is no explicit cancer waiting time 
target that is specific to this time period. The 62 day target from GP referral to the patient’s 
first treatment  (Department of Health, 2007) encompasses time to diagnosis but also 
includes time to treatment. The most recent guidelines that are still being rolled out and 
have not yet been fully implemented, stipulate replacing the two week waiting time target 
with a four week time to diagnosis from referral in 95% of cases and two week time to 
diagnosis for 50% of cancer cases (Independent Cancer Taskforce, 2015). Pathology 
digitisation can play a role in achieving these waiting time targets for breast cancer patients. 
Knowledge of the overall pathway in chapter 4 together with an understanding of the effects 
of pathology digitisation for the breast cancer pathway in chapter 3 facilitated the illustration 
of the process networks for digital pathology, figure 4-15. The chain of events describes how 
the various effects of pathology digitisation feed-into targeted processes which in turn feed-
into clinical processes and eventually the desired outcomes.  The efficiency gains reported 
with digitisation can in theory result in patients being diagnosed, treated and discharged 
earlier while the accuracy gains have the potential to alter the treatment packages 
prescribed and therefore patient outcomes.  
While these impacts are welcome and theoretically support care providers in meeting cancer 
waiting time targets as well as better planning treatment they have not been measured in 
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combination to value their collective benefit to breast cancer patients when compared to 
using standard non-digital pathology methods in the lab.  
In addition to the benefits described when adapting the pathology lab to digital systems, 
costs consequences of pathology digitisation are expected. High upfront investment and 
regular maintenance costs can make digital pathology appear unattractive to NHS budget-
holders. Though savings in resource use costs owing to treatment avoided or the reduction 
in test requests due to accuracy gains may also be experienced within the lab.  
The cost of investment and maintenance can be weighed against changes in the cost of 
treatment and benefit gains such as time savings in the pathology workflow, improved 
efficiency in running MDT meetings and better test result accuracy.  If the total cost of 
managing each breast cancer patient in secondary care is reduced with digital pathology 
when compared to conventional pathology, there is a case to support the adoption of digital 
pathology at least from the breast cancer care perspective if gains in outcomes are proven, 
digital pathology will dominate conventional microscopes in the lab.  Where the cost per 
breast cancer patient for digital pathway is greater than that under the conventional 
pathology pathway, a cost-effectiveness ratio can be generated to determine cost-
effectiveness and support decision-makers’ investment choices. Costs and outcomes must 
be measured alongside each other through an economic evaluation in order to determine 
the suitability of investment in digital pathology.  
To measure and quantify all the expected gains in the breast cancer pathway as described in 
the process chains in chapter 4, several steps were taken to transform the breast cancer 
pathway illustrated in chapter 4 into a software based decision analytical model to be used 
for the economic evaluation of digital pathology. 
5.1.1 Decision modelling for economic evaluation 
Alternative to immediate investment in high-end technologies, decision modelling allows the 
synthesis of the available primary evidence on effects and costs within an analytical 
framework (Philips et al., 2006). The model is altered and modified to reflect digital 
pathology, allowing the comparison and analysis of outcomes from the model prior and post 
pathology digitisation. The results of the analyses are used by decision makers to make 
judgements on the adoption of new technologies (Petrou and Gray, 2011) such as digital 
pathology, in resource limited systems such as the NHS.  
There are various models that can be developed and used for healthcare decision making, 
these include decision trees, markov models, microsimulation models, dynamic models and 
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discrete event simulation models  (Kuntz et al., 2013). The choice of model is largely driven 
by the clinical question and the presence of interactions between the individuals and systems 
that are modelled (Barton et al., 2004). Digital pathology’s main influences are on efficiency, 
consequently time to diagnosis and treatment and so an approach that explicitly 
incorporates time into the modelling process is needed. Discrete event simulation (DES) 
models will simulate the exact time of each activity in the pathway (O’Mahony et al., 2015). 
This approach to modelling will enable the development of an understanding of changes in 
time in the patient’s pathway as a result of changes in time seen in the pathology lab due to 
efficiency improvements with digitisation.  
Furthermore, progression of patients through the breast cancer pathway is limited by 
resource availability, particularly pathology staff working hours and the frequency and length 
of MDT meetings. DES modelling can capture these constraints, blocking the progression of 
individuals through the model when resources are limited and capturing the changes that 
pathology digitisation can bring. An additional challenge to modelling the breast cancer 
pathway is the level of complexity that needs to be incorporated within the model to fully 
represent all the activities and decisions that are made within the pathway. Various tests are 
carried out and results reported as patients move through the breast cancer pathway, DES 
allows the assigning of attributes to individual patients in the model while concurrently 
integrating an underlying decision algorithm that controls how patients travel through the 
model based on their test results (Karnon et al., 2012). DES models are designed to imitate 
the processes of complex systems, in this case the breast cancer pathway.  The pathway is 
represented in the model and events at different time points can be altered (Jacobson et al., 
2006) to reflect the changes predicted with digitisation and analyse their impacts.   
Unlike the majority of healthcare interventions, pathology digitisation has more than one 
outcome of interest, including time spent in secondary care, recommended treatment plans 
and the number of MDT discussions per case. It is difficult to summarise these into one 
comprehensive unit of effect to carry out a cost-effectiveness or cost-utility analysis. The 
research into the impacts of pathology digitisation on both patient care and pathology 
workflow are still in the early stages as is evident through the quality and size of the literature 
described in chapter 3. The systematic review in chapter 2 did not identify any economic 
evaluations of digital pathology or an evaluation of other pathology process interventions 
that developed a DES model as a vehicle for their economic evaluation. The purpose of an 
economic analysis at this stage is to explore and highlight the effects of digital pathology on 
the breast cancer pathway that are of the greatest value.  
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Cost-consequence analyses (CCA) are a suitable approach for carrying out this type of 
economic analysis. They allow the presentation of all costs and outcomes of an intervention 
in a disaggregated format providing decision makers with the most comprehensive 
information on the value of an intervention (Mauskopf et al., 1998). This exploratory 
economic analysis will act as a platform from which to identify and justify additional targeted 
research into both the effects and thus the cost-effectiveness of pathology digitisation. 
To measure and value the changes in both accuracy and time to the breast cancer pathway 
when pathology labs move from conventional approaches to more digital techniques for 
examination and reporting on tissue specimens, a DES model was developed based on the 
breast cancer pathway described in chapter 4. The model is founded on both research and 
clinical practice and has been modified through simplifications to particularly represent 
pathology activities and the interactions they have with other services along the breast 
cancer pathway. Digital pathology’s influences on the breast cancer patient are indirect and 
the model allows the linkage between these and the patient. The model was initially 
populated with parameters that reflect the use of conventional microscopes for pathology 
reporting. Adjustments were made to the relevant model parameters during 
experimentation to reflect digitisation of pathology services and compare changes in costs 
and outcomes for the breast cancer patient with each approach.  
5.2 Aims 
There are two aims to this chapter: 
1. To develop a DES model of the breast cancer pathway that can be manipulated for 
use in the evaluation of pathology interventions 
2. To carry out a cost-consequence analysis of pathology digitisation when compared 
to conventional microscopes for the examination and reporting on breast tissue 
specimens. A list of disaggregated costs and benefits for the breast cancer pathway 
is presented for each pathology approach for comparison 
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5.3 Methods 
This section of the chapter is split into two parts. Firstly, the steps taken to develop a DES 
model of the breast cancer pathway that can be used in the evaluation of pathology 
interventions are described. This includes the steps in producing the model structure and 
data collection methods adopted to inform the models’ time, cost and accuracy parameters 
so that the model reflects the standard practice of conventional microscope use in the 
pathology lab.  
The second part of this section describes the steps taken for the economic evaluation of 
digital pathology. A description of how the experimental factors within the DES model 
structure are manipulated to reflect pathology lab digitisation are given. Followed by a 
summary of the cost and benefit outputs that are compared across both CM and DP systems. 
5.3.1 DES model development 
It is vital models are developed to accurately reflect the real system they are based upon 
with all underlying assumptions and simplifications justified satisfactorily. Any policy changes 
built on erroneous outcomes as a result of  inadequate modelling will not only have a 
negative cost impact but in the healthcare setting maybe detrimental to a patients’ wellbeing 
(Jacobson et al., 2006). Due to the complex nature of DES modelling a step-by-step approach 
as detailed in figure 5-1 was adopted to develop the model that is used in the analysis of 
digital pathology. Error! Reference source not found. 5-1 is adapted from information learnt 
from a combination of resources including Law (2003), Carson et al. (2005), Hoad (2016) and 
Robinson (2004).   
The steps outlined in figure 5-1 were followed. The review of UK guidelines and interviews 
with UHCW clinicians have already taken place and have been described in chapter 4. The 
resultant breast cancer clinical practice pathway was used to inform the conceptual model 
that is transformed into the DES model to be used in the evaluation of pathology 
interventions. The clinical practice pathway represents the full spectrum of events along the 
breast cancer pathway, simplifications and assumptions were made to this to design the 
conceptual model structure of the DES model so that it was relevant to the research question 
and all unnecessary processes are removed. This was followed by the collection of the 
appropriate time, cost and probability data from UHCW and other sources to inform the 
model parameters so that the model reflects the standard use of conventional microscopes 
in the lab. The conceptual model and the data collected were used to develop the DES model 
using Simul8 software. Verification and validation processes were carried out to check the 
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model was developed correctly and confirm that it can be used in the evaluation of pathology 
interventions.   
Figure 5-1 Steps in DES model development 
UHCW Data 
Collection and 
Analysis
Model Coding in 
Simul8
UK Breast Cancer 
Guidelines and 
Recommendations
Interviews with 
UHCW Clinicians
Digital 
Pathology
Dilemma
Conceptual 
Model of the 
Breast Cancer 
Pathway
DES Model 
of the 
Breast Cancer 
Pathway
Results
Validation of DES 
Model against Real 
System
Experimentation 
using DP Parameters
Implementation?
Verification of DES 
Model against 
Conceptual Model 
Output Analysis 
based on CM 
Parameters
  
5.3.1.1 The conceptual model 
“The conceptual model is a non-software specific description of the computer simulation 
model (that will be, is or has been developed), describing the objectives, inputs, outputs, 
content, assumptions and simplifications of the model.” (Robinson, 2008, p.282) 
Conceptual model development is the first phase of DES modelling; this is a schematic of the 
breast cancer pathway that is relevant to the model objectives.  The purpose of the final DES 
model is to explore the implications of digital pathology for the breast cancer patients’ 
management pathway. To ensure the digital pathology experimental factors as well as the 
model outputs are modelled appropriately they were identified at this stage of model 
development and explicitly incorporated into the conceptual model so that the model 
objectives and the necessary analyses to be undertaken were at the centre of all model 
development.  
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An overview of the process chain network for digital pathology was given in figure 4-15 in 
chapter 4, this outlines the processes within the breast cancer pathway that are expected to 
be influenced by digitisation and must be represented within the DES model for evaluation. 
However, primary data comparing CM and DP outputs for each of these processes is not yet 
available as reported in chapter 3. Whilst the conceptual model made sure that all processes 
were included they will not all be explored in the experimentation phase of the evaluation. 
Time savings in the pathology pathway, increased productivity during MDT meetings, 
improvements in HER2 accuracy and changes to the tumour grade reported are the main 
outcomes of digitisation that were explored, these were the experimental factors of interest. 
The remaining processes in figure 4-15 were still represented in the model so that as primary 
data becomes available for each of these experimental factors the evaluation can be updated 
to explore further the impact of digitisation.  
The experimental factors listed will have a knock-on effect on time in the pathway, the 
treatment plans prescribed, the number of MDT discussions per patient as well as NHS costs. 
These are the model outputs of interest.  
In essence, the clinical practice pathway described in chapter 4 is the foundation of the 
conceptual model. Whilst it embodies all stages of the breast cancer pathway, relationships 
do not exist between the experimental factors and the full scope of activities represented. 
The pathway was simplified to incorporate sufficient detail to capture the activities that are 
sensitive to the experimental factors, avoiding unnecessary complex modelling. The model 
structure represents the network of pathology interactions within the breast cancer pathway 
in its simplest form, ensuring that model accuracy is not undermined whilst meeting the 
research objectives.  
Conceptual model development is an iterative process, so whilst the initial version was based 
on information learnt in chapter 4 further information about the pathway was derived from 
the data collection activities carried out at UHCW. The majority of the data collected was 
used to inform the model parameters and is discussed in the next sections of this chapter 
however in some instances the data highlighted features of the clinical practice pathway that 
were not modelled or had not been previously considered. This was particularly around the 
types and features of the tissue specimens removed rather than the pathway structure itself. 
For ease of reporting, where information not previously known was learnt about the breast 
cancer pathway through data collection it is described and justification for its omission or 
inclusion are given in this section.  
94 
 
The full breast cancer pathway in chapter 4 was reviewed and any sections considered not 
relevant to the ultimate model purpose were removed. These are clearly listed and 
justifications for each omission or assumption are given. The conceptual model is a simpler 
version of the clinical practice pathway designed to meet the evaluation objectives.  
5.3.1.1.1 Simplifications and Assumptions 
The pathway of a patient with suspected breast cancer referred to secondary care for 
investigation can be summarised into three phases as illustrated in figure 5-2:  
(1) Breast Clinic: Patients arrive here for triple assessment including the removal of biopsy 
samples 
(2) Pathology: The initial biopsy and other specimens removed are taken to the pathology 
labs for investigation.  
(3) Treatment: The pathology results guide treatment planning, including both surgical and 
non-surgical interventions where recommended.  
Figure 5-2 Summary breast cancer pathway through secondary care 
Patients go back and 
forth between pathology 
and the breast clinic and 
between pathology and 
treatment depending on 
results and the need for 
additional testing. 
Between each of these 
MDT meetings and OPAs are taking place to decide the course of action and communicate 
this to the patient. This is just an overview, in reality each one of these phases is made up of 
a series of activities and decision points. The challenge is to identify which elements of the 
initial schematic of the breast cancer pathway are to be included in the conceptual model 
for conversion into the DES model. A summary of all model simplifications and omissions 
from the breast cancer pathway are listed in table 5-1 and an overview of basic structure of 
the conceptual model is in figure 5-3. This is a representation of the elements of the original 
breast cancer pathway that are eventually included in the model, in reality the conceptual 
model is a lot more detailed than this.  
 
Arrival
Breast Clinic Pathology
Surgery
Treatment
End
Non-Surgical 
Interventions
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Table 5-1 Summary of simplifications in DES model 
Simplifications/omissions  Justification 
Breast clinic 
The breast clinic and triple assessment activities are not represented They do not interact with and therefore are not sensitive to changes in pathology  
Patients are managed in the same way regardless of source of referral 
Differences in patient management due to source of referral only arise in the breast 
clinic and this not modelled.  
Breast clinic and the activities within it are not modelled 
Pathology – First specimen 
Breast reductions are not represented 
They are not part of the cancer pathway, cancer for these cases has previously been 
managed and patient has come back for procedure to manage risk 
Soft tissue specimens are not represented Where cancer is suspected, a core biopsy is always carried out 
Assume only one breast investigated for all patients  Patients are managed according to breast with most serious result 
Assume only one core biopsy taken for all patients Patients are managed according to biopsy with most serious result 
First specimen is a core biopsy of one lesion of one  breast 
Pathology – CB results 
B1 and B2 core biopsies cases are merged into one group These cases are managed in the same way 
B3 and B4 cases are not represented 
These cases always go on to have a second biopsy that eventually gives a B1, B2, 
B5a or B5b result. There incidence is not influenced by pathology 
Core biopsies have one of 3 diagnoses B1/B2, B5a or B5b 
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Treatment  
Assume that all patients follow through their treatment plans Beyond the scope of the study to model interim changes in treatment plans 
Assume all patients are early breast cancer cases 
Beyond the scope of the study to model metastatic and recurrent cases as their 
management plans differ to early breast cancer cases 
Delayed breast reconstruction omitted This activity is not influenced by pathology 
Radiotherapy activities This activity is not influenced by pathology 
Excision of B1/B2 lumps not modelled Not restricted by cancer waiting time targets 
The use of MRI to monitor the size of tumour  during Herceptin 
treatment  
The model previously assumes that patients follow through their treatment plans 
MRI guides if treatment should be continued so this activity is no longer relevant 
Chemotherapy regimens summarised in one activity 
Pathology influences whether chemotherapy is prescribed not the type of 
chemotherapy regimen 
Hormone therapy regimens summarised into one activity Pathology influences whether hormone therapy is prescribed not the regimen type 
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Figure 5-3 Overview of the conceptual model 
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Breast Clinic 
1. Triple assessment 
Patients are first exposed to pathology services after they have completed their triple 
assessment in the breast clinic. The biopsy specimen of the unexplained tissue mass is sent 
to pathology labs for further investigation. All the steps in the breast cancer pathway prior 
to this are not sensitive to changes in pathology. DP will not influence clinical examination, 
the imaging options or even methods of biopsy. The impacts of pathology digitisation will 
start to be seen from the point of arrival of the biopsy specimen at pathology through to 
treatment design and initiation. With this in mind, it is clear the level of detail found in the 
clinical practice pathways prior to pathology do not need to be represented in the conceptual 
model.  The model is simplified by removing the arrow from the breast clinic to pathology, 
omitting all activities involved in triple assessment. 
2. Source of referral 
Patients arriving in secondary care with suspected breast cancer either have presented to 
their GP with symptoms or have been recalled from routine assessment as part of the breast-
screening programme. Even though there are small differences in the activities and decisions 
that make up triple assessment for these two groups, once biopsy specimens have been 
removed, all patients are managed in the same way regardless of their source of referral. As 
the activities representing triple assessment have already been removed from the model, 
there is no need to differentiate breast cases by their source of referral. Breast cancer cases 
arriving in the conceptual model are simplified and treated as one homogenous group. The 
model begins with the arrival of the first biopsy specimen for each breast case at the 
pathology lab.  
Pathology 
1. First specimen 
The evidence and clinical practice pathways point to the core biopsy as the first tissue 
specimen to be removed from the patient on arrival in secondary care for investigation. In 
the UHCW dataset, over 85% of patients had a core biopsy (CB) of the breast removed with 
or without a lymph node biopsy (LNB) as their initial tissue specimen, this matches the breast 
cancer pathways developed in chapter 4.  However, the remaining 14% of patients have 
other initial tissue samples, including skin biopsies from the areola and/or nipple, soft tissue 
specimens taken from the chest wall and breast reduction tissue. 
a. Breast reductions 
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Reductions are indicative of a previous episode of breast cancer; here the patient has 
returned to either have their non-cancerous breast operated on to bring its size in line with 
the cancerous breast that has undergone a previous surgical procedure. For some patients a 
breast reduction is carried out to reduce the risk of recurrence even though the breast 
operated on does not yet show any signs of malignancy. This group of patients are excluded; 
in most cases there is a long period between first diagnosis with breast cancer and the breast 
reduction procedure and so for many of these patients information is not available for their 
previous cancer episode. It is not necessary for the model to represent these cases since 
breast reductions are in reality not the first tissue specimen removed in their pathway.  
b. Soft tissue specimens 
The soft tissue specimens in the dataset are extracted as a result of a suspected lipoma. 
These are benign lumps which are typically completely excised. Since they are not suspected 
cancers and do not follow through the breast cancer pathway there is no need for them to 
be represented in the model. For the skin biopsies in the dataset, only one case was 
confirmed to be cancer and this was only after a core biopsy was performed when signs of 
malignancy were seen on examination of the skin biopsy in pathology.  The core biopsy for 
this patient can be considered their initial specimen in the pathway and skin biopsies are not 
represented in the model.  
c. Two breasts investigated 
The UHCW dataset showed the vast majority of patients undergo investigation in one breast 
alone, however approximately 3% of the patients in the dataset had biopsies taken from 
each breast due to palpable lumps in both. For ease of modelling and simplification purposes 
these patients were assumed to only have one breast investigated but will be processed 
through the model according to the breast with the more serious diagnosis as this is what 
occurs in practice.  The inconsistencies between the model and reality are associated with 
the cost and time needed to process two core biopsies rather than one and the cost and time 
of surgery if recommended for both breasts rather than just one; the remaining aspects of 
these patients pathway will be identical to patients that have only one breast under 
investigation. 
d. Two core biopsies  
Similarly, some patients have more than one core biopsy lesion removed from the same 
breast where there are several palpable lumps. In most cases these have the same result but 
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where they differed, the patient is treated according to the more serious outcome. Once 
more for simplification purposes, results for more than one lesion in the same breast have 
been combined to give an overall breast result that is included for the particular patient. The 
model assumes a diagnosis is made with one core biopsy which is labelled and processed 
through the model according to the lesion with the more serious diagnosis. The irregularities 
between the model and reality are associated with the cost and time to process more than 
one core biopsy in pathology rather than one lesion as is the case in the model.  
In summary, it is maintained that the breast cancer case arriving at the start point of the 
model has had a single core biopsy removed with or without a lymph mode biopsy form one 
breast. All other specimen types are not considered. 
2. CB result 
Pathologists classify breast core biopsies with a B1 to B5 result as outlined in table 5-2 below 
(Andreu et al., 2007). 
Table 5-2 Summary of pathology CB results 
 
 
 
 
 
The majority of initial biopsies in the dataset were determined to B1, B2, B5a or B5b. In a 
minority of cases a diagnosis is more difficult and the lesion is determined B3 or B4.  
a. B1/B2 cases 
B1/B2 core biopsies represent either normal or benign tissue, the benign classification 
embodies a diverse group of lesions ranging from cysts to fibroadenomas (Guray and Sahin, 
2006). In most cases these lesions do not require intervention by clinicians but there are 
some instances where surgical removal of the lump is recommended. In the UHCW dataset 
90% of patients’ with B1/B2 core biopsies are discharged post MDT and for 10% of cases 
MDT advise the excision of the benign lump. 
 
B1 Normal 
B2 Benign 
B3 Lesion of uncertain malignant potential 
B4 Suspicious 
B5a Malignant – Insitu 
B5b Malignant – Invasive 
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b. B5a cases 
A B5a result on CB denotes an insitu lesion, ductal carcinoma insitu (DCIS). These lesions are 
found in the milk ducts and have not spread to other parts of the breast (Ernster and Barclay, 
1997). DCIS can appear alongside an invasive lesion and in such a case it is treated as invasive 
breast cancer (IBC). These lesions are straightforward to diagnose and manage; at this stage 
it is known that they are malignant but have not spread into the breast. B5a lesions are 
generally managed by surgery to remove the tumour; either a mastectomy or wide local 
excision (WLE) depending on the size of the area of the breast affected (Health and 
Excellence, 2009).  
c. B5b cases 
A B5b result on a CB indicates an invasive lesion. Unlike DCIS, IBC has spread from the ducts 
and into the surrounding breast tissue. These cancers are also more likely to be involved with 
lymph nodes indicating potential metastasis through the lymphatic system (Rahman and 
Mohammed, 2015). Resection of IBC tumours is at the core of the management strategy for 
this category.  Like DCIS tumours; patients will either undergo a mastectomy or a WLE, 
though some patients that meet the criteria for WLE will opt for a mastectomy instead 
(Rostas and Dyess, 2011). As well as surgical resection these patients will also have an 
assessment of their lymph nodes by way of a sentinel lymph node biopsy (SLNB) to determine 
if the cancer has spread and thus guide subsequent treatment (Rostas and Dyess, 2011). 
B1, B2 and B5 lesions are relatively straightforward to manage (Pinder and Reis-Filho, 2007). 
B1 and B2 lesions are mostly discharged and B5 will be discussed by MDT for treatment 
management.  The delay arises around B3 and B4 lesions as these will require repeat 
assessment  to make a definitive diagnosis and plan treatment accordingly (Pinder and Reis-
Filho, 2007).  
d. B3/B4 cases 
The B3 category includes a diverse range of lesions of differing levels of possible malignant 
potential (Strachan et al., 2016); these include: 
 Epithelial Atypia 
 Atypical Intraductal Proliferation 
 In Situ Lobular Neoplasia 
 Papillomas 
 Radial Scars 
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 Fibroepithelial Lesions     (Strachan et al., 2016) 
B4 lesions are highly suspicious of malignancy; either DCIS or IBC, but a definite diagnosis 
cannot be made for various reasons (Bilous, 2010b). Both B3 and B4 lesions are dealt with 
by further investigation, explaining the arrow in figure 5-2 from pathology back to the breast 
clinic. This is normally a diagnostic excision biopsy (DEB) or a vacora biopsy (VB).  A vacora 
removes more tissue per sample (Ames and Britton, 2011)  compared to a core biopsy whilst 
a diagnostic excision involves the removal of the complete palpable lesion.  
In the UHCW dataset, 15 patients had an initial B3/B4 result and required further 
investigation to make a final diagnosis and initiate their treatment. They underwent either a 
vacora or a diagnostic excision, the results of these biopsies for each patient are given in 
table 5-3. Only one patient (ID 80) is found to be cancerous when the second specimen is 
analysed. The remaining all have benign results and two patients; 108 and 234 had no further 
investigations.  
The need for repeat biopsy is largely due to unusual breast cancer types or when the core 
biopsy specimen appears to not be completely representative of a larger lesion seen on 
imaging and so further sampling is needed (Bilous, 2010a). DP will not play a role in 
overcoming the challenge of inadequate tissue specimens as this is related to biopsy 
techniques rather than specimen analysis. 
Table 5-3 Management of B3/B4 core biopsies in the dataset 
ID CB Comments VB DEB 
9 B3 Spindle Cell   Spindle Cell  
17 B3 2 Lesions (B1 & B3) B2  
19 B3 Sclerosed Papillary Lesion without atypia  Benign 
44 B3 Intraductal Papilloma  Benign 
68 B3 Papillary Lesion no atypia  Normal 
104 B3 
Infarcted papillary lesion + atypia 
amounting to FEA/ADH 
 
Low Grade 
DCIS 
106 B3 
Part of a papillary lesion without atypia + a 
focus of atypical intraductal proliferation 
B1/B2 Benign 
108 B3 Intraductal Papilloma   
146 B3 Focal Epithelial Atypia  Benign 
157 B3 Atypical Intraductal Proliferation B3 Benign 
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The proportion of CBs classified as B3/B4 will not be influenced by pathology. The model is 
simplified so that all breast cases at the start of the model are assumed to have their 
definitive CB result assigned on their initial specimen. The route back to the breast unit from 
pathology in figure 5-2 is omitted; the breast clinic is now not represented in the conceptual 
model. Furthermore, core biopsies with a B1 or B2 result are managed in a similar manner; 
these are merged into one group in the model. In summary CBs at the start point of the 
model have one of three diagnoses; B1/B2, B5a or B5b. 
Treatment 
The UHCW dataset shows that treatment plans for some patients will not match clinical 
practice as described by the clinician’s interviewed, either from outset or if adjustments to 
plans are made once treatment is initiated. This can be due to a number of reasons including; 
the experience of side effects, presence of co-morbidities, non-response or refusal of 
treatment by the patient. These external factors are not influenced by pathology and it is 
beyond the scope of the evaluation to capture these in the model. For simplification 
purposes the model assumes all patients follow through their care plans as would be 
recommended in the breast cancer clinical practice pathway without taking into 
consideration any external factors beyond disease characteristics that may influence the 
treatment decisions made. 
The additional factor to take note of at this stage of the modelling process is breast cancer 
recurrence. Representing these cases in the model adds further layers of complexity; these 
patients have already received a combination of both surgical and systemic therapy with 
their first round of treatment. Their treatment management differs to cases presenting with 
breast cancer for the first time and they have not been covered by the guidelines used to 
develop the pathway in chapter 4. The model was developed with early breast cancer cases 
in mind and does not represent the pathways of advanced or recurrent breast cancer cases, 
162 B3 Atypical Intraductal Proliferation B2  
166 B3 
Spindle cell lesion, likely 
myofribroblastoma 
 Fat only 
211 B3 Atypical Intraductal Proliferation B2  
234 B3    
80 B4  B5a  
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for this reasons all suspected breast cancer biopsies at the start point of the model are 
related to early breast cancers only.  
1. Surgery 
All surgical activities in the clinical practice pathway are kept in the conceptual model except 
for delayed breast reconstruction. This procedure is largely down to patient preference and 
is not influenced by pathology outcomes. The model is simplified by removing it.  
2. Radiotherapy 
Recommendations for radiotherapy are guided by the surgical procedure and the LN status 
reported in the pathology report. It was previously highlighted in chapter 4 that LN 
evaluation and reporting is fairly accurate with conventional microscope. As long as 
digitisation does not undermine accuracy there will be no impact on the prescription of 
radiotherapy regimens. The model was simplified by removing all radiotherapy activities.   
3. Systematic therapy 
Several simplifications are made to systemic therapy. Firstly, both the use of MRI to monitor 
tumour size during the course of neoadjuvant therapy and the assessment of cardiac 
function during Herceptin treatment are not included in the model. Based on the outcomes 
of both activities, clinicians modify treatment accordingly, but as the model will assume that 
patients follow through and complete their initial treatment plans it is not necessary to 
model either of these activities. Furthermore, neither interact with pathology services. 
Secondly, as described in previous chapters there are several options for chemotherapy drug 
regimens and dosage in breast cancer. For simplification purposes due to the excessive 
complexity of attempting to model each of these, chemotherapy will be represented by one 
activity in the model. The same also applies for hormone therapy. Pathology results influence 
the prescription or not of these treatments whereas other patient factors, external to 
pathology will influence the specific drug to be prescribed.  
4. MDT 
Observations of hospital practice and knowledge of pathology processes gained through data 
collection at UHCW indicated that pathology reports are in some cases added to MDT lists 
for discussion prior to all test results becoming available. This scenario was not seen for CBs 
with either B5a or B1/B2 status since only the biopsy diagnosis is reported with no further 
testing needed. In most cases theses were incomplete reports for B5b CBs where other test 
results are not yet available especially if HER2 FISH testing is being outsourced due to an 
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equivocal IHC outcome.  Rather than wait for a compete pathology report which includes the 
results of all supplementary tests, the cases are sent to MDT for discussion then returned to 
the pathology lab for the missing results to be included before being discussed once again at 
MDT.  Alongside MDT meetings, OPAs are pre-scheduled to communicate the agreed care 
plan with the patient on the day of or day following the MDT meeting where their case is due 
to be reviewed.  
In essence, a case may appear at more than one MDT meeting before a final treatment plan 
can be proposed resulting in both a waste in clinician time and an inconvenience to patients 
who are going back and forth for hospital appointments without being given a 
comprehensive explanation of their diagnosis. Ideally all test results should be available at 
the first MDT discussion so that results and treatment plans can be discussed with patients 
at the OPA.  
DP is set to improve pathology workflow and consequently reduce the time to test results 
becoming available. In theory, this will reduce the number of breast cases arriving at MDT 
meetings with incomplete reports. The impact of DP on the number of times a breast case 
passes through MDT is one of the investigations explored in the model manipulation stage 
later on in this chapter.  
5.3.1.2 DES model  
To capture all the time and accuracy consequences of pathology digitisation a DES model 
was developed using Simul8 Professional software (Simul8, 2019), this is based on the 
conceptual model described so far, and an overview of this is given in figure 5-3. 
A step-by-step approach was taken to develop the model in Simul8: 
1. Model assembly 
The initial structure was built incorporating all pathology outputs and routing decisions that 
are made based on these. This was completed using combinations of batching, labels, 
queues, routing and visual logic code in Simul8 to move entities (breast cases) appropriately 
through the activities in the model. A description of the Simul8 building blocks is given in 
appendix C and an illustration of the Simul8 model structure is given in figure 5-4. 
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Figure 5-4 DES model structure in Simul8 
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2. Verification 
Verification makes sure that the visual logic codes input are correct so that work items are 
routed through the pathway as described in the conceptual model. Using the step function 
in Simul8 software allows the tracing of any chosen entity using its unique ID label, this is 
continually done with the addition of any new code or routing logic during the development 
phase. Following the addition of any new visual logic code, label updates or routing function 
at an activity, the model is run and the queue contents are examined to ensure work items 
are being routed correctly and labels are being updated appropriately. This is an ongoing 
process and has been carried out thoroughly with every step of model development ensuring 
the model is running and updating as expected. Owing to continual verification; on 
completion of the model structure, breast cases are routed in an identical way to that 
described in the conceptual model with all bugs and errors removed.  
3. Model parameters 
Once the model structure was completed and all entities were passing through the model, 
appropriately reflecting the conceptual model, time distributions and costs were added to 
the DES model at the appropriate activities. A summary of all model parameters and sources 
is given in the next part of this section.  
4. Validation 
As well as verification it is essential the model is validated by comparing it to the real system 
(Robinson, 1997); in this case the breast cancer pathway at UHCW. If the inputs to the model 
are the same as reality then the outputs from the model should also be reasonably similar to 
real data. The final step involved validation of the DES model against the real system (UHCW) 
by comparing model outputs against UHCW data.  
The verification and validation processes of developing a DES model are essential in 
determining whether the model developed is similar enough to the real system for it to be 
used in meeting the study objectives (Sargent, 2009). Verification focuses on determining 
the accuracy of the DES model in relation to the conceptual model and validation centres on 
how close the model represents  the true system (Cook and Skinner, 2005).  
5.3.1.3 Data collection 
From the conceptual model, it was possible to identify the data required in order to populate 
the DES model.  The model parameters can be split into three categories:   
1. Probability data 
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2. Time data 
3. Cost data 
The first two categories were collected from and are based on UHCW data. The cost data 
was largely based on the published literature with some data points taken from UHCW 
systems. The model parameters reflect clinical practice at UHCW i.e. the use of conventional 
microscope in the pathology lab.  
UHCW data 
A list of hospital numbers for breast patients was provided by the pathology department at 
UHCW. These patients had at least one tissue specimen included in the DP validation study 
carried out at UHCW by Snead et al. (2015). The study included over 3000 specimens of which 
265 were breast specimens removed from 235 patients.  These were selected at random 
from February 2013 to April 2014 by taking record cards for breast pathology specimens from 
the filing tray, once the pathologist had reported their findings. A breakdown of the number 
of specimens per patient included in the validation study is presented in table 5-4. These 
breast tissue specimens were the initial source of all the required data to be collected to 
inform the model parameters.  
Table 5-4 Number of breast tissue specimens per patient 
Specimens Patients Total 
1 210 210 
2 20 40 
3 5 15 
Total 265 
 
The tissue specimens ranged from simple biopsies to more complex surgical procedures. Not 
all of a patient’s tissue samples associated with the breast episode were included in the 
validation study. For example, a biopsy for patient A is included but they later have a WLE 
that is not picked up in the random selection of records and vice versa. 210 patients are 
represented by only one tissue specimen in the study; 20 patients have two and for 5 patients 
there are three breast tissue specimens included in the validation study. The 235 patients 
were each given a unique ID number from 1 to 235. Three patients were eventually excluded 
from the dataset; one was discovered to be a gastric biopsy, most likely included in error. 
Two patient’s records could not be found on CRRS. Data for the remaining 232 patients were 
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either requested from hospital staff or manually extracted from systems where it was 
possible to gain access. 
1. Requested data 
All MDT data were requested for patients with breast tissue specimens included in the 
validation study. These were extracted by staff at UHCW and included information on the 
date of meetings, specimen discussed and MDT outcome. 
It was not possible to calculate the inter-arrival rate of breast specimens received in the 
pathology lab from the validation study cases. They did not include all the breast cases 
arriving at pathology during the study period. The basic information for breast cases arriving 
at pathology between January 2013 and January 2015 was requested. This included 
information on specimen type, date of arrival and the diagnosis made. From this information 
an inter-arrival rate was worked out for use in the model.  
2. Manually extracted data 
As well as data requested, other relevant information necessary to populate the model was 
manually extracted. There were two sources for this: 
The UHCW central results reporting system (CRRS) was the main source of data, from here 
information on pathology, surgery and oncology treatment plans were extracted. Data was 
collected on all pathology specimens related to the patients’ breast episode not just the 
specimen included in the validation study.  
The oncology information system at UHCW; MOSAIQ was also accessed through the 
pharmacy department. Information on patient’s drug history and treatment plans was taken 
from here. 
Data were extracted from reports associated with events taking place along the patient’s 
breast cancer pathway that are included in the conceptual model. Table 5-5 presents a 
summary of all records obtained and their source.   
Table 5-5 UHCW data collected 
Data Group Source Parameters 
First 
appointment 
Dendrite System 
Manager 
 Date of first visit 
MDT meetings 
 Dendrite System 
Manager 
 Date of meeting 
 Breast tissue specimen discussed 
 MDT outcome 
110 
 
Breast pathology 
reports 
Manual CRRS 
extraction 
This includes pathology reports for all breast 
tissue specimens removed during the 
patients’ course of management in 
secondary care. Encompassing both the 
cases included in the validations study as 
well as other breast specimens. The 
following information was extracted: 
 Date of specimen receipt 
 Date of pathology report 
 Main results reported 
 Supplementary results reported 
Surgery 
Manual CRRS 
extraction 
 Surgical procedure 
 Date of surgery 
Pharmacy 
Clinical letters stored 
under CRRS 
AND  
information from the 
MOSAIQ database 
 Chemotherapy regimen details: 
 Endocrine therapy details: 
 Herceptin therapy details: 
 
Model probabilities 
The majority of model probabilities were estimated from the UHCW data described in table 
5-5. A summary of all model probabilities and their sources are given in table 5-6.  
Table 5-6 Model probabilities 
Model parameter Value Probability Sources 
CB result 
B1/B2 
B5a 
B5b without a LNB 
B5b with a LNB 
59% 
6% 
26% 
9% 
UHCW data 
Upgrade of B5a case to 
invasive status on surgery 
Upgraded to invasive 
Remain in situ 
26% 
74% 
Brennan et al. 
(2011) 
Surgery if invasive 
WLE  
Mastectomy 
57% 
43% 
National Cancer 
Intelligence 
Network (2006) 
Surgery if in situ  
WLE  
Mastectomy 
65% 
35% 
HER2 IHC results +3 positive 14% UHCW data 
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+2 equivocal 
+1 Negative 
23% 
63% 
HER2 FISH results round 1 
Amplified  
Repeat test  
Non-amplified 
21% 
72% 
7% 
UHCW data 
HER2 FISH results round 2 
Amplified  
Not-amplified 
50% 
50% 
UHCW data 
ER results 
Positive  
Negative 
83% 
17% 
UHCW data 
LNB status 
Involved  
Not involved 
57% 
43% 
UHCW data 
Systemic therapy plan 
Neoadjuvant treatment 
Adjuvant treatment 
3% 
97% 
UHCW data 
Margin status 
Involved  
Not involved 
12% 
88% 
UHCW data 
SLNB status 
Involved 
Not involved 
13% 
87% 
UHCW data 
Neo adjuvant surgery 
WLE  
Mastectomy 
64% 
36% 
Mieog et al. 
(2007) 
Grade if HER2 negative 
1 
2 
3 
30% 
44% 
26% 
UHCW data 
Grade if HER2 positive 
1 
2 
3 
0% 
33% 
67% 
UHCW data 
 
Time data 
One of the main objectives of the simulation model is to capture the time changes in the 
breast cancer patients’ pathway that will be seen with the digitisation of pathology services. 
Experimentation will investigate how digitisation influences the time to complete tasks in 
the pathology lab, for this reason all pathology related activities are assigned a time 
distribution as these will need to be manipulated to meet the main objective of the model. 
The time estimates that were used in the model were based on UHCW data and reflect the 
pathway when conventional microscopes are used. For each breast patient included in the 
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UHCW dataset described earlier, the dates of all activities in their treatment and 
management pathway were extracted. These data points were used to generate time 
estimates for the activities that take place along the patients’ breast pathway and are 
represented in the conceptual model. Where possible simplifications were made by 
combining data points and generating a single time estimate that was later used at more 
than one activity in the model. If it was considered appropriate to merge data points, for 
example, the time taken to report on a CB with malignant status versus non-malignant status, 
two-sample t-tests were used to compare the data. Where there was no difference at the 
95% level of significance, the data was merged and one time estimate generated. Where 
there was evidence of a difference between the activity times, the data points were kept 
separate and two distributions used at their matching activities. All time estimates as used 
in the model are reported in table 5-7.  
Table 5-7 Model time parameters in days 
 Mean (95% CI) 
Time to process malignant CBs  in pathology  3.41 (3.16 to 3.66) 
Time to process non-malignant CBs  in pathology 2.78 (2.82 to 3.14) 
Time to process LNBs in pathology 3.38 (2.93 to 3.83) 
Time to process surgical specimens in pathology 9.64 (8.91 to 10.37) 
Time to report ER test on CB 5.60 (5.14 to 6.07) 
Time to report ER test on surgical specimen 13.42 (10.48 to 16.35) 
Time to report IHC test on CB 6.49 (5.92 to 7.01) 
Time to report IHC test on surgical specimen 17 (13.53 to 20.47) 
Time to receive FISH test result 11.58 (9.06 to 14.10) 
Time to first surgery from MDT 18.32 (16.70 to 19.94) 
Time to second surgery from MDT 14.21 (11.61 to 16.82) 
Treatment period: Neoadjuvant chemotherapy and  Herceptin 305 days 
Treatment period: Neoadjuvant Herceptin 90 days 
 
In addition to the time estimates input into the model at the relevant activities, a couple of 
other time parameters were considered to complete the model in Simul8.  
1. Arrival rate 
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On any given day, the number of breast cores arriving at the pathology lab at UHCW ranged 
from 0 to 12 cores with a mean of 2.36 arrivals per day. A summary of the data is given in 
figure 5-5.  
It was not possible to record the exact point in the day of arrival for each specimen and so 
for the model an inter-arrival time was calculated by taking the average number of biopsies 
arriving in one day and spacing these equally through the day using the following equation: 
                                                                Inter-Arrival Time =            1 
                Arrival Rate 
The inter-arrival time was worked out to be 0.381 days. This was used in the model at the 
arrival activity. It was set to an exponential distribution. 
Figure 5-5 Frequency of breast core arrivals at UHCW 
 
 
 
 
 
 
2. MDT length 
The MDT activity in the DES model is based on UHCW schedules where meetings take place 
twice a week on Tuesdays from 12:45 to 13:30 and on Thursdays from 12:30 to 14:00.The 
length of time each breast case spends at this activity is equal to the time required for MDT 
to discuss each case as reported in the National Cancer Peer Review Self-Assessment report 
for UHCW. 15 cases are discussed at Tuesday’s meeting and 40 cases are discussed at 
Thursday’s meeting and so the MDT activity’s timing is dependent on the day of the week. 
For Tuesday, it will take on average 3 minutes to discuss each case and on Thursdays on 
average, it will be 2.25minutes per case. A review of MDT effectiveness across several 
specialists by the London Cancer Network found that the average discussion time per case 
was 3.4 minutes, ranging from 1.8 to 8.6 minutes (Mughal and Goodman, 2017).  In addition, 
a clinical audit of specifically breast MDTs found the time for discussion per case to be an 
average 3 minutes ranging from 2 to 4 minutes (Ruiz-Casado et al., 2014). UHCW’s time for 
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discussion of each case falls within the ranges expressed in both studies and so it is 
appropriate to use these time values in the simulation.   
The model is setup so that the MDT activity only accepts breast cases to travel through during 
the set times on a Tuesday and Thursday. Outside these times the breast cases travelling 
through the model wait in a queue preceding the activity.  
3. Simul8 clock 
The DES model in Simul8 has an inbuilt clock that controls the times the model is running 
and how long the model runs for. The Simul8 clock properties were set based on UHCW 
working practices. Histopathology labs run from 7am-6pm Monday to Friday. This is the 
department open the longest hours in the pathway so the clock is set to run for this time. All 
travel time between activities in the model are set to zero under clock properties and added 
manually. Results are collected and analysed for a period of one year; 52 weeks starting at 
7am on a Monday and ending on Friday at 6pm. Work items arrive into the model for a period 
of 1 year but the model is run for 3 years to ensure all work items have completed their 
pathways when the model stops. This is done by setting a results collection period of 780 
days but adding a constraint of 260 days at the arrival point limiting the duration of arriving 
work items to one year.  
Cost data 
In addition to time distributions, costs were assigned to all the activities in the model, 
including pathology activities, surgery, MDT meetings and systemic treatment. Costs were 
based on 2017 estimates and were obtained from various sources. These included NHS 
reference costs (2016-2017), BNF 73 (March 2017), UHCW costs and published literature 
where unit cost values could not be sourced from the other references.  The model takes an 
NHS perspective using 2016-2017 costs; the model cost parameters and their sources are 
given in table 5-8.  
Table 5-8 Model cost parameters 
Cost parameter Cost (£) Description Source 
Pathology process £98.03 
Cost per specimen processed 
in pathology 
UHCW 
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FISH test £115 
Additional cost for 
outsourcing FISH 
UHCW 
MDT meeting 
 £95  
(£60 - £108) 
CMDT_B - Breast Cancer MDT 
Meetings (Cost per case 
discussed)  
NHS Ref 2016 - 
2017 
WLE surgery £967.50 
JA43B - Unilateral 
Intermediate Breast 
Procedures with CC Score 0-2 
NHS Ref 2016 - 
2017 
Mastectomy 
surgery 
£2419.86 
 JA20F - Unilateral Major 
Breast Procedures with CC 
Score 0-2 
NHS Ref 2016 - 
2017 
WLE and SLNB £1383.95 Cost of WLE x 1.43 
NHS Ref 2016 - 
2017 and 
Pandharipande et 
al. (2008) 
Mastectomy and 
SLNB 
£3460.40 Cost of Mastectomy x 1.43 
NHS Ref 2016 - 
2017 and 
Pandharipande et 
al. (2008) 
WLE and ALND £1615.73 Cost of WLE X 1.67 
NHS Ref 2016 - 
2017 and 
Pandharipande et 
al. (2008) 
Mastectomy and 
ALND 
£4041.17 Cost of Mastectomy x 1.67 
NHS Ref 2016 - 
2017 and 
Pandharipande et 
al. (2008) 
Re-biopsy £293.64 
YJ02Z - Unilateral Core 
Needle Biopsy of Lesion of 
Breast 
NHS Ref 2016 - 
2017 
Chemotherapy £3026.51 
Average of the 4 FEC 
regimens 
Joint Formulary 
Committee (2017)  
Chemotherapy and 
Herceptin 
£27626.51 £24,600 + £3026.51 
NICE 
(2006b)+Joint 
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Formulary 
Committee (2017) 
Cavity shave £354.47 
JA45Z -Unilateral Minor 
Breast Procedures 
NHS Ref 2016 - 
2017 
ALND 
£1420.90 
 
WH54B - Procedures on the 
Lymphatic System with CC 
Score 0 
NHS Ref 2016 -
2017 
Margin and ALND £1775.37 JA45Z + WH54B 
NHS Ref 2016 - 
2017 
Hormone therapy £790.83 5 year course of Tamoxifen 
Joint Formulary 
Committee (2017) 
 
The 2017 pathology process costs per specimen were obtained from the finance manager at 
UHCW. £98.03 is the cost of handling each specimen in the pathology lab regardless of the 
number of sections. This is a one off cost encompassing all specimen processing activities 
and tests carried out onsite, for specimens that have an ER and an IHC test also, the costs of 
these tests are included in the £98.03.For this reason all activities in the model associated 
with ER and IHC HER2 testing do not have a cost assigned. 
The model follows UHCW processes where FISH is outsourced and as such this is reflected in 
an extra cost at FISH activities.  A total cost of £115 is assigned to all FISH related activities; 
this is based on UHCW values and is made up of £110 for tests at the external laboratory and 
£5 delivery costs.  
No reference costs are available for breast surgery carried out alongside a SLNB or ALND; this 
was also reported by Cooper et al. (2011), Huxley et al. (2015) and Rafia et al. (2016). All 
three studies adopted the same method to calculate the costs of these procedures; the same 
method was adopted here. Pandharipande et al. (2008), a US based economic evaluation 
reported the cost of breast surgery alone, with SLNB and with ALND. The ratio of the cost of 
breast surgery alone to that with each of the lymph node interventions was calculated. This 
ratio was then used with the NHS reference costs for WLE and Mastectomy to estimate the 
costs to be included in the model at WLE with SLNB or ALND and Mastectomy with SLNB or 
ALND.   
Chemotherapy is given alone or in combination with Herceptin depending on the patients’ 
grade and HER2 status. The most commonly prescribed chemotherapy at UHCW is the FEC 
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group but at different doses and with or without docetaxel.  Table 5-9 gives an overview of 
the various FEC regimens given at UHCW. The model assumes patients are given 6 cycles of 
FEC or 3 cycles of FEC and 3 cycles of T when docetaxel is prescribed. The cost for each 
regimen is worked out based on 1.71m2; the average body surface area of a female cancer 
patient in the UK (Sacco et al., 2010). The total cost calculation assumes any unused content 
in vials is discarded. The cost for chemotherapy used in the model and reported in table 5-8 
is the average of the four regimens in table 5-9 below. 
Table 5-9 Summary of chemotherapy regimens at UHCW 
 FEC 75 FEC 100 FEC-T 75 FEC-T 100 
Dose 
Fluorouracil 
(600mg/m2)mg 
Fluorouracil 
(500mg/m2)mg 
Fluorouracil 
(600mg/m2)mg 
Fluorouracil 
(500mg/m2)mg 
Epirubicin 
(75mg/m2)mg 
Epirubicin 
(100mg/m2)mg 
Epirubicin 
(75mg/m2)mg 
Epirubicin 
(100mg/m2)mg 
Cyclophosphomide 
(600mg/m2)mg 
Cyclophosphomide 
(500mg/m2)mg 
Cyclophosphomide 
(600mg/m2)mg 
Cyclophosphomide 
(500mg/m2)mg 
  
Docetaxel (T) 
(75mg/m2)mg 
Docetaxel (T) 
(100mg/m2)mg 
Regimen 6 Cycles FEC  6 Cycles FEC 
3 Cycles FEC + 3 
Cycles T 
3 Cycles FEC + 3 
Cycles T 
Total 
Cost*  
£2482.02 £2379.66 £2845.26 £4399.08 
*F: 2.5g/100ml solution for infusion £32, E: 200mg/100ml solution for infusion £347.55, C: 1g powder solution for injection £17.06, T: 
80mg/8ml solution for infusion £534.75 (Joint Formulary Committee, 2017)  
UHCW patients are prescribed the 3weekly course of Herceptin for a period of 12months. 
NICE (2006b) Technology Appraisal (TA) works out the average cost per patient for this 
regimen to be £24,600. The TA is based on 2008 drug costs for Herceptin, however BNF 73 ( 
Joint Formulary Committee, 2017, pg. 796) states the cost per 150mg vial to remain at 
£407.40; identical to the value used in the TA. For this reason, the £24,600 is not adapted 
and the same cost for Herceptin is used in this model. The cost for hormone therapy is based 
on a 5-year course of Tamoxifen (Joint Formulary Committee, 2017).  
A DES model representing the breast cancer pathway that can be used in the evaluation of 
digital pathology has been developed and validated. The model parameters currently 
represent current practice, conventional microscope time and test result data based on 
UHCW data was used to inform the model parameters. This is ready for experimentation 
118 
 
through the modification of the appropriate parameters to reflect digitisation of pathology 
systems. Outputs from the DES model can be observed and measured to compare the time 
and cost implications for breast cancer patients prior and post-digitisation.  
5.3.2 Economic evaluation 
The DES model follows women with suspected early breast cancer through the stages of their 
management in secondary care.  
Entities arriving in the DES model can be defined as all new suspected breast cancer cases 
with one core biopsy from which a definitive diagnosis can be made. These can be with or 
without a lymph node biopsy specimen attached 
The model starts with the arrival of the first breast core biopsy specimen at the pathology 
lab and ends when the final steps of patients’ treatment plans are initiated. The model does 
not represent recurrent or malignant cases that have spread to other parts of the body, 
where cancer is diagnosed these are all early breast cancers that have not been previously 
treated.  
All cost and time model parameters are described and methods for estimation are given in 
the previous section, at this point the model reflects the use of conventional microscopes in 
pathology. The appropriate model parameters reflecting test results and time estimates that 
will be influenced by pathology digitisation can be manipulated to evaluate the changes in 
treatment prescribed and time to treatment that are expected with digitisation.  
The breast cancer pathway activities that are expected to be influenced by pathology 
digitisation were identified, these are referred to as the experimental factors and are listed 
in figure 5-6. The majority of these are associated with pathology TAT (turnaround time) or 
the biomarker results required to guide breast cancer treatment. Furthermore, changes in 
MDT efficiency with DP systems were also investigated. The appropriate parameters were 
adjusted to reflect digitisation as described in the published literature in chapter 3 or through 
discussion with clinicians at UHCW; these are highlighted and explained through the 
remainder of this section.  
5.3.2.1 Turnaround time 
Recent research suggests improvements in the time to diagnosis with digitisation. One study; 
Vodovnik (2016) measured and reported a 6% time reduction over the diagnostic period as 
well as suggesting based on observations, albeit not measuring these, a 10% overall time 
saving in the pathology workflow when time savings in the non-diagnostic period are 
considered. The DES model does not differentiate between the diagnostic and non-
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diagnostic elements, specimen processing in pathology is characterised by one activity 
encompassing both phases. The time distributions attached to these represent the time from 
the arrival of the specimen in pathology to the point a report is generated by the pathologist 
and is ready for discussion at MDT. This structural decision was largely driven by the UHCW 
data, independent time data for each phase of the pathology workflow was not available.   
With limited information, it is difficult to define the overall efficiency implications of 
digitisation for the pathology workflow with certainty.   A 10% hypothetical time saving was 
applied to all the corresponding activities in the model listed with TAT as an experimental 
factor in figure 5-6. This was not applied to FISH testing activities as these are carried out 
offsite and will not be influenced by digitisation at UHCW. The time estimates in the model 
that reflect CM were altered in parallel to reflect DP and are used to investigate the 
implications of this hypothetical time saving for the breast cancer pathway.  
In addition to overall time savings, the UHCW digital pathology business case suggests DP 
systems will make possible the availability of pathology reports for 50-60% of CBs on the 
same day as specimen arrival in the lab. The one day target is applied to CB processing and 
biomarker reporting on these specimens, depicting a second scenario for TAT.  
Through discussion with UHCW pathologists it was also understood that theoretically it was 
possible for CBs to be turned around on the same day, within 6 hours of specimen arrival in 
the lab, a third scenario for TAT will investigate the implications of this hypothesis for the 
breast cancer pathway.  
The consequences of digitisation for FISH reporting is the final TAT to be explored. Currently 
glass slides are sent from UHCW to an external pathology lab for FISH testing as UHCW do 
not have the infrastructure in place to perform this test onsite. The benefits of digitisation 
will be realised for this particular biomarker test only if the reporting laboratory also has 
digital systems set up to accept and examine electronic slides, in this situation glass slide 
delivery times will be eliminated. For FISH TAT, under the digital pathology scenarios, the 
model assumes that the reporting lab also has access to digital systems and the time to 
obtain a FISH result is equal to the time to report on IHC since delivery times are reduced 
from days to seconds.  
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Table 5-10 Summary impacts of Digital Pathology 
Time implications Accuracy implications 
Parameter Digital Pathology Reference Parameter Digital Pathology Reference 
Pathology  
TAT 
10% time saving in pathology activities  Vodovnik (2016) 
Grade 
results 
If HER2 negative:  Grade1-29%  
                                 Grade2-43%  
                                 Grade3-28% 
If HER2 positive:   Grade2-32%  
                                 Grade3-68% 
Longacre et 
al. (2006) 50% of CB cases reported in 1 day UHCW Business Case 
100% of CB cases reported in 6 hours UHCW pathologists 
MDT  All cases discussed in 2minutes 
Ruiz-Casado et al. 
(2014) 
HER2 IHC 
results 
22% reduction in 2+ scores 
7% reduction in positive cases 
9% increase in negative cases 
(Dobson et 
al., 2010) 
FISH TAT Equal to IHC TAT  ---- 
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5.3.2.2 MDT efficiency 
The current time taken to discuss each case at UHCW MDT ranges from 2.25 to 3 minutes 
depending on the day of the week. Research into DP impacts on MDT are limited and only 
one study truly measured and compared the MDT discussion time per case when 
conventional and digital systems are in place. Thorstenson et al. (2014) observed a 40% 
decrease in discussion time, from 6 minutes with conventional to 3.6 with digitisation per 
case. Currently without DP, UHCW cases take less time than this to discuss at MDT, a 40% 
reduction in current discussion time will imply cases are discussed in 1.35 or 1.8 minutes 
depending on the day of the week which logically is not practical. 
A second study, Ruiz-Casado et al. (2014) implemented an audit of cancer MDT meetings, 
they reported an average 3 (2 to 4) minute discussion time per breast case which falls in line 
with UHCW data. Although Ruiz-Casado et al. (2014) did not particularly investigate 
digitisation, under the digital pathology scenario the effects on the breast cancer pathway if 
all cases are discussed by MDT in 2 minutes i.e. the lower bound of time when conventional 
microscopes are used for pathology reporting, was explored.   
5.3.2.3 Reporting Accuracy 
In addition to the pathology workflow and MDT impacts, digitisation of pathology systems 
are expected to have influence on the accuracy of test results as described in chapter 3, 
particularly where image analysis alongside digital pathology systems are used to 
supplement pathologist’s reporting. Notably for breast cancer patients the outcomes of 
interest are ER, HER2 and grade results.  
ER 
It was evident through discussion with pathologists at UHCW that they expected minimal or 
no impact of digitisation on the ER status reported. They already considered these results to 
be fairly accurate. The ER biomarker test is generally easy and quick to carry out, it follows a 
binomial scoring pattern, tumours are either strongly positive or negative, very rarely will 
there be a mid-range reading that is difficult to interpret. Among the digital pathology 
research described in chapter 3 there were no published study reporting the accuracy of ER 
scoring with each of the two pathology techniques but several measured and reported a 
good level of concordance at best showing ER scoring with digital to be equivalent to that 
with conventional microscopes. The economic analysis assumes ER result proportions are 
not influenced by pathology digitisation, the model distribution representing this test result 
that is used for the conventional analysis remains identical under the digital model scenarios.  
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HER2 status 
The second breast cancer test to be considered is that to determine HER2 IHC status. Dobson 
et al. (2010) published study specifically compares HER2 IHC scoring using conventional 
microscopes to digital pathology with image analysis and measures these against an agreed 
reference standard to define the reporting accuracy of each approach for this biomarker test. 
Sensitivity and specificity are improved with digitisation with the former increasing from 65% 
to 68% and the latter from 99% to 100%. Furthermore the share of equivocal results reported 
fall from 23.5% with conventional to 18.4% with digital.  
UHCW data showed the divide between the three HER2 IHC scores to be 14% as positive, 
23% as equivocal and 63% as negative results. If the result changes with digitisation observed 
by Dobson et al. (2010) are applied to the UHCW data, the HER2 results will split  so that 13% 
of all cases are positive, 18% are equivocal and 69% are negative. A model distribution to 
reflect these results is generated and input in the model at the appropriate parameters when 
conducting the digital pathology analysis. 
Grade 
The accuracy of the grade result reported on the surgical specimen is the final model 
parameter that is predicted to be influenced by digitisation. As with ER results, no published 
study has carried out a head-to-head study comparing grade using CM and DP. Longacre et 
al. (2006) studied the accuracy of grade classification and reported this for each of grades 1, 
2 and 3 breast cancers. They compared the breast cancer grade reported using conventional 
microscopes to an agreed reference standard. The results of their study are given in table 5-
11.  
Table 5-11 Accuracy of breast cancer grade reporting 
Since there is no current published research on the 
implications of digitisation for breast cancer grade 
a hypothetical scenario is constructed. It is 
assumed that the accuracy of the grade 
distribution reflecting UHCW results that is input 
into the model is accurate at the mean rates reported in Table 5-11. An assumption is made 
that with digitisation, accuracy improves to the upper limits reported in table 5-11 so that 
16.7% of grade 1 cancers are upgraded with DP and 7.75% of grade 3 cancers are 
downgraded. For grade 2 cancers, HER2 status is also considered alongside since the model 
includes a separate grade distribution for each HER2 result. 18.7% of grade 2 cancers are 
Grade Mean Lower Upper 
1 83.3% 75% 100% 
2 64.6% 50% 83.3% 
3 92.3% 79% 100% 
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assumed to alter with DP. For the HER2 negative cases the 18.7% error rate is split equally 
i.e. 9.4% are downgraded to grade 1 and 9.4% are upgraded to grade 3. For the HER2 positive 
group there are no grade 1 cancers so an assumption is made that all these are upgraded 
with digitisation to grade 3 cancers.  
5.3.2.4 Scenario Analysis 
Due to the extent of the impact of digitisation there were several model parameters that 
need to be altered to reflect this scenario. These include both time and test result 
parameters as described in table 5-12. The scenarios constructed for experimentation are all 
hypothetical due to the limitations of the primary research around the impacts of 
digitisation.  
Table 5-12 Experimental scenarios 
CM: Base case scenario 
Pathology TAT As described in table 5-7 
MDT Tuesday: 3min/case Thursday: 2.25min/case 
FISH TAT 11.58 days 
Grade 
If HER2 negative Grade 1: 30%  Grade 2: 44%   Grade 3: 26% 
If HER2 positive Grade 1: 0%     Grade 2: 33%   Grade 3: 67% 
HER2 IHC results  Negative: 63%  Equivocal: 23% Positive: 14% 
DP: Scenario 1 
Pathology TAT 
10% overall time saving at all pathology related 
activities 
MDT  All breast cases discussed in 2min 
FISH TAT Equal to IHC TAT 
Grade 
If HER2 negative Grade 1: 29%  Grade 2: 43%   Grade 3: 28% 
If HER2 positive Grade 1: 0%     Grade 2: 32%   Grade 3: 68% 
HER2 IHC results Negative: 69%  Equivocal: 18% Positive: 13% 
DP: Scenario 2 
Pathology TAT 50% of CB cases reported in 1 day 
MDT  All breast cases discussed in 2min 
FISH TAT Equal to IHC TAT 
Grade 
If HER2 negative Grade 1: 29%  Grade 2: 43%   Grade 3: 28% 
If HER2 positive Grade 1: 0%     Grade 2: 32%   Grade 3: 68% 
HER2 IHC results Negative: 69%  Equivocal: 18% Positive: 13% 
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DP: Scenario 3 
Pathology TAT 100% of CB cases reported in 6 hours 
MDT  All breast cases discussed in 2min 
FISH TAT Equal to IHC TAT 
Grade 
If HER2 negative Grade 1: 29%  Grade 2: 43%   Grade 3: 28% 
If HER2 positive Grade 1: 0%     Grade 2: 32%   Grade 3: 68% 
HER2 IHC results Negative: 69%  Equivocal: 18% Positive: 13% 
 
In order to grasp the full extent of potential implications, three hypothetical scenarios were 
drawn up as listed in Table 5-12. The first explores the impacts of an overall 10% time saving 
in workflow for all pathology related activities, the second investigates implications if CBs are 
reported on in one day from arrival in the lab and the third if CBs are reported on in 6 hours. 
All three scenarios are altered similarly to reflect test results, FISH TAT and MDT efficiency 
when digital methods are used in pathology.  
5.3.2.5 Output Analysis 
Four model outputs were measured under each digital pathology scenario and compared 
against the CM model outputs. These are: 
1. The time each breast patient spends in the pathway  
The time effect of pathology digitisation for breast cancer patients is one of the outcomes to 
be investigated. The DES model allows the tracking of different groups of patients through 
the breast cancer pathway recording the time each spent in the DES model. All breast cases 
have the same start point i.e. the arrival of CBs in pathology. However each breast case will 
take a different route through the model each with its own endpoint depending on the initial 
CB result. The total time spent in the model pathway will vary, therefore the model time 
outputs were analysed separately dependent on the initial CB result of the breast case. 
Patients can be spilt into 4 groups as described in table 5-13.  
Table 5-13 Patient groups to be analysed independently 
Initial CB result Arrival Point End Point 
Benign (B1/B2) 
Arrival of CB with 
definite diagnosis 
in pathology 
Date of discharge 
In situ (B5a) Date of discharge  
Invasive (B5b) 
Neoadjuvant 
Date of oncology meeting post-surgery where 
final systemic treatment agreed with patient 
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Invasive (B5b) 
Adjuvant 
Date of oncology meeting where adjuvant 
treatment plan agreed with patient 
 
2. The recommended treatment packages 
In addition to time savings, accuracy adjustments resulting from pathology digitisation will 
impact the treatment prescribed. Simul8 allows the capture of this information by counting 
the number of work items passing through an activity related to a treatment package, 
facilitating the comparison of treatment plans before and after digitisation. 
3. The number of FISH tests requested 
Accuracy adjustments in particular those related to HER2 assessment whereby the 
probability of reaching a definitive diagnosis on the first IHC test improves will also impact 
the number of times cases are discussed at MDT and the number of external FISH tests 
ordered. 
4. The number of MDT discussions per patient 
5. Cost/patient 
All performance measures and the simulation object from which they are collected are given 
in table 5-14. The inbuilt Simul8 trial calculator was used to determine the number of runs 
to be carried out to reach a 5% precision level for each performance measure. The results 
are given in table 5-14 and based on this the model is run 1114 times for each scenario trial.  
Table 5-14 Simul8 trial calculator results 
Outcome Simulation Object Performance Measure 
Recommended Runs 
for 5% precision 
Treatment 
plans 
Neoadjuvant 
chemotherapy  
Number completed Jobs 334 
Adjuvant 
chemotherapy 
Number completed jobs 12 
Neoadjuvant 
chemotherapy and 
Herceptin 
Number completed Jobs 730 
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Adjuvant 
chemotherapy and 
Herceptin 
Number completed jobs 26 
FISH test 
ordered 
Three FISH related 
activities included 
in the model 
Number completed jobs 30 
Number completed jobs 33 
Number completed jobs 1114 
MDT 
discussions 
MDT Number completed jobs 9 
Time to 
endpoint 
Benign cases Average Time in system 4 
DCIS cases Average time in system 4 
IBC and 
neoadjuvant  
Average time in system 125 
Invasive and 
adjuvant 
Average time in system 4 
 
The original version of the model representing the use of conventional microscopes in the 
pathology lab was initially run to generate outputs for conventional microscope for each of 
the performance measures against which the digital pathology outputs from each of the 
three scenarios can be compared. The pathway is modified to reflect each of the scenarios 
listed in table 5-12, outputs are generated and compared to those of the conventional 
microscope scenario. Due to the many hypothetical impacts of digitisation, the inclusion of 
many experimental scenarios will identify the model parameters that are likely to have the 
most impact and need to be explored further to ascertain their influences on the breast 
cancer pathway.  
The economic evaluation takes an NHS perspective and follows patients through secondary 
care. A one-year time horizon over which costs and outcomes are evaluated is sufficient and 
discounting does not need to be applied.  
The arrival rate of breast core biopsy specimens in the pathology lab does not change with 
digitisation. The mean number of breast cases arriving in the model over a one-year period 
is 682, the model has been programmed to follow these through to the various end points 
depending on the initial CB result as described earlier. After running for one year, the model 
prevents any further breast cases arriving in the model but continues to allow already 
entered cases to follow through and complete their pathways. The model is designed to stop 
running once all breast cases have reached their appropriate endpoints
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5.4 Results 
5.4.1 Model validation 
Prior to carrying out any analysis, the model was validated by running it and comparing it to 
the real system, the breast cancer pathway at UHCW. If the inputs to the model are the same 
as reality then the outputs from the model should also be reasonably similar to real data. 
The total time a breast cancer patient spends in the model is compared to the data collected 
in order to validate the model. However as there are two groups of cancer patients 
dependent on their treatment plans and each with a different end point these are first 
separated out.  
The first model output to be compared is the time it takes for a breast case to reach the point 
of adjuvant treatment planning in oncology from CB specimen arrival in pathology. In 
particular these are cases that have been diagnosed as invasive whose treatment plan was 
made up of surgery followed by adjuvant therapy. The data collected from UHCW is 
compared to the model output. Figure 5-7 illustrates the point estimate of the number of 
days with 95% confidence intervals and figure 5-8 shows the results of a two sample t-test.  
At the 0.05 level of significance there is no evidence to suggest that there is a difference in 
the mean total time between the model output and the data collected at UHCW.  
Figure 5-7 Days from CB arrival in pathology to adjuvant treatment plan 
 
 
 
 
 
 
Figure 5-8 Two sample t-test comparing data and model output 
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Identical steps were also carried out for the patients recommended neoadjuvant therapy in 
the dataset and in the model. For this group the time from CB arrival in pathology to 
discharge from secondary care is calculated. The mean output from the model at this stage 
is 227 (95%CI: 125, 330) days with the time for neoadjuvant cases in the dataset falling within 
the model’s confidence interval.  
5.4.2 Conventional microscope outputs 
The first stage in determining the impacts of digitisation is to understand the model outputs 
when conventional microscopes are used in the pathology lab.  The model was run as it is 
constructed and populated initially, reflecting current standard practice for breast cancer. 
The outputs for this scenario against which those from the three digital pathology scenarios 
were compared are given in table 5-15.  
The number of completed jobs recorded at the MDT activity includes all suspected breast 
cancer cases referred for investigation. Patients with a benign or in situ diagnosis are 
relatively simple to handle and the number of MDTs they are discussed at will not be 
influenced by pathology digitisation since no supplementary testing beyond the basic tissue 
analysis is carried out on these specimens. Contrarily, invasive cases are a lot more complex 
to manage and will present at MDT meetings at least twice for discussion. These are 
separated from the remainder of breast cases and the number of times each patient is 
discussed at MDT is recorded. Each invasive breast cancer case is discussed on average 4.5 
times when conventional microscopes are used, with nearly 60% of patients presenting at 3 
or 4 MDT meetings over the course of their breast cancer pathway. Summary of the number 
of MDT discussions per invasive breast cancer case is given in figure 5-9. 
Figure 5-9 Histogram of the number of times an invasive breast cancer case is discussed at 
the MDT meeting 
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Table 5-15 Model outputs under each scenario 
Model output CM DP1 DP2 DP3 
Average time in pathway (days) 
Benign cases 4.46 3.90 3.21 1.76 
∆ ↓0.56 ↓1.25 ↓2.7 
DCIS cases 34.40 32.45 32.69 31.08 
∆ ↓1.95 ↓1.71 ↓3.32 
IBC cases: Neoadjuvant treatment 251.53 231.62 233.24 240.33 
∆ ↓19.91 ↓18.29 ↓11.2 
IBC cases: Adjuvant treatment 60.22 55.81 55.42 52.52 
∆ ↓4.41 ↓4.8 ↓7.7 
Annual number of patients recommended each treatment package  
Neoadjuvant: Chemotherapy 5.73 5.95 
Neoadjuvant: Chemotherapy and Herceptin 2.60 2.18 
Adjuvant: Chemotherapy 123.74 132.14 
Adjuvant: Chemotherapy and Herceptin 65.39 55.98 
Annual number of FISH tests requested 98.14 76.23 
∆ ↓21.91 
Annual number of MDT discussions 1616.12 1496.99 1366.98 1248.76 
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 ∆ ↓119.13 ↓249.14 ↓367.36 
Annual total cost of systematic therapy 
Neoadjuvant: Chemotherapy £17,354.89 £17,996.05 
Neoadjuvant: Chemotherapy and Herceptin £71,819.01 £60,163.30 
Adjuvant: Chemotherapy £374,510.24 £399,934 
Adjuvant: Chemotherapy and Herceptin £1,806,461.28 £1,546,489  
Total  systemic therapy cost £2,270,145.42 £2,024,582.35 
∆ ↓£245,563 
Annual cost of FISH testing  £11,286.62 £8,765.70 
∆ ↓£2520.92 
Annual cost of MDT £153,531.08 £142,213 £129,863 £118,631 
∆ ↓£11,317 ↓£12,667 ↓£34,889 
Annual ∆ costs 
∆ Total  -£259,401 -£271,751 -£282,983 
∆ Cost /patient -£380 -£398 -£414 
∆ Cost /IBC patient -£1085 -£1137 -£1184 
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5.4.3 Digital pathology outputs 
The model outputs are not influenced by all the experimental factors. The treatment plans 
prescribed and the number of FISH tests ordered are driven by test results, which do not 
change across the three digital pathology scenarios, one model output distribution is given 
for each of these performance measures. The number of MDT discussions and the time to 
end-point for each breast case type are influenced by both the accuracy and time 
experimental factors, for these measures an output distribution is given for each digital 
pathology scenario. The results of the digital pathology scenarios are given in table 5-15 
alongside the CM outputs.   
The DP scenario model outputs suggest changes in breast cancer treatment plans with 
digitisation; these are very small for the neoadjuvant cases primarily due to the very limited 
sample size. However for adjuvant cases the variations are greater, ten patients will avoid 
chemotherapy treatment altogether and 9 patients are downgraded from Herceptin and 
chemotherapy regimen to chemotherapy treatment only. This change corresponds to an 
overall cost saving since the combined treatment plan is associated with greater cost. In 
addition, more than one in every five FISH tests ordered under the conventional microscope 
scenario are avoided with digitisation, corresponding to over £2500 saved on offsite FISH 
testing and contributing to time savings in the pathway whilst awaiting the arrival of external 
test results.  
Similar trends are realised for the total number of MDT discussions, these are reduced across 
all three digital pathology scenarios corresponding to annual cost savings of approximately 
£11000, £24000 and £35000. Through modelling it was possible to combine the impacts of 
changes in pathology workflow on MDT discussions per case with the effects of changes in 
accuracy, particularly the reduction of FISH testing and the increased availability of definitive 
HER2 results on the first round of testing.  A histogram of the number of MDT discussions 
per case for each pathology scenario is given in figure 5-10.  
DP1 scenario reduces the upper limit of MDT discussions/patient from 11 with CM to 8 
presentations. Over 60% of cases are now discussed at a total of 3 or 4 meetings.  DP2 
reduces the upper limit to 7 days whilst maintaining that over 60% of cases are discussed at 
3 or 4 meetings.  DP3 reduces the maximum even further to 5 meetings and ensures that 
over 80% of cases are present at no more than 3 meetings for discussion. Figure 5-11 
illustrates a statistically significant reduction in the mean number of MDT meetings/patient, 
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decreasing from an average 4.5 discussions IBC patient with CM to 4, 3.5 and 3 with DP1, 
DP2 and DP3 respectively.  
Figure 5-10 Histogram of the number of MDT discussions/IBC patient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-11 Mean number of MDT discussions/IBC patient 
 
 
 
 
 
 
 
 
 
 
133 
 
The final performance measure of interest is average time in the breast cancer pathway for 
each group of patients. Across all three DP scenarios, time savings are observed for all the 
types of breast cases, whether these are benign and discharged or are invasive and are 
exposed to the full extent of activities in the pathway. For the benign cases, time savings in 
the pathway ranged from half a day to over 2.5 days. For the DCIS cases this ranged from 
nearly 2 days to over 3 days. For the IBC cases time savings can be as high as 7.7 days if 
patients are recommended an adjuvant treatment plan or over 11 days where a patient is 
recommended a neoadjuvant treatment plan.  
As with MDT discussions, modelling allows the analysis of the combined time impact of 
pathology workflow efficiency and accuracy effects. The changes seen in time to End for 
benign cases and IBC cases are due to pathology workflow improvements only. For time to 
END for IBC cases who receive adjuvant treatment, time savings result from a combination 
of pathology workflow efficiencies and test result changes. Finally for IBC cases who receive 
neoadjuvant treatment the time savings in the pathway are the greatest, this is largely due 
to the inclusion of time for neoadjuvant treatment being in the time to end-point. The time 
savings observed are a combination of enhancements in pathology workflow, accuracy and 
changes in treatment plans which influence the time taken to administer neoadjuvant 
therapy.  
When all cost consequences were combined, cost savings were observed across all three DP 
scenarios. For every patient referred to secondary care with suspected breast cancer the 
total cost saving ranged from £380 to £415. All performance measures on which the total 
cost savings are based are borne as a result of changes in the pathways of IBC patients.  
Benign and DCIS cases do not undergo FISH testing or supplementary reporting beyond the 
classification of the type of cancer cells. These cases are discussed at MDT once if benign and 
twice when DCIS. When the cost savings are attributed to IBC cases only they ranged from 
£1085 to £1184 per patient depending on the DP scenario under investigation.  
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5.5 Discussion 
A DES model representing the breast cancer pathway that can be used in the evaluation of 
pathology interventions has been developed and validated. The model was used to measure 
the costs and consequences of pathology digitisation through the manipulation of the model 
parameters that correspond to the experimental factors of digitisation.  Outputs from the 
DES model were measured to compare the time and cost implications for breast cancer 
patients prior and post pathology digitisation.  
The economic analysis showed pathology digitisation to result in time savings in the pathway 
for all types of suspected breast cancer cases, whether they are determined to be benign 
and discharged or are invasive cases that go on to surgery and systemic treatment. All breast 
cases experience a time saving in their pathway under all of the three scenarios that 
represent pathology digitisation. Furthermore, there was a reduction in the number of MDT 
discussions for invasive cases and the number of FISH tests requested with evidence of an 
overall cost saving across all the DP scenarios when compared to the use of CM.  
Accuracy of test results drives the largest cost saving, producing changes in the systemic 
therapy prescribed, the number of FISH tests ordered and in addition playing a role in 
adjustments in the number of MDT discussions over the time horizon of the study. The cost 
of outpatient appointments are not computed in the model, these run in parallel to MDT 
meetings, a reduction in MDT will result in a similar decrease in OPAs, leading to greater NHS 
cost savings, better use of clinician time and avoiding unnecessary hospital visits by the 
patient. However the cost-savings listed do not take account of the investment needed to 
setup digital pathology systems. According to the UHCW business case digital pathology 
requires nearly £2,000,000 of investment over the initial 7years of the project, this is 
equivalent to approximately £277,000 per annum. This figure is very similar to the annual 
cost savings predicted under each of the breast cancer digital pathology scenarios 
considered. Under scenario 1 there is a £259,000 cost saving, scenario 2 there is over 
£270,000 saved and for scenario 3 over £282,000 is saved.  Undeniably the benefits of 
digitisation will not stretch to the breast cancer pathway only but to other cancers and 
beyond these to other disease areas. If similar cost savings are observed for each of these 
disease areas, it will certainly make digital pathology a cost-saving venture.  
The time savings observed under each DP scenario will support the realisation of government 
cancer waiting time targets. The 62-day target from arrival in secondary care through to the 
date of treatment overlaps with the start and end point in the model of invasive breast 
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cancer cases that are recommended surgery followed by adjuvant treatment. These cases 
experience a 4.4, 4.8 or 7.7 daytime saving under each of the DP scenarios. Under the CM 
scenario the 62 day target is already met at UHCW, the average time being 60 days with 96% 
of breast cases starting treatment within 62days.  Under the DP scenarios this period is 
reduced further. 
 A similar trend was seen when analysing the UHCW data around the time for discussion of 
each case in MDT, it appeared that UHCW was well within the standard ranges for this. 
UHCW is a large teaching hospital with the infrastructure and resources in place to provide 
the best standard of care for patients. For features of the breast cancer pathway that already 
are at maximum efficiency at UHCW, digitisation has little influence, this may not be true for 
smaller, less well maintained hospitals. Digital pathology can be a means by which to get 
standards of care closer to those seen at a larger teaching hospital, reducing inequalities in 
diagnosis and treatment and improving outcomes, here the impacts of digitisation can be 
greater. The appropriate model parameters, especially those associated with time can be 
manipulated to reflect practice at smaller hospitals, the outcomes from such an analysis can 
be compared to the outcomes reported when time parameters are based on UHCW data to 
overcome the issues of generalisability of the results. 
The economic analysis described in this chapter presents results for three different scenarios 
representing digital pathology. Whilst the CM analysis is based on UHCW patient level data 
and is not hypothetical, the impacts of pathology digitisation that are applied to the CM 
model are in most cases hypothetical. The changes in HER2 test results reported with 
digitisation is based on a head-to-head study, however grade is based on the hypothesis that 
digitisation will eliminate current levels of inaccuracy in grade reporting. No primary research 
has compared the breast cancer grade reported using CM and DP. Identical HER2 and grade 
changes are applied across the three scenarios.  
While the results of the economic analysis are promising for digitisation the primary research 
used to inform the experimental factors are not without flaws. Research into the impacts of 
pathology digitisation is limited, the scenarios setup are largely based on assumptions. 
Ideally head-to-head studies comparing results for each of the experimental factors under 
the conventional and digital scenarios are needed. Based on these, distributions can be 
constructed and input into the model for each scenario analysis. This sort of data was only 
available for HER2 status reporting. Information on the accuracy of breast cancer grade 
reporting with digitisation is non-existent and for time savings the data is very limited. This 
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issue was also evident in the economic analysis carried out by Ho et al. (2014), many of their  
model inputs were based on author assumptions rather than good-quality primary research. 
Evaluation of pathology services carries with it additional challenges not present across other 
healthcare interventions largely due to the indirect relationship between pathology and the 
patient. Perhaps the results of the economic analysis are overly optimistic but it is 
challenging to carry out a good-quality economic evaluation based on which decisions can 
be made with limited available research to inform the model parameters. 
The aim of the economic analysis was not to estimate the cost-effectiveness of digitisation 
but to provide an overview of the experimental factors and model outputs that appear to 
make the greatest contribution to patient care in order to justify further research to support 
the introduction of digitisation. The accuracy of test results used to guide treatment is the 
experimental factor of greatest interest, it made the largest contribution to cost savings and 
is expected to improve patient quality of life where improved accuracy with digitisation 
makes for better management of treatment. Although the analysis measured changes in 
treatment plans, this remains an intermediate outcome and findings need to be extrapolated 
to determine the consequences for patient quality of life. Invasive breast cancer cases are 
the group most influenced by digitisation, through both accuracy changes and time savings 
thus justifying the focus of future research on this group of patients. Of the biomarker tests 
used to guide breast cancer treatment, HER2 testing was the most explored with several 
research publications comparing the sensitivity and specificity of this test under each of the 
pathology approaches. Further research around this particular biomarker is needed to 
consolidate the various literature and start to build a portfolio of research to support 
investment in digital pathology.  
In reality the DES model developed can not only be used as a tool to investigate further the 
impacts of pathology innovation on the breast cancer pathway but can be also  be used to 
explore the impacts of modifications at any point of the pathway. It has been developed with 
pathology services in mind but the availability of the schematic of the overall breast cancer 
pathway in chapter 4 means the model can easily be adapted to focus the investigation on 
other services in the pathway.  
The economic benefit of digital pathology through its speed and accuracy implications is 
conditional on the effect of these on the patient experience through the breast cancer 
pathway. Changes in test results and time savings pave the way for improved and early 
management of disease. These are the targeted processes that are the stepping stone 
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between pathology and patient care. The value of pathology digitisation can only be 
measured when the full sequence of events is considered.  Current published literature 
spanning across all three domains is non-existent, research highlighting the effects of 
digitisation on the pathology workflow and the accuracy of biomarker tests is becoming 
increasingly available, yet these do not go beyond these transitional points by extrapolating 
outcomes to breast cancer patients.  
Current knowledge around the cost benefit of digitisation is scarce, one study Ho et al. (2014) 
measured the cost savings based on pathologist time saved and improved interpretive 
accuracy. However, they do not extrapolate time savings in pathology to explore time savings 
for the patient’s cancer pathway. The accuracy improvements they assume with digitisation 
are based on the removal of current interpretive errors rather than a comparison of current 
accuracy with estimated accuracy with digitisation. Furthermore, their accuracy 
investigations are based on diagnosing one subtype of breast cancer correctly and they do 
not go as far as considering the accuracy of the underlying biomarkers that guide treatment 
management. Nonetheless, their economic analysis reports cost savings of $17.73 million 
over the 5 year roll out period of digital pathology.  
5.6 Conclusion 
The economic analysis has shown digital pathology to be associated with positive outcomes 
for the breast cancer pathway through both time and cost savings. This analysis acts as a 
preliminary study in determining the cost-effectiveness of pathology digitisation. The 
scarcity of research comparing conventional and digital pathology outcomes for each of the 
experimental factors has been highlighted. As data becomes available through head-to-head 
studies or even through systematic review and meta-analysis, the model can be updated 
through the amendment of the model distributions to reflect these and the results of the 
analysis updated for use by decision makers.   
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Chapter 6: Systematic review and meta-analysis of HER2 
testing accuracy 
6.1 Introduction 
The previous chapters investigated the impacts of pathology digitisation as a generic process 
by measuring its combined effects within the breast cancer pathway. Evidence of time 
savings in the pathway and changes in treatment plans for breast cancer patients exist. 
However, model probabilities reflecting changes in time and test results with digitisation 
were largely hypothetical or based on single-study estimates.  Of the experimental factors 
listed in the previous chapter, the HER2 biomarker IHC test had the largest published 
evidence base comparing HER2 test results reported by CM and DP.  
This chapter aims to build on the available literature by adopting data synthesis methods to 
compare the accuracy of CM and DP. Systematic review methods were used to retrieve 
individual studies comparing HER2 IHC scores across both arms. The accuracy data from each 
of the studies identified were synthesised by using meta-analysis techniques to generate 
pooled accuracy estimates for each of CM and DP.    
6.1.1 HER2 amplification and overexpression 
Human Epidermal Growth Factor Receptor 2 (HER2) is found on the surface of all cells since 
it is involved in normal cell growth and division (Rubin and Yarden, 2001). The HER2 receptor 
is encoded by a HER2 gene controlling the number of receptors on the surface of the cell. 
When this gene is amplified HER2 receptors are overexpressed (Slamon et al., 2001) and thus 
cell growth and division intensifies; a typical characteristic of cancerous cells.  Figure 6-1 
taken from The Journal of the Advanced Practitioner in Oncology (JADPRO, 2016) illustrates 
this process.   
This situation is not found in all cancer cells as it is only one of the many ways by which they 
will proliferate. Breast cancers that show HER2 gene amplification or HER2 receptor 
overexpression have been reported to represent up to 30% or less of all cases (Mitri et al., 
2012). Prior to the introduction of any targeted therapy for HER2; Slamon et al. (1987) 
investigated the correlation of HER2 status with relapse and survival; they found a strong 
and significant correlation with both. Women confirmed as positive for HER2 experienced a 
more aggressive form of the disease with markedly reduced disease free and overall survival 
(Mitri et al., 2012) compared to those with negative HER2 status.  UK audits have shown that 
overall 14.5% of breast cancers are HER2 positive (Ellis et al., 2016). 
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Figure 6-1 HER2 receptor expression in normal and cancerous cells         
                                        
 
 
 
 
 
 
 
 
 
6.1.2 Anti-HER2 therapy 
Advances in medicine have resulted in the discovery of anti-Her2 therapy; specifically 
targeting cancerous cells that show HER2 amplification or overexpression. The monoclonal 
antibody Trastuzumab more commonly known as Herceptin attaches itself to the receptors 
on the surface of the cells blocking those signals that are telling it to continue growing and 
dividing (CARLSON, 2008). The clinical trial HERceptin Adjuvant (HERA) comparing Herceptin 
with no Herceptin showed a 50% reduction in the recurrence rate when initial results were 
reported at the one year point of median follow up (Piccart-Gebhart et al., 2005). Moving 
forward the final report on this trial further reaffirmed the improvement in disease free 
survival. Cameron et al. (2017) reported their findings after a median 11 years of follow up; 
their conclusions showed a reduction in the risk of disease-free survival (HR 0·76, 95% CI: 
0·68, 0·86) and death (0·74, 95% CI:0·64, 0·86) when one year of Herceptin treatment is given 
compared to just observation. With these encouraging outcomes came recommendations 
for Herceptin to be introduced into the treatment plans of HER2 positive breast cancer 
patients. NICE’s first recommendations for the use of Herceptin by the NHS came in 2006 
(Mayor, 2006) with the publication of guidelines for its use in early stage breast cancer (NICE, 
2006b); notably this was following HERA trials publication of initial one year results.  
6.1.3 Approaches to HER2 testing 
It is has now been established that Herceptin is an effective anti-HER2 therapy; treatment 
will only succeed if the cancer is confirmed to be positive for HER2 amplification or 
overexpression; thus it is important that true HER2 status is established correctly prior to 
administration of Herceptin.  Data collected at UHCW has shown that all core biopsies with 
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an invasive result are routinely referred for HER2 testing. Any patients upgraded from a non-
invasive lesion on biopsy to an invasive lesion on their surgical specimen will have their HER2 
testing at this point. In most cases HER2 tests are not repeated on the surgical excision if a 
result is available from biopsy since research has shown high levels of concordance between 
both (Rakha et al., 2014). In particular a meta-analysis by Chen et al. (2012) showed  over 
97% specificity when HER2 results were reported on biopsy compared to surgical specimen. 
The specimen type used for HER2 testing does not impact results reported eliminating the 
introduction of uncertainty through this avenue.  
6.1.3.1 IHC versus FISH 
Two tests are available to determine HER2 positivity; immunohistochemistry (IHC) and 
fluorescence in situ hybridisation (FISH). They each measure different features of the cell to 
determine HER2 status. IHC counts the receptors on the surface of the cell whilst FISH 
quantifies gene amplification (Hicks and Schiffhauer, 2011). Though they both determine 
HER2 status for guiding Herceptin treatment there are differences in how they are 
performed, which leads to the general recommendation that IHC is carried out initially 
followed by FISH if results are inconclusive. HER2 IHC results on breast specimens are scored 
as 0 or 1+; considered negative, or 2+; showing an equivocal result or 3+; reported positive. 
IHC is cheaper and easier to perform than FISH (Schmidt, 2011) but reporting of results is 
subjective, potentially leading to inter-observer variability (Nitta et al., 2016). While this may 
not be a major setback for equivocal scores on IHC since they are generally confirmed by 
FISH, it poses a problem for 1+ and 3+ results. Here Herceptin can in theory be omitted where 
needed or prescribed when not required if results reported do not reflect true status since 
1+ and 3+ IHC are not routinely referred for FISH testing for confirmation.  
On the other hand slides for FISH are examined using a fluorescence microscope rather than 
a conventional bright field microscope as with IHC (Nitta et al., 2016) making it a lot more 
expensive and time intensive; but reporting results takes a more quantitative approach than 
IHC (Furrer et al., 2015). However, not all laboratories have the resources to undertake FISH 
testing onsite; this is especially the case at UHCW where FISH testing is outsourced not 
merely adding the cost of an extra test but also the further cost of delivery to and from the 
second laboratory. Due to the more quantitative method for scoring FISH results it is 
considered the gold standard in HER2 testing (Panjwani et al., 2010) irrespective of its 
associated shortcomings.   
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HER2 IHC
1+ 
Negative
3+ 
Positive
2+ 
Equivocal
HER2 FISH
Amplified
Non-
Amplified
14.7% 85.3%
0
Negative
21.7%
11.6%
33.6%
33.1%
6.1.3.2 Developments in testing 
Approaches for the quantification of HER2 IHC scoring; producing results closer to FISH have 
been suggested. Conventionally slides for IHC are prepared and viewed under a microscope 
by a pathologist who reports these results for discussion at MDT meetings. Digital Pathology 
(DP) allows these same glass slides to be scanned and viewed on a computer screen ready 
for examination by a pathologist. Additionally with the introduction of DP comes the 
opportunity for Image Analysis (IA) computer software to support the pathologist’s 
reporting. These produce more accurate and reproducible results by way of digital 
measurement (Nassar et al., 2011a) rather than subjective pathologist interpretation. IA 
involves the use of algorithms to quantify and score a range of cell features (Webster and 
Dunstan, 2014) including the presence of HER2 overexpression or amplification. There are 
several IA software available all of which have their own integrated method for scoring HER2 
on breast specimens; for ease of interpretation at MDT these are translated to the 
conventional IHC 0, +1, +2 or +3 score for reporting.  
6.1.4 HER2 testing algorithm 
Irrespective of the method that will be used for viewing IHC glass slides, HER2 testing follows 
a two-step process as observed at UHCW. Firstly, the IHC test is carried out followed by FISH 
if needed. This testing process is illustrated in Figure 6-2. The algorithm is based on UHCW 
testing practices which compares with current UK recommendations as described by Rakha 
et al. (2014) and Ellis et al. (2016). 
Figure 6-2 HER2 testing algorithm 
 
 
 
 
 
 
 
 
 
 
(Ellis et al., 2016) 
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Patients with a 2+ outcome on IHC will go on to FISH testing to confirm their HER2 status. A 
break-down of the proportion of the different HER2 results found during UK audits presented 
in Ellis et al. (2016) are given in figure 6-2 alongside the testing algorithm. 21.7% of all HER2 
breast cancer cases initially had an equivocal result on IHC and required further FISH testing 
to verify their HER2 status (Ellis et al., 2016). A patient with a IHC 0/1+ result or non-amplified 
FISH will not be recommended for Herceptin whereas those with a IHC 3+ result or FISH 
amplified will be considered for Herceptin after taking into account other factors such as age 
and comorbidities.  
6.1.5 Testing thresholds 
Pathologists report HER2 IHC and FISH results based on recommended underlying cut-off 
points for each score. The American Society of Clinical Oncology/College of American 
Pathologists (ASCO/CAP) provide a summary of what these should be; issuing 
recommendations in 2007 followed by an update in 2013. The latest guidelines match those 
issued by the Royal College of Pathologists (RCPath) in their most recent publication on 
reporting of breast disease by Ellis et al. (2016).  
In order to improve the accuracy of HER2 testing; the latest ASCO/CAP guidelines modified 
the thresholds for scoring when compared to the previous 2007 recommendations. Table 6-
1 gives an overview of the differences in these as detailed by Wolff et al. (2013).  
The continual update of recommendations for scoring, ensuring they represent the true 
underlying HER2 status as well as giving clear and straightforward guidelines for pathologists 
to follow, works in the interest of both the reporting clinician and the patient due to the 
consequent result in accurate treatment plans.  On the other hand shifting scoring thresholds 
over time presents a challenge when trying to summarise the diagnostic accuracy of a given 
test since what is determined to be a positive or negative test result has now changed. This 
is further amplified in the HER2 scenario as the thresholds for both IHC and FISH, which is 
considered the gold standard in HER2 testing have seen alterations in their thresholds 
between the 2007 and 2013 guidelines.  
Several studies; Varga and Noske (2015), Shah et al. (2014) and  Long et al. (2015) 
investigated the impact of the updated recommendations, with all showing similar results, 
an increase in overall HER2 positive cases. Thus, it is crucial any proposed summary measure 
of diagnostic accuracy takes into consideration the underlying method for the classification 
of both IHC and FISH HER2 scores.  
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Table 6-1 HER2 scoring thresholds, 2007 versus 2013 
IHC 
Score 2007 2013 
3+ Uniform intense 
membrane staining of > 
30% of invasive tumour 
cell 
Based on circumferential membrane 
staining that is complete, intense. Observed 
in a homogeneous and contiguous 
population and within >10% of the invasive 
tumour cells. 
Equivocal IHC 2+ IHC 2+ based on circumferential membrane 
staining that is incomplete and/or 
weak/moderate and within >10% of the 
invasive tumour cells; or complete and 
circumferential membrane staining that is 
intense and within ≤10% of the invasive 
tumour cells  
1+ HER2 0: no staining 
HER2 1+: Weak 
incomplete membrane 
staining in any proportion 
of tumour cells or weak, 
complete membrane 
staining in <10% of cells 
IHC 0 as defined by no staining observed or 
membrane staining that is incomplete and is 
faint/barely perceptible and within ≤10% of 
the invasive tumour cells 
IHC 1+ as defined by incomplete membrane 
staining that is faint/barely perceptible and 
within >10% of the invasive tumour cells 
FISH 
Amplified HER2 to CEP17 of > 2.2 Dual-probe HER2/CEP17 ratio ≥2.0 
Equivocal HER2/CEP17 ratio of 1.8-
2.2  
---- 
Non-
Amplified  
HER2/CEP17 ratio of < 1.8  Dual-probe HER2/CEP17 ratio <2.0  
(Wolff et al., 2007) and (Wolff et al., 2013) 
 
6.1.6 Accuracy of HER2 tests 
Herceptin is currently only available at a high cost and is associated with cardiotoxicity 
reported to be as high as 27% (Keefe, 2002) . Any administration of Herceptin where it is not 
needed will only lead to unnecessary costs to the NHS and potential side effects to the 
patient with no clinical benefit. Alternatively, HER2 positive patients may lose the 
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opportunity of treatment if their HER2 status is not confirmed correctly; these will miss out 
on a potentially life changing intervention. In both HER2 positive and negative breast cancers, 
it is vital that results are reported as near as possible to the patient’s true status to allow for 
the design of the most suitable care plans.  
Accurate methods and clear scoring thresholds will increase pathologists’ confidence in 
scoring HER2 especially for borderline and uncertain cases. This is particularly true for the 
HER2 IHC test owing to the presence of the 2+, equivocal group. These cases are referred for 
the more definitive FISH test. Methods increasing pathologist confidence in scoring that also 
reduce the number of uncertain cases will certainly shrink the total number of 2+ scores and 
a greater number of cases will be given a definitive result on their first round of testing. In 
an ideal scenario, results equivalent to FISH are reported on the initial IHC test with minimal 
2+ scores. In theory this will allow the development of treatment plans most suited to the 
patient and will reduce the cost of testing to the NHS as well as the time to result 
confirmation; both as a consequence of the elimination of the need for confirmatory FISH 
testing.   
The implications of digitisation for test reporting accuracy is one of the justifications for the 
use of DP IA and will form a substantial part of the rationale to support investment and the 
use of this technology in pathology practice.   
6.1.7 Quantifying accuracy 
Accuracy is an important indicator of the superiority of one testing method over another. 
When summarising the accuracy of HER2 IHC there are two layers to consider: 
1. Non-equivocal IHC cases that are given a +1 or +3 score 
2. Equivocal IHC cases  
Novel scoring methods such as DP IA, that show greater accuracy in the first group and a 
simultaneous reduction of cases in the second group are worthy of consideration for 
introduction in pathology lab procedures.  To measure accuracy the results of the test of 
interest need to be compared against the true HER2 value, established by using FISH, the 
agreed upon reference standard. 
6.1.7.1 Non-equivocal cases 
Sensitivity and specificity are measures of diagnostic test accuracy, under the HER2 scenario, 
sensitivity refers to the ability of a test to detect a +3 result in patients that are HER2 positive 
and specificity refers to the ability of a test to detect a +1 result in patients that are HER2 
negative (Lalkhen and McCluskey, 2008). The calculation of both requires the construction 
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of a 2x2 table for both CM and DP comparing the index test (HER2 IHC) against the reference 
standard (HER2 FISH). An example 2x2 table to determine the sensitivity and specificity of 
HER2 IHC is given below.  
Table 6-2 Example 2x2 table 
 FISH score 
(reference standard) 
Amplified Non-amplified 
IHC score 
(index test) 
+3  TP FP 
+1  FN TN 
 
Better diagnostic tests will increase the number of true positive (TP) and true negative (TN) 
cases whilst simultaneously reducing false negative (FN) and false positive (FP) results that 
lead to incorrect treatment management. Sensitivity and specificity are calculated using the 
following equations: 
Sensitivity = TP/(TP + FN) Specificity = TN/(TN + FP) 
Values closer to 1 for each of these accuracy measures are ideal, demonstrating the ability 
of the index test to detect the true HER2 status.  When sensitivity and specificity are 
calculated for each HER2 IHC method they can be compared to confirm the dominance of 
one over another.  
Generally, the sensitivity and specificity of a particular test are estimated using data from 
individual studies, meta-analysis offers the opportunity to pool results from two or more 
studies into a single summary of effect (Haidich, 2010). Meta-analyses and systematic 
reviews are at the top of the pyramid of hierarchy of evidence (Murad et al., 2016), they 
provide high quality research evidence to inform decision-making in medicine.  Meta-
analyses of the sensitivity and specificity for each HER2 IHC method allows a more 
statistically robust comparison of accuracy than the use of single study estimates. 
There are two challenges when summarising sensitivity and specificity into a single measure 
using meta-analyses approaches. First, the underlying trade-off between sensitivity and 
specificity (Irwig et al., 1995), as sensitivity increases, specificity decreases, thus they cannot 
be pooled without taking this into account. The second challenge is the use of scoring 
thresholds, these may vary across the individual studies from which accuracy results are 
extracted to be combined so that the HER2 status of a particular case may change across 
different thresholds.   
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Univariate meta-analysis approaches are not suitable when combining estimates of 
sensitivity and specificity since they pool these values separately ignoring the existing 
correlation between both (Takwoingi et al., 2017). Two approaches to meta-analysis exist 
that can be adopted for combining sensitivity and specificity estimates, these are the 
bivariate random effects model and the hierarchal summary receiver operating 
characteristic (HSROC) model (Menke, 2014) since both models allow for the correlation 
between sensitivity and specificity (Takwoingi et al., 2015). The bivariate model is used for 
meta-analysis if all included studies share a common underlying threshold (Takwoingi et al., 
2015) otherwise the HSROC approach is appropriate as it allows the illustration of changes 
in sensitivity and specificity as the threshold varies (Rutter and Gatsonis, 2001). 
Pathology labs are expected to follow guidelines when scoring HER2 IHC, these were set by 
ASCO/CAP and adopted in the UK. The accuracy measures determined for the IHC tests 
should reflect and match the most up to date thresholds to ensure they are relevant to 
current decision makers.  Summary estimates of sensitivity and specificity can be reported 
for each of the 2008 and 2013 recommendations by subgrouping individual studies according 
to the thresholds that match the guidelines. The Cochrane handbook for systematic reviews 
of diagnostic test accuracy (Macaskill et al., 2010) recommends a bivariate model when 
studies are matched according to threshold.  
6.1.7.2 Equivocal cases 
Equivocal cases will not be included in the calculations of sensitivity and specificity since they 
are not represented in the 2x2 tables. Knowledge of their frequency is important when 
determining the superiority of one testing medium over another; they cause delays and add 
avoidable costs to the HER2 testing pathway. There are two groups of equivocal cases 
conditional on the true status, these must be separated in analyses as their proportions may 
differ. Once again, a meta-analysis summary estimate is superior to results taken from a 
single study but unlike sensitivity and specificity a univariate approach is sufficient. The 
probability of an equivocal score will be influenced by the underlying thresholds, so in the 
same way as for sensitivity and specificity they should first be sub-grouped by the threshold 
used prior to meta-analysis.  
6.1.7.3 Current knowledge 
Sensitivity, specificity and the probability of an equivocal score conditional on true status are 
the test performance measures of interest when comparing DP IA to CM for scoring HER2 
IHC. A scoping search of the published literature was carried out to establish the extent of 
the available published evidence that reports the accuracy of HER2 IHC.   
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Dendukuri et al. (2007) and Cuadros and Villegas (2009) are two systematic reviews that 
summarised the level of agreement between the IHC and FISH tests for HER2.  They both 
concluded that the IHC test was suitable for scoring negative HER2 cases but FISH was more 
reliable for the equivocal and positive cases. Unfortunately, both overlooked the thresholds 
and the approach taken to view the glass slides. A third review; a meta-analysis by Bahreini 
et al. (2015) pooled the concordance between IHC and FISH, proportion of false negatives, 
proportion of FISH positivity in IHC 2+ and 3+ score group. Again, they missed the effects of 
threshold and methods used. All three studies presented evidence of reduced accuracy with 
IHC compared to FISH but none addressed the issue of test performance with the different 
IHC testing methods.  
A combined total of 58 studies were eligible for inclusion across the three reviews, out of 
these only two compared DP IA and CM for IHC scoring. Through citation and reference 
searching using these two studies, three further studies were identified comparing the two 
reporting mediums proving that studies exist from which the sensitivity and specificity for 
each IHC scoring medium can be determined.  
However evidence of completed or ongoing reviews that attempt to pool the results from 
these and establish the accuracy of digitisation in comparison to the use of conventional 
microscopes when scoring HER2 IHC are not registered in PROSPERO, the Cochrane Library 
or the TRIP database. Unfortunately, there is not a robust evidence base in the literature to 
support the assertion of improved accuracy with DP IA in comparison to CM techniques. 
6.2 Aims 
This chapter aims to establish and compare the accuracy of digital pathology image analysis 
when compared to conventional microscopes by systematically reviewing the published 
literature and using meta-analysis methods to summarise accuracy data.  
1. The primary aim is to generate and compare pooled estimates of accuracy when 
scoring HER2 IHC at the 2013 ASCO/CAP threshold levels 
2. The secondary aims are to explore differences in the pooled accuracy estimates 
when 2008 thresholds are followed and to investigate differences in accuracy across 
the various digital technologies adopted 
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6.3 Methods 
The Centre for Reviews and Disseminations guidance for carrying out reviews in healthcare 
(CRD, 2009) were followed to guide the systematic review process.  
6.3.1 Information sources 
A literature search was carried out to identify all the published head-to-head studies 
comparing HER2 IHC results using conventional and digital image analysis methods. Both 
bibliographic database searches and forensic searching techniques were carried out to 
identify all the relevant literature.  
6.3.1.1 Electronic searches 
The following databases were searched: 
1. Medline 
2. Embase 
3. Web of Science 
4. PubMed 
5. Cochrane Library 
6. Open Grey 
Five key studies identified through the systematic reviews previously described, known to be 
relevant to the research aims were used to develop the search strategy. These were Dobson 
et al. (2010), Laurinaviciene et al. (2011), Minot et al. (2012), Mohammed et al. (2012) and 
Skaland et al. (2008). The key words were extracted from each paper and their titles and 
abstracts screened for any additional suitable search terms. These are listed in appendix D. 
Initially the search strategy combined five key concepts to describe invasive breast cancer 
patients tested for HER2, the digital pathology intervention as well as the conventional 
microscope comparator, the reference standard FISH and accuracy. Terms from the original 
key word list in appendix D were grouped under each of these key concepts. These formed 
the initial stage of the search strategy development and are given in appendix D.  
Several iterations were made to the original strategy to arrive at the final version. The aim 
was to develop a strategy that retrieved the original five head-to-head studies listed above 
to be confident that it had identified all the available published evidence that met the study 
aims.  
The search strategy was first developed in Medline and adapted for use in the remaining 
databases. The final search strategies for each of these are given in appendix F. These were 
used to conduct searches in each of the databases. A list of potential studies to be assessed 
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for inclusion in the systematic review was exported into EndNote and duplicates removed 
ready for screening. 
6.3.1.2 Other sources 
Forward and backward citation was carried out on all the eligible studies identified through 
the electronic searching process.  
6.3.2 Eligibility criteria 
6.3.2.1 Types of studies 
All prospective and retrospective head-to-head studies comparing digital pathology image 
analysis to conventional microscope scoring of HER2 were eligible for inclusion in the review. 
All single arm studies were excluded to reduce the risk of bias due to confounding (Macaskill 
et al., 2010).  Conference proceedings were as a rule excluded, however if they referred to a 
potentially eligible study, the corresponding full paper was retrieved where possible and 
screened against the inclusion criteria.   
6.3.2.2 Types of participants 
Studies that analysed the HER2 test results of women diagnosed with invasive breast cancer 
were eligible for inclusion in the review. The study population could either be randomly 
selected or comprise consecutive cases. This eliminated the risk of selection bias so that the 
participants were representative of the population of interest. It was noted in the scoping 
search prior to the electronic database searches that some studies over represent one or 
more of the HER2 scores or aim to include equal numbers of each in their study for analysis. 
Under these circumstances the study population did not represent the true prevalence of 
HER2 overexpression/amplification. These studies were excluded from the review. Studies 
that followed the testing pathways of patients diagnosed with cancers other than of the 
breast were also excluded.  
6.3.2.3 Types of interventions 
The intervention of interest was digital pathology with image analysis computer software to 
support the pathologists’ reporting of HER2 IHC status. The study had to clearly specify the 
digital pathology platform and the image analysis software that were used to be eligible for 
inclusion in the review.  Studies that use a digital pathology platform alone without image 
analysis software or do not mention the technology used were not eligible for inclusion in 
the review. 
6.3.2.4 Types of comparators 
Studies had to include a comparator arm representing standard practice in their analysis i.e. 
a pathologist reporting IHC HER2 status using a glass slide that is viewed under a microscope 
without the assistance of digital tools.  Pathologists assign HER2 IHC status using pre-defined 
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scoring thresholds, to be eligible for inclusion in the review the study had to describe or give 
reference to the underlying scoring thresholds used by the pathologist. Where these were 
not given, the study was excluded from the review. Finally, the study had to provide the 
details of the assay used to stain the glass slide prior to HER2 reporting. 
6.3.2.5 Type of reference standard 
To be eligible, studies had to include a reference standard against which the HER2 IHC scores 
of the intervention and comparator arms can be compared. The reference standard must be 
FISH since it is considered the gold standard for HER2 scoring. Studies that did not include a 
reference standard or used other methods such as consensus scoring to confirm HER2 status 
are excluded from the review. In addition, the study had to specify the FISH assay used and 
the underlying scoring threshold followed by the pathologist.  
In summary, all eligible studies include a sample of glass slides with tissue specimens taken 
from a group of women diagnosed with invasive breast cancer. Each slide is subjected to 
three versions of HER2 testing, IHC digital, IHC manual and FISH as the reference standard so 
that each invasive breast cancer patient has a score for each method.  
6.3.2.6 Types of accuracy measures 
There were four accuracy measures of interest; sensitivity, specificity, the probability of an 
equivocal score if true status is negative and the probability of an equivocal score if true 
status is positive. The reference standard HER2 results had to be compared against both the 
intervention and the comparator results independently. Studies were eligible for inclusion in 
the review if they presented the raw data needed to populate a 2x2 table for each arm of 
the study plus the number of equivocal cases for each IHC method split between those that 
are FISH positive and FISH negative. Where a study met all the eligibility criteria but there 
were gaps in the data described, study authors were contacted. Where access to missing 
data was granted the study was considered eligible, otherwise it was excluded from the 
review.  
6.3.2.7 Study limits 
A limit on the publication date was not set as thresholds for scoring HER2 have altered in the 
past 10 years. Rather all studies comparing DP IA and CM to FISH were included but grouped 
by the threshold used for scoring for data analysis. Only English language publications were 
included.   
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Table 6-3 Systematic review of accuracy - summary inclusion criteria 
 Include Exclude 
Population 
Women diagnosed with invasive breast 
cancer that are tested for HER2 
Conditions other than 
breast cancer  
Intervention 
HER2 IHC digital pathology image 
analysis 
No Image Analysis 
  
Comparator HER2 IHC conventional microscope None or other comparator 
Reference 
standard 
HER2 FISH None or other reference 
standard 
Accuracy 
measure 
Raw data available to populate 2x2 
tables for intervention and comparator 
Data missing and 
unobtainable 
Study Design Retrospective and prospective studies  ----- 
Language English only publications Non-English publications 
Publication Date None None 
 
6.3.3 Data collection and analysis 
6.3.3.1 Study selection 
Study selection followed a two-step process and involved two reviewers. To start; the first 
reviewer screened all titles and abstracts against the pre-specified inclusion criteria. Where 
it was obvious that papers did not meet the review objectives they were excluded at this 
stage. The full papers of the remaining studies were retrieved for a second round of 
screening. These were screened by the first reviewer against the inclusion criteria, 
publications that were not eligible were excluded. The final list of studies were considered 
eligible for inclusion in the systematic review. 
A second reviewer screened all papers that were included by the first reviewer as well as 
screening a random subset of excluded papers to ascertain that the first reviewer made no 
inappropriate exclusions. Disagreement between the two reviewers were mediated through 
consultation with a third reviewer.  
6.3.3.2 Data extraction 
Data was extracted from the eligible studies using a pre-designed data extraction form given 
in appendix G. This included information on the thresholds used for subjective scoring of 
conventional IHC and quantitative FISH scoring including the assays used for staining slides. 
For digital systems; information on the scanner and methods of image analysis were 
extracted. Finally, the data needed to populate the 2x2 tables and to calculate the probability 
152 
 
of an equivocal score for each IHC method were extracted from each included study. Where 
the study generated results to populate more than one 2x2 table, each was treated as an 
independent study.  
6.3.3.3 Reporting quality 
All eligible studies were quality assessed using the Quality Assessment of Diagnostic Accuracy 
Studies (QUADAS-2) tool (Whiting et al., 2011).  The signalling question related to the interval 
between the index test and reference standard was not relevant so was excluded. The 
questions related to how the cases were selected, blinding of results and thresholds 
described were all included. The findings from each study were summarised and compared 
to identify any trends in the risk of bias. All primary studies were included in the meta-
analysis regardless of risk of bias or applicability concerns. Where appropriate in the 
sensitivity analysis, studies are grouped according to their QUADAS-2 outcomes to identify 
any association between these and the accuracy result reported.   
6.3.4 Data synthesis 
For each study the scoring thresholds used for the IHC test on conventional microscope and 
for the FISH test as well as the technology and software used for the DP IA arm were 
recorded. The studies were organised according to the thresholds used into three groups: 
1. Comply with 2008 ASCO/CAP guidelines  
2. Comply with 2013 ASCO/CAP guidelines  
3. A miscellaneous group that do not match either of the two sets of recommendations. 
It was anticipated that across the eligible studies the technology used for the DP IA arm will 
differ. Developers of the technology have incorporated their own unique underlying 
methods for scoring HER2 positivity which they convert to the conventional 0, +1, +2 and +3 
scores. However many of these are still in development and the systematic review was not 
expected to retrieve many studies that matched on both thresholds used and technology to 
take account of this second layer of sub-division.  For the main analyses, studies were 
grouped by thresholds only, if enough studies were retrieved that match on both threshold 
and technology, a sensitivity analysis scenario will explore accuracy outcomes using this 
grouping.  
6.3.4.1 Base case analysis  
The base case analysis (BCA) represented current HER2 scoring recommendations and 
included the studies that follow the 2013 ASCO/CAP guidelines.  
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6.3.4.2 Sensitivity analysis  
Sensitivity analysis (SA) explored changes in estimates of accuracy with different scoring 
threshold and technology adopted in the digital arm. In summary, the accuracy under three 
scenarios was investigated: 
1. SA1: Studies that adhere to the 2008 ASCO/CAP guidelines for scoring were grouped  
and data from these pooled to generate accuracy estimates at the 2008 threshold 
2. SA2: If appropriate the studies used in the base case analysis were further sub-
divided according to the digital technology used and analysed independently. 
3. SA3: The final scenario sub-divides all eligible studies by DP IA technology and groups 
them accordingly. A bivariate meta-analysis will explore differences in sensitivity and 
specificity estimates with each technology used 
6.3.4.3 Meta-analysis  
Across the base case and sensitivity analysis scenarios four indicators of test performance 
with 95% confidence intervals (CI) were estimated for each of CM and DP IA for IHC testing: 
1. Sensitivity 
2. Specificity 
3. Probability of equivocal status conditional on true positive HER2 
4. Probability of equivocal status conditional on true negative HER2 
6.3.4.3.1 Sensitivity and specificity 
Sensitivity and specificity were calculated for each of the eligible studies using RevMan 
software and presented in a forest plot for illustrative purposes only, they were not pooled 
at this stage.  
Raw data from each individual study was entered into R software and the Mada (Doebler 
and Holling, 2015) package used to carry out the bivariate meta-analysis of sensitivity and 
specificity. Point estimates with 95% confidence intervals were generated and summary ROC 
curves were used to compare accuracy outputs across the two IHC testing methods.  
6.3.4.3.2 Equivocal scores 
A random effects univariate meta-analysis was carried out to pool the proportion of 
equivocal scores conditional on true status for each IHC testing method. This was completed 
using the Meta (Schwarzer, 2007) package in R for all of the base case and the first and 
second sensitivity analysis scenarios.  
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6.4 Results 
A total of 495 publications were identified through the electronic database searches, 240 
were excluded when reviewing the titles and abstracts. Access was not available for two of 
the studies, an abstract was available for Bishop et al. (2002) but not for Judd et al. (2001), 
based on this information alone it was not possible to make an eligibility decision so they 
were both excluded from the review. 45 studies were excluded on the second round of 
screening the full papers. The Preferred Reporting Items for Systematic Review and Meta-
analysis (PRISMA) flowchart (Moher et al., 2015) summarising the process for the 
identification and selection of studies is given in figure 6-3.  
Figure 6-3 Study identification and selection process 
Records Identified through 
database searching (n=495)
Records after duplicates removed
 (n=298)
Titles/Abstracts Screened
 (n=296)
Records Excluded
Cannot Access: (n=2)
Records Excluded
(n=240)
Full-text articles assessed for 
eligibility
 (n=56)
Full-text articles excluded
(n=45)
Studies Included
 (n=11)
 
The 45 full text articles were excluded for a number of reasons, including:  
 8 studies deliberately over representing one of the IHC HER2 outcomes or included 
an equal number for each category.  
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 8 papers had issues with their reference standard;  
o 5 did not carry out FISH testing on all cases and  
o 3 directly compared CM and DP IA without including a reference standard  
 15 studies had an issue with the index test or comparator or both;  
o 6 compared DP IA to FISH with no CM,  
o 7 compared CM to FISH with no DP IA and  
o 2 papers didn’t carry out DP IA by IHC but compared DP IA by FISH to 
standard FISH.  
 4 studies did not include enough data to populate 2x2 tables and so it was not 
possible to calculate the sensitivity and specificity for these 
 1 paper was a non-English publication  
 1 paper did not specify the thresholds used to score both IHC and FISH  
 1 paper was a narrative review and so did not present any relevant data 
 7 records were conference abstracts which were included initially to establish if they 
presented any new information that could be included in the meta-analysis. 
o 2 of the conference abstracts were related to two published papers already 
included in the review and  
o The 5 remaining did not include enough data in the abstract to populate 2x2 
tables. Published papers related to these conference abstracts were sought 
but without success. All five were excluded.  
It is worth highlighting that all known five head-to-head studies were retrieved by the search 
strategy and met the inclusion criteria. These made up nearly 50% of the studies included in 
the systematic review. An overview of the reference list of all included papers and a citation 
search identified no further relevant evidence to be included in the review.  
6.4.1 Study characteristics 
Table 6-4 gives an overview of the assays and scoring thresholds used in the included studies. 
Eight out of the eleven studies used Herceptest (DAKO) for IHC staining on all or a group of 
their slides. Dobson et al. (2010) sample was made up of consecutive cases from two 
hospitals where one used both Herceptest (DAKO) and Oracle (Leica) and the second used 
Pathway (Ventana) for HER2 staining. Also Joshi et al. (2007) used both Herceptest (DAKO) 
and Pathway (Ventana). Finally Wang et al. (2001) uses a different antibody but from the 
same manufacturers as the HercepTest. The IHC assay used is the same across both CM and 
DP IA since the same stained slides are viewed under a microscope and scanned and analysed 
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digitally. A similar pattern can be seen across the studies for the FISH analysis, 10 out of the 
11 studies used PathVysion (Abbott) as their preferred assay.  
When considering the accuracy of the CM scoring method to report on HER2 status there are 
two levels of threshold variability; one at the subjective IHC scoring level and the second 
when confirming FISH status. For each study these are compared to the ASCO/CAP scoring 
recommendations of 2008 and 2013 as described by Nitta et al. (2016). The final column in 
table 6-4 summarises this; giving the year of the ASCO/CAP guidelines to which each paper’s 
scoring threshold for subjective IHC and FISH match. Only 6 out of the 11 studies adhere to 
either the 2008 or 2013 thresholds when scoring, the remaining studies use alternative 
combinations of FISH and IHC thresholds to define positivity.  
For the DP IA arm in each review there are two steps to consider; firstly the method and 
equipment used for digitisation and secondly the algorithm used to analyse the digital slides 
and give a HER2 score. These are summarised in table 6-5. ACIS is the most commonly used 
platform for both digitisation and analysis; this system was used by 4 of the included studies. 
Dobson et al. (2010) and Mohammed et al. (2012) both use SlidePath for digitisation but the 
former use their own IA algorithm and the latter using the SlidePath system. Two studies use 
the Ariol system, one uses MDS and one uses Visiopharm technology for both digitisation 
and analysis. Finally Joshi et al. (2007) use either a scanner or microscope for generating a 
digital image which is analysed using the authors developed algorithms.  
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Table 6-4 Summary of included studies 
Study 
Sample  
Size 
Country of 
Research 
IHC FISH 
ASCO/CAP 
Guidelines1 Assay 
Positivity 
Threshold 
Assay 
Positivity 
Threshold 
Bloom and Harrington (2004) 129 USA HercepTest  >10% Inform & PathVysion ≥2.0 2013 
Ciampa et al. (2006) 108 USA HercepTest >10% PathVysion ≥2.0 2013 
Dobson et al. (2010)  136 Ireland HercepTest & Oracle & Pathway >30% PathVysion >2.2 2008 
Ellis et al. (2005) 114 UK HercepTest >10% PathVysion >2.2 NA 
Joshi et al. (2007) 450 USA HercepTest & Pathway >10% PathVysion ≥2.2 NA 
Laurinaviciene et al. (2011) 152 Lithuania Pathway >10% PathVysion >2 2013 
Minot et al. (2012) 154 USA HercepTest >30% PathVysion >2.2 2008 
Mohammed et al. (2012) 431 UK HercepTest >10% Vysis >2 2013 
Skaland et al. (2008) 219 Norway HercepTest >10% PathVysion >2.2 NA 
Turashvili et al. (2009) 579 USA Pathway >10% PathVysion >2.2 NA 
Wang et al. (2001) 189 USA A0485 >50% PathVysion ≥ 2 NA 
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Table 6-5 Summary digital pathology image analysis methods adopted in each study 
Study Digitisation method 
Image Analysis 
Algorithm 
Bloom and 
Harrington 
(2004) 
ACIS digital microscope 
An ACIS assisted 
HER2 score is 
generated by the 
system software 
Ciampa et al. 
(2006) 
The ACIS system includes an automated 
robotic bright field microscope and a windows 
NT-based computer.  
The microscope scans the slide and the 
computer generates a digital image  
ACIS system 
generates a HER2 
score 
Dobson et al. 
(2010)  
SlidePath using a NanoZoomer DP system to 
digitize the slides 
IA algorithm 
developed by 
authors and used 
within SlidePath’s 
tissue IA system 
Ellis et al. 
(2005) 
Micrometastasis detection system (MDS) is a 
computer controlled scanning microscope 
A digital scoring 
application 
developed for MDS  
Joshi et al. 
(2007) 
Either a scanner or microscope with a digital 
camera attached  
Algorithm developed 
by authors 
Laurinaviciene 
et al. (2011) 
ArrayImager software module from Visopharm 
HER2-CONNECT 
software module 
from Visopharm 
Minot et al. 
(2012) 
ACIS 
ACIS assisted 
assessment 
Mohammed 
et al. (2012) 
Slides are scanned with Hamamatsu 
NanoZoomer 
SlidePath Tissue 
Image analysis 
system 
Skaland et al. 
(2008) 
Ariol SL 50 system made up of an automatic 
slide loader and scanner 
Paper states IA 
algorithm applied. 
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Does not indicate if 
this was part of the 
DP system or 
developed by 
authors 
Turashvili et 
al. (2009) 
Ariol system based on an Olympus microscope 
and equipped with a black and white video 
camera 
Ariol IA software 
automatically 
generates a score 
Wang et al. 
(2001) 
ACIS consisted of an automated robotic bright-
field microscope module, a computer, and a 
Windows NT-based software interface. 
Robotic microscope scanned slides. Computer 
monitor displayed digital images 
ACIS able to 
quantitate HER2 
staining to determine 
HER2 status 
 
6.4.2 Quality assessment 
The quality of the studies included in the review were evaluated for bias and applicability 
concerns using the QUADAS-2 tool. A summary of the results is given in table 6-6. All except 
one study performed well on applicability confirming that the primary studies included are 
applicable to the research question (Whiting et al., 2011).  Dobson et al. (2010) is the only 
study where there was some concern around the applicability of patient selection but this 
was due to lack of information rather than a clear problem.  Even though the study mentions 
invasive breast cancer extensively in the introduction this is not explicitly stated in the 
methods or results section when describing the study sample. Dobson et al. (2010) simply 
refer to cases without describing the types of cases included. Other than this minor issue 
there were no other concerns regarding applicability across all published studies included in 
the review.  
The risk of bias was variable both across studies and across the criteria. Bias due to both the 
performance of the reference standard and index test was of the highest concern followed 
by patient selection and flow and timing. 7 out of the 11 studies scored poorly on both the 
index test and reference standard components. The scoring thresholds were clearly stated 
and the same reference standard i.e. FISH testing was used in all the studies as these are 
both fundamental criteria for inclusion in the review. The main concern in both arms was 
failure on blinding. Either it was obvious that the tests were interpreted with prior knowledge 
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of the other test results or it was not clear if blinding was considered at all.  Blinding of test 
results has been reported elsewhere as a design feature of diagnostic accuracy studies that 
consistently introduces bias (Furukawa and Guyatt, 2006), the studies included support this 
finding. 
Under patient selection, there was some concern around the sample selection process. It 
was unclear in 4 of the studies how this was carried out raising concerns about potential 
selection bias. This occurs when eligible cases are not selected consecutively or at random 
(Roever, 2015). Finally, out of the 4 domains to assess risk of bias; published studies in most 
cases scored positively on flow and timing. Dobson et al. (2010) and Turashvili et al. (2009) 
had issues around data exclusion; it was not clear or was obvious that data was excluded but 
no justification for this was given.  
Table 6-6 Quality assessment of included studies 
Study 
ASCO/CAP 
guidelines 
RISK OF BIAS APPLICABILITY CONCERNS 
PATIENT 
SELECTION 
INDEX 
TEST 
REFERENCE 
STANDARD 
FLOW AND 
TIMING 
PATIENT 
SELECTION 
INDEX 
TEST 
REFERENCE 
STANDARD 
Bloom and 
Harrington (2004) 
2013        
Ciampa et al. 
(2006) 
2013        
Dobson et al. 
(2010) 
2008       ?   
Ellis et al. (2005) None        
Joshi et al. (2007) None        
Laurinaviciene et 
al. (2011) 
2013        
Minot et al. (2012) 2008        
Mohammed et al. 
(2012) 
2013        
Skaland et al. 
(2008) 
None        
Turashvili et al. 
(2009) 
None   ?     ?    
Wang et al. (2001) None        
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6.4.3 Accuracy data extraction 
The main aim of the review was to summarise estimates of sensitivity and specificity for DP 
IA and compare these against those for CM. Data to populate 2x2 tables for each arm of the 
analysis were extracted from the eligible studies. The individual studies presented enough 
data to populate at least one pair of 2x2 tables. Data was available to populate more than 
one 2x2 table in the following studies: 
1. Bloom and Harrington (2004) had ten independent pathologists score IHC slides 
using both a microscope and the ACIS digital pathology system. This study generated 
10 pairs of 2x2 tables to be included in the review.  
2. Joshi et al. (2007) included two groups of breast cancer cases; those set up as WMdes 
(WS) and a second group of cases as Tissue Microarrays (TMA). Data to populate two 
2x2 tables representing each of the WS and TMA groups were available for the CM 
arm of the analysis. For the DP IA arm they presented two methods of scoring; an 
ordinal algorithm (OA) and a continuous algorithm (CA). These were applied to both 
the WS and TMAs giving data to populate four 2x2 tables to represent DP IA 
accuracy.  
3. For Laurinaviciene et al. (2011) the same pathologist performed the subjective 
microscope evaluation twice but with a two month interval. For this paper two 2x2 
tables were generated for CM and one for DP IA.  
4. Minot et al. (2012) had 3 pathologists score manually and 3 cytotechnologist (CyT) 
score both manually and digitally. The Pathologists scores were excluded since there 
was no digital equivalent included in the review. This paper generated three pairs of 
2x2 tables, one for each CyT to be included in the review.  
5. Skaland et al. (2008) subjective IHC scoring was carried out by 3 independent 
pathologists giving 3 sets of 2x2 tables for CM. They also presented a subjective 
consensus score but this was excluded from the analysis since in reality it is not 
common practice for more than one clinician to be available when scoring HER2. 
Only one 2x2 table is generated for DP IA. 
6. Turashvili et al. (2009) study has two independent pathologist carry out subjective 
scoring using CM. This study gives two 2x2 tables for the CM arm of the analysis and 
one for the DP IA arm.  
In total there are 11 publications to be included in the review giving enough data to populate 
27 2x2 tables for CM and 25 2x2 tables for DP IA. The 2x2 tables are used to evaluate the 
concordance between IHC and FISH and so determine the difference in accuracy between 
conventional subjective methods and quantitative digital techniques. From each 2x2 table 
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the sensitivity and specificity were calculated for each study. For the same number of 2x2 
tables it was also possible to calculate the split between cases scored as equivocal and those 
giving a definite score with IHC.  
Improvements in the accuracy of IHC HER2 scoring are characterised by increases in both 
sensitivity and specificity together with a reduction in the number of equivocal scores 
generated. Table 6-7 summarises the direction of change when comparing accuracy point 
estimates for DP IA against those for CM.  More than one set of outputs are generated for 
many of the studies as described on page 160. 
There does not appear to be a general trend to support the superiority of digital methods 
over conventional techniques. In 14 out of the 27 comparisons, there is a reduction in the 
sensitivity of IHC scoring with digital and in 11 cases there is also a reduction in specificity. 
An improvement in the proportion of 2+ scores is observed in 16 of the summary point pairs 
given.  
Forest plots of the sensitivity and specificity for CM and DP IA scoring are given in figure 6-4 
and 6-5 respectively. There appears to be a greater level of uncertainty around sensitivity in 
both the CM and DP IA data due to the wider confidence intervals, in addition there is also 
evidence of greater variability in the sensitivity than in specificity estimates due to the scatter 
of the points.  The variability in specificity estimations decreases with digital pathology but 
it is not so clear if there is a difference in sensitivity between microscope and digital 
techniques. 
Based on this data alone there is not enough evidence to conclude the ability of DP IA to 
improve the accuracy of IHC reporting and so meta-analyses were carried out. 
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Table 6-7 Summary change in point estimates of sensitivity (SN), specificity (SP) and 
proportion of equivocal results reported in each study when comparing DP to CM 
Studies 
Accuracy ∆ 
SN SP %2+ 
Bloom and Harrington (2004) 
P*1 ↓ ↑ ↓ 
P2 ↓ ↓ ↓ 
P3 ↓ ↑ ↓ 
P4 ↓ ↑ ↓ 
P5 ↓ ↑ ↓ 
P6 ↓ ↓ ↓ 
P7 ↑ ↓ ↓ 
P8 ↓ ↓ ↓ 
P9 ↓ ↓ ↓ 
P10 ↓ ↓ ↓ 
Ciampa et al. (2006)  ↑ ↑ ↑ 
Dobson et al. (2010)  ↑ ↓ ↓ 
Ellis et al. (2005)  ↑ ---- ↓ 
Joshi et al. (2007) 
WS OA ↑ ---- ↑ 
WS CT ↑ ↑ ↑ 
TMA OA ↑ ---- ↑ 
TMA CT ↑ ↑ ↑ 
Laurinaviciene et al. (2011) 
P1 ↑ ↓ ↑ 
P2 ↑ ↓ ↑ 
Minot et al. (2012) 
CyT1 ↓ ---- ↓ 
CyT2 ---- ---- ↓ 
CyT3 ↑ ↓ ---- 
Mohammed et al. (2012)  ↓ ---- ↓ 
Skaland et al. (2008) 
P1 ↑ ---- ↑ 
P2 ↑ ---- ↑ 
P3 ↑ ---- ↑ 
Turashvili et al. (2009) 
P1 ↓ ↑ ↑ 
P2 ↓ ↑ ↑ 
Wang et al. (2001)  ↓ ↓ ↓ 
↑ /↓Favourable for DP ↓/↑Favourable for CM ----No Change (P refers to the pathologist)
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Figure 6-4 Sensitivity and specificity of HER2 IHC using CM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies are included more than once in the forest plot where data was available to populate more than one 2x2 table as described on pg162   
P-Pathologist TMA-Tissue Microarrays WS-Whole Slides CyT-Cytotechnologist 
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Figure 6-5 Sensitivity and specificity of HER2 IHC using DP IA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies are included more than once in the forest plot where data was available to populate more than one 2x2 table as described on pg162 
P-Pathologist TMA-Tissue Microarrays WS-Whole Slides Ord-Ordinal Algorithm Cont-Continuous Algorithm CyT-Cytotechnologist 
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6.4.4 Base case analysis 
Four studies met the criteria of the ASCO/CAP 2013 guidelines; data extracted from these 
were included in the base case meta-analyses. These papers were:  
1. Bloom and Harrington (2004)  
2. Ciampa et al. (2006) 
3. Laurinaviciene et al. (2011)  
4. Mohammed et al. (2012)  
The bivariate meta-analysis for base case analysis estimated sensitivity as 0.934 (95%CI: 
0.863, 0.970) and the false positive rate (FPR) as 0.061 (95%CI: 0.027, 0.131) for the CM arm. 
For DP IA, sensitivity was estimated 0.877 (95%CI: 0.832, 0.912) and the FPR as 0.049(95%CI: 
0.036, 0.067). The point estimates suggests a decrease in sensitivity with DP IA with a 
simultaneous decrease in the FPR denoting an increase in specificity. The summary Roc curve 
for the base case analysis comparing both IHC scoring methods is given in figure 6-6.  
Figure 6-6 BCA comparison of CM and DP IA with SROC curves 
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The confidence regions for sensitivity and specificity overlap but cover a tighter area for the 
DP IA data suggesting a lower level of uncertainty around the predictions with digitisation.  
Meta-analysis of the proportion of equivocal results conditional on true status were also 
carried out as part of the base case analysis. Forest plots for the HER2 positive cases across 
each IHC method are given in figures 6-7 and 6-8 and the HER2 negative cases in figures 6-9 
and 6-10. 
Figure 6-7 BCA proportions of equivocal scores if HER2 positive: CM 
 
 
 
 
 
 
 
 
 
Figure 6-8 BCA proportion of equivocal scores if HER2 positive: DP IA 
 
 
 
 
 
 
 
 
Across both the positive and negative arms there appears to be a statistically significant 
reduction in the proportion of HER2 IHC tests scored as equivocal when going from the CM 
to DP IA approach. However high levels of heterogeneity exist especially for the comparison 
across the HER2 negative cases due to high value of I2 accompanied with a low p-value.  
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Figure 6-9 BCA Proportion of equivocal scores if HER2 negative: CM 
 
 
 
 
 
 
 
 
Figure 6-10 BCA proportion of equivocal scores if HER2 negative: DP IA 
 
 
 
 
 
 
 
6.4.5 Sensitivity analysis  
6.4.5.1 SA1 2008 thresholds 
The base case analysis limited the studies to only include those that met the 2013 guidelines. 
The first sensitivity analysis explored the impacts on the accuracy measures when analysing 
data from studies that base their scoring on the 2008 guidelines.  There were 2 studies that 
met this criteria, Dobson et al. (2010) and Minot et al. (2012).  
Under this scenario for CM the sensitivity was determined to be 0.744 (95%CI: 0.610, 0.843) 
and the false positive rate as 0.011 (95%CI: 0.004, 0.029). For DP IA the estimate of sensitivity 
was 0.758 (95%CI: 0.630, 0.851) and for the FPR 0.009 (95%CI: 0.004, 0.025). The point 
estimates suggest that sensitivity has increased and so has the specificity owing to an 
increase in the FPR, however once again there is considerable overlap between the 
confidence intervals. The SROC in figure 6-11 supports this notion since both confidence 
regions almost overlap each other, signifying no difference in accuracy between each HER2 
IHC scoring method.   
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Figure 6-11 SA1 Comparison of CM and DP IA with SROC curves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The differences in the proportion of equivocal scores was also meta-analysed under this 
scenario, the results for the HER2 positive cases are given in figures 6-12 and 6-13 and for 
the negative cases in figures 6-14 and 6-15. There is evidence of a reduction in equivocal 
scores for both HER2 positive and negative cases but these may not be statistically significant 
due to the overlap of confidence intervals. Unlike the BCA, lower levels of heterogeneity exist 
when pooling the studies but in the same way as for the BCA, heterogeneity is lower across 
analyses for positive HER2 cases. 
Figure 6-12 SA1 Proportion of equivocal cases if HER2 positive: CM 
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Figure 6-13 SA1 Proportion of equivocal cases if HER2 positive: DP IA 
 
Figure 6-14 SA1 Proportion of equivocal cases if HER2 negative: CM 
 
Figure 6-15 SA1 Proportion of equivocal cases if HER2 negative: DP IA 
 
 
6.4.5.2 SA2 Thresholds and DP IA technology matched 
The scanning and scoring technology varied across the studies included in the BCA; two 
studies used ACIS technology, one VisioPharm and the last SlidePath. This scenario 
summarised test performance using data from the two studies using ACIS technology; Bloom 
and Harrington (2004) and Ciampa et al. (2006). The studies matched on thresholds used for 
scoring the CM IHC test and the DP IA technology used.  
Under this scenario for the CM analysis, sensitivity was 0.960 (95%CI: 0.925, 0.979) and the 
FPR was 0.086 (95%CI: 0.035, 0.192). For DP IA the point estimate for sensitivity decreased 
to 0.900 (95%CI: 0.850, 0.935) and the point estimate for the FPR also decreased to 0.059 
(95%CI: 0.045, 0.079) signifying an increase in specificity. The SROC curve in figure 6-16 
suggests sensitivity decreases with DP IA even though there is some overlap between the 
two confidence regions and for specificity, DP IA appears to more precisely identify negative 
HER2 cases hence the narrower  confidence region for the FPR i.e. specificity. Similar trends 
for equivocal scores as those seen under BCA are observed under this scenario. There is a 
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statistically significant reduction in the proportion of HER2 equivocal IHC cases however 
these estimates are coupled with high levels of heterogeneity due to high value of I2 
accompanied with a low p-value.  
Figure 6-16 SA2 Comparison of CM and DP IA with SROC curves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-17 SA2 Proportion of equivocal cases if HER2 positive: CM 
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Figure 6-18 SA2 Proportion of equivocal cases if HER2 positive: DP IA 
 
 
 
 
 
 
 
 
Figure 6-19 SA2 Proportion of equivocal cases if HER2 negative: CM 
 
Figure 6-20 SA2 Proportion of equivocal cases if HER2 negative: DP IA 
 
6.4.5.3 Grouping by DP IA technology 
The final sensitivity analysis scenario focused on the differences in sensitivity and specificity 
between the DP IA technologies. The eligible studies were grouped and analysed according 
to the technology used as follows: 
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1. ACIS used by Bloom and Harrington (2004), Ciampa et al. (2006), Minot et al. (2012) 
and Wang et al. (2001) 
2. Ariol used by Skaland et al. (2008) and Turashvili et al. (2009) 
3. SlidePath used by Dobson et al. (2010) and Mohammed et al. (2012) 
The remaining three studies identified through the systematic review could not be grouped 
and were excluded from this analysis. Table 6-8 provides a summary of the estimated 
sensitivity and specificity with confidence intervals for each DP IA technology and figure 6-
21 illustrates the SROC curve. There is clear overlap between the confidence regions of Ariol 
and SlidePath, ACIS appears to have reduced specificity and possibly better able to score 
HER2 positive cases owing to a greater level of sensitivity compared to the other two 
technologies.  
Table 6-8 Sensitivity and specificity estimates by DP IA technology 
 
Figure 6-21 Comparison of DP IA technologies with SROC curves 
 
 
 
 
 
 
 
 
 
 
 
 
 
DP IA technology Sensitivity False Positive Rate 
ACIS 0.873 (95%CI: 0.831, 0.905) 0.057 (95%CI: 0.043, 0.075) 
Ariol 0.676 (95%CI: 0.590, 0.751) 0.009 (95%CI: 0.004, 0.022) 
SlidePath 0.760 (95%CI: 0.607, 0.867) 0.011 (95%CI: 0.003, 0.037) 
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6.5 Discussion 
Accurate HER2 testing and reporting is imperative to breast cancer treatment planning.  
Inaccuracies result in missed or over treatment in turn impacting vulnerable patients; in 
particular for FN cases, preventing patients benefiting from the improvement in both overall 
and disease free survival seen with Herceptin treatment (Zardavas et al., 2013) and 
increasing the risk of cardiotoxicity for FP cases (Onitilo et al., 2014).  
Any innovation in pathology designed to contribute towards a more accurate HER2 test 
result and so a more precise management of disease is welcome. However, it is important to 
be able to analyse and collate available evidence in order to make a clear judgement on the 
superiority of one technique over another and thus support its implementation. The 
systematic review and meta-analysis were designed to achieve this by estimating the 
sensitivity, specificity and the proportion of 2+ scores when a pathologist uses DP IA versus 
CM to score the HER2 IHC test. 
Owing to the challenges of pooling data from studies that use different scoring thresholds, 
the eligible studies identified through the systematic review were grouped according the 
threshold used. The base case analysis encompassed studies that followed current 
recommendations. The point estimates suggest a decrease in sensitivity with a concurrent 
increase in specificity when DP IA is compared to CM. The confidence regions for both scoring 
methods overlap in the ROC space, with that for digital lying nearly completely within that 
for CM. Whilst it is not possible to firmly conclude that HER2 accuracy using digital systems 
is superior to conventional methods as the overlap in confidence regions suggests no 
significant difference; the narrower confidence intervals for DP IA suggest it to be a more 
precise prediction method for HER2 scoring than a microscope. Most likely due to the 
reduction of variability that comes with subjective scoring when using a CM. In essence this 
shows that DP IA has the potential to support pathologists scoring reducing inter- and intra- 
observer variability. In addition, there was a statistically significant reduction in the 
proportion of equivocal scores across both the HER2 negative and positive groups however 
high levels of heterogeneity exist around these estimations.  
Equivocal score proportions, sensitivity and specificity cannot be considered independently. 
The base case scenario suggests a more precise but not an improved estimation of sensitivity 
and specificity with DP IA. So while the reduction in equivocal scores is welcome there is a 
risk here of an increase in FP and FN cases as there is no evidence of an explicit improvement 
in sensitivity and/or specificity with DP IA. Reducing equivocal scores saves costs and 
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improves the time to diagnosis but there will potentially be a greater chance of patients 
receiving incorrect treatment owing to fewer patients receiving FISH testing, the gold 
standard in HER2 status confirmation.  
Three scenarios were explored through sensitivity analysis, the first summarised accuracy 
estimates that were based on studies that follow the 2008 scoring thresholds to compare 
these to the base case scenario that adopt the 2013 thresholds. The estimates under this 
scenario suggest an increase in sensitivity and specificity however the confidence regions are 
virtually identical in ROC space for DP IA and CM. There is a reduction in equivocal scores for 
both the negative and positive HER2 group however these are not statistically significant due 
to overlapping confidence intervals.  At the 2008 thresholds, the evidence suggests that 
there is no difference between DP IA and CM for scoring HER2 IHC. 
The motivation behind the update of thresholds is the enhancement of the test’s ability to 
distinguish between HER2 positive and negative cases.  When comparing the bivariate meta-
analysis outputs of the 2008 and 2013 thresholds there is a clear increase in sensitivity and 
a decrease in specificity across both the CM and DP IA arms when adopting the 2013 
thresholds. The ability of both tests to identify positive cases has improved, decreasing the 
number of FN cases. There is a decrease in the ability of the IHC tests to identify negative 
cases so that the number of FPs have increased. With the revision of guidelines from the 
2008 to 2013 thresholds, patients are more likely to be prescribed Herceptin however there 
is a greater number of people that are being prescribed Herceptin but don’t need it. These 
results support the findings of other studies that have investigated the impact of changing 
thresholds on the given HER2 score. Stoss et al. (2015) re-evaluated the HER2 status of over 
6000 breast cancer cases that were part of the HERA trial, with the updated thresholds they 
also reported an increase in the positivity rate and a decrease in the number of cases scored 
negatively.  
The second scenario compared accuracy estimates for studies that matched on the 
thresholds used in the conventional arm but also on the technology used in the digital arm. 
Across the eligible studies there was a lot of variation in the technologies used for the DP IA 
arm of the analyses contrasting to the IHC and FISH assays which were largely consistent. DP 
IA systems are novel technologies which are in most cases under development and are yet 
to achieve approval for use. The ideal scenario for meta-analysis is to group studies on both 
thresholds and technology used. Two studies that met the base case criteria also matched 
on technology. The sensitivity and specificity outputs as well as the summary proportion of 
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equivocal scores were similar to those under BCA and the same trends were observed i.e. 
decreased sensitivity, increased specificity and reduced equivocal scores.  
A final scenario explored changes in sensitivity and specificity estimates with digital 
technology. Results from the ACIS studies overlap with the base case DP IA results whereas 
SlidePath and Ariol are statistically different to base case but overlap with each other, for 
both of these technologies sensitivity is lower and specificity is higher than that estimated 
for DP IA under the under the base case scenario. ACIS is better able to identify positive cases 
whilst Ariol and SlidePath are better at identifying negative cases. When compared to CM 
base case accuracy, with SlidePath and Ariol, sensitivity is reduced and specificity increases. 
Preferably these should be evaluated against CM accuracy estimations generated by pooling 
results from the same studies that Ariol and SlidePath DP IA accuracy estimates are based 
on. However this proved challenging due to the different thresholds used in each group, 
limiting the number of studies that match on threshold and technology.  
It is worth noting that the Bloom and Harrington (2004) study is included in both the BCA, 
the ideal scenario analysis and the ACIS group. This paper generated 10 pairs of 2x2 tables 
as ten different pathologists were involved each scoring the breast cancer slides 
independently. In both the base case and the ACIS group data from Bloom and Harrington 
(2004) study accounts for over two thirds of the included evidence. Under the ideal scenario 
analysis it makes up more than 90%.  
Thus far the focus has been on estimating the accuracy of HER2 reporting using meta-
analyses, but there are limitations to this approach. The systematic review identified in total 
eleven eligible studies, of these only four were included in the base case 2013 meta-analysis 
estimations and two in the 2008 meta-analysis.  
Once the scoring thresholds have been taken into consideration there are not many 
published head to head to studies to be included in each scenario of the review. There are 3 
possible sources of heterogeneity that need to be controlled for: 
1. IHC threshold in the CM arm 
2. FISH threshold in the CM and DP IA arm 
3. Technology used in the DP IA arm 
To control for the first two excludes the majority of published head-to-head studies from the 
various meta-analyses. To go a step further and sub-group according to technology used 
significantly reduces the number of eligible studies. The limited number of studies identified, 
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coupled with the wide range of technologies and algorithms used, each with their own 
unique HER2 scoring methods introduces a degree of heterogeneity into both the 2013 and 
the 2008 group. 
Across the 11 studies included in the review, 7 different digital technology systems are used 
for HER2 scoring. These will differ in a number of ways including; the components they are 
made up of, the illumination method, computer hardware, monitors used, the digitisation 
process and digital slide visualisation techniques (Rojo et al., 2006).  Keay et al. (2013) 
investigated the reproducibility of HER2 scoring across 3 different digitisation systems and 
across two different image analysis algorithms. There were high levels of variability in the 
results between systems and also between algorithms (Keay et al., 2013). However a review 
of the published evidence on reproducibility found levels to be acceptable and in no way 
poorer than that found when using conventional approaches (RIBER‐HANSEN et al., 2012). 
Bloom and Harrington (2004) found inter-observer agreement among the 10 pathologists to 
improve with digitisation however each pathologist used identical technology for their DP IA 
scoring. Further work on the standardisation of digital techniques and algorithms needs to 
be carried out to limit inter-laboratory variability and ensure all HER2 cases are scored 
appropriately especially as there is some evidence of reduced equivocal scores with 
digitisation. 
The proportion of equivocal scores varied greatly between the head-to-head studies 
included in the review; ranging from 5 - 44% for conventional scoring and 0 - 58% for digital 
technology. Revised ASCO/CAP guidelines recently released in July 2018 refine the definition 
of 2+ scores (Wolff et al., 2018). As there has always been confusion on the classification of 
equivocal HER2 cases; pathologists are cautious, giving a 2+ score where there is uncertainty 
(Helin et al., 2016) to ensure the gold standard more definitive FISH test is carried out. This 
is more evident among junior rather than senior pathologists.  With the updated guidelines, 
it is anticipated there will be greater uniformity in scoring this indeterminate HER2 group. If 
the revised guidelines are able to bring CM scoring results closer to the gold standard 
outcomes, arguably DP IA accuracy maybe equivalent to subjective pathologist scoring when 
guidelines are in place and applied consistently. It is too early to know if this will be the case 
and further research is needed as the new guidelines are implemented across laboratories.  
Equivocal test results can essentially be classified as a non-evaluable index test result since 
they are neither negative nor positive and have simply been omitted from the bivariate 
meta-analysis when constructing the 2x2 tables. Questions arise as to whether this is the 
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best way to handle such results when carrying out a meta-analysis. Schuetz et al. (2012) 
compared diagnostic accuracy outcomes when non-evaluable results are omitted or all 
classified positive or all classified as negative. They found both sensitivity and specificity to 
be overestimated under the exclusion method and one or the other to be inflated when all 
non-evaluable results are classed as negative or positive. The European network for health 
technology assessment recommend in their guidelines on meta-analysis of diagnostic test 
accuracy the use of an intention-to-diagnose approach and include all non-evaluable results 
in 3x2 tables (EUnetHTA, 2014). Equivocal results from patients that have the disease are 
considered false negative and equivocal results of patients that do not have the disease are 
considered false positive (Ma et al., 2014). Unfortunately adopting this method would not 
meet the review objectives; the sensitivity and specificity are not the only outcomes of 
interest but also independently measuring the probability of obtaining an equivocal score 
needed to be established.  A more appropriate method would be to extend the bivariate 
model to take account of the equivocal risk by using a trivariate model as demonstrated by 
Chu et al. (2009).  Sensitivity, specificity and equivocal proportions can be simultaneously 
analysed  to take account of correlation between each effect (Riley et al., 2017). A trivariate 
model will determine whether the sensitivities and specificities worked out from the 
included studies are dependent on the probability of obtaining a definite score on the first 
round of testing (Chu et al., 2009). 
The review could have also go further in its analysis by taking into consideration the level of 
experience of the reporting clinician in each primary study. DP IA is a means to overcome 
discrepancies in subjective scoring that may result from differences in levels of experience 
(Walker, 2006). For example at the individual study level the scoring fluctuations observed 
between CM and DP IA are perhaps greater with pathologists at the start of their career in 
comparison to more experienced consultants. However to take this into account would have 
undoubtedly meant a reduction in the overall number of included studies making it 
impractical to carry out a meta-analysis of this nature. For the same reasons it was also not 
possible to separate out and analyse the primary research by level of quality as there were 
not enough studies of similar quality that use identical thresholds to score HER2. 
There is much debate on the most appropriate study design method for estimating 
diagnostic test accuracy. An alternative approach to cohort studies is the use of RCTs. A large 
well conducted RCT will overcome the issues of study heterogeneity and differences in 
population (Walker et al., 2008) found when carrying out a meta-analysis of much smaller 
cohort studies. While RCTs are considered the gold standard in intervention studies they are 
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extremely rare when investigating diagnostic accuracy (Rodger et al., 2012), none were 
picked up through the systematic review process. Beyond meta-analyses and RCTs there is 
potential to make accuracy estimations based on a single good quality cohort study. 
Diagnostic studies involve the management of glass slides rather than individuals and all tests 
of interest are generally conducted on all tissue specimens in the study sample; no doubt 
making them less prone to the risks of bias experienced with intervention studies. Certain 
biases for example performance, detection and attrition (Mansournia et al., 2017) are not 
applicable.  
6.6 Conclusion 
While there is no robust evidence and further primary research is needed to support the 
superiority of digital systems over conventional microscopes there is also no indication that 
it is inferior and in reality it is expected to be at least equivalent to a pathologist’s subjective 
scoring. Nonetheless the benefits of DP IA in HER2 breast cancer must be measured against 
the cost implications of the adoption of such a system in pathology. This information can be 
used in economic evaluations to determine the cost-effectiveness of DP IA in scoring HER2 
IHC and results used to support the adoption or rejection of this technology.  
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Chapter 7: Economic evaluation of digital HER2 testing 
7.1 Introduction 
A systematic review and meta-analyses comparing HER2 IHC test accuracy when using CM 
and DP IA were carried out and reported in the previous chapter. Meta-analyses were used 
to pool data and to generate test accuracy estimates for CM and DP IA to score HER2 IHC, 
with the results demonstrating improvements in the precision of scoring with digital 
methods and a reduction in the number of equivocal cases. Evidence of accuracy changes 
with digitisation are of limited benefit to decision makers if not considered in light of their 
implications for clinical and cost outcomes to support adoption.  
7.1.1 Patient care 
Concurrent to weighing up accuracy developments with new diagnostics, attention must be 
given to the grander scheme of patient care. Test accuracy alone does not improve clinical 
outcomes; yet it is the pivot on which investment and adoption decisions are made (Rodger 
et al., 2012). It is necessary to include breast cancer treatment following testing to assess 
and value the full benefit of scoring HER2 IHC using digital methods. Herceptin treatment, a 
clinical process that sits between the HER2 biomarker and the patient, its prescription or 
avoidance as a result of the test’s outcome defines whether any clinical or cost benefits are 
seen. An ideal scenario would feature reductions in FP and FN cases and an increase in 
diagnoses that match to the patient’s true HER2 status with digitisation, leading to greater 
precision in the design of care plans and limiting avoidable NHS costs. Diagnostic RCTs or 
modelling approaches where both the test and the therapeutic intervention are combined 
in one study (Lu and Gatsonis, 2013) can be used to determine the value to breast cancer 
care of DP IA to score HER2 IHC. 
7.1.2 Economic evaluation 
Economic evaluations can be used to predict changes in the cost and patient outcomes with 
the introduction of new DP IA technology for HER2 IHC testing. By taking a modelling 
approach the appropriate connection can be made between the HER2 testing algorithm, test 
performance under each intervention, treatment prescribed and patient and cost outcomes. 
Each of the IHC testing methods can be represented by manipulating model parameters to 
reflect each method appropriately. The main adaptation in the HER2 model from CM when 
evaluating DP IA are the probability values that are input since these are largely driven by 
the test performance estimated under each method.  
Economic evaluation results can be expressed in terms of incremental net benefit (INB) 
where both costs and effects (e.g. QALYs) are valued and expressed in monetary terms, using 
181 
 
the NICE recommended willingness to pay threshold of £20,000 to £30,000 (McCabe et al., 
2008). Any INB result above zero suggests that the intervention is cost effective and supports 
its adoption. For this to occur the monetary value of the difference in effect must be greater 
than the difference in costs between conventional and digital. Conversely, a negative INB 
does not provide evidence to support the adoption of digital techniques and based on the 
economic evaluation alone the concept of pathology digitisation will be rejected. 
No previous economic evaluation has been carried out to justify the introduction of digital 
pathology image analysis into the UK Healthcare setting. The results of the economic 
evaluation can be used to inform decision making relating to digital pathology while 
recognising that the effects of digitisation will undoubtedly be realised beyond this single 
biomarker. Digitally upgrading any pathology lab will not only be of value when scoring HER2 
or even just in the management of breast cancer cases; but rather it will replace every task 
in the pathology lab where a microscope is used. Ideally the introduction of digital techniques 
should be weighed up against possible accuracy benefits across all disease areas but in reality 
this is challenging due to the extent and range of available biomarkers and tests where digital 
technology can theoretically have an influence. For this reason it is difficult to explore the 
cost-effectiveness of digitisation across all tests of interest but only from the perspective of 
one biomarker at a time.    
All of the eligible studies identified in the systematic review of economic evaluations that 
was carried out in chapter 2 used estimates of sensitivity and specificity based on single 
studies. None attempted to pool estimates of test performance using meta-analysis 
techniques to inform their model. This chapter also explore the impacts on cost-effectiveness 
estimates when accuracy parameters are based on a good-quality single study compared to 
when they are based on pooled estimate 
7.2 Aims 
This economic evaluation will focus on the impact of digital pathology image analysis when 
scoring HER2 IHC as part of invasive breast cancer management process.  
1. The primary aim is to determine the cost-effectiveness of Digital Pathology Image Analysis 
when compared to Conventional Microscopes in determining HER2 status for invasive 
breast cancer patients.  
2. The secondary aim of the study is to explore changes in decisions made when HER2 
accuracy estimates are based on one good quality cohort study compared to when they 
are based on the results of a meta-analysis  
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7.3 Methods 
The cost effectiveness analysis was designed to measure the change in costs and QALYs for 
invasive breast cancer patients with the introduction of digital pathology image analysis 
technology for scoring HER2 IHC compared to conventional microscope methods. The 
analysis involved several stages. Firstly, a conceptual model was developed, this was simply 
extracted from the information learnt about the HER2 testing algorithm that had previously 
been incorporated into the conceptual model of the DES model described in chapter 5. The 
conceptual model allowed the identification of all the model parameters; estimates of these 
were taken from various sources including both single and synthesis based studies. The 
model structure and its parameters were computed using R software and designed to 
generate an INB result. Sensitivity analyses were carried out to establish the impact of 
parameter uncertainty on the INB estimations. In addition a value of information analysis 
(VOI) was performed to measure the expected gain from further research.  
7.3.1 Model structure 
A decision tree model was developed to be used for the economic evaluation; it principally 
aimed to capture all the stages of the HER2 testing strategy. The tree structure has two arms 
with identical branches; one representing digital pathology image analysis and the second 
conventional microscopes. A schematic of one of the arms is given in figure 7-1; the model 
structure for the digital pathology image analysis arm is a replica of that for conventional 
microscope examination.  To start a decision node divides the tree into each arm of the 
analysis. At this point based on UK HER2 prevalence data; patients are designated to be 
either HER2 positive or negative reflecting their true status. Of these a fraction are equivocal 
prior to HER2 status confirmation by FISH testing and as such are directed to the Equivocal 
(EQ) arm. Those that are Not Equivocal (NEQ) initially on IHC and are given a HER2 result are 
directed to the NEQ arm. If their true HER2 status is positive; they can either be a True 
Positive (TP) or a False Negative (FN) on IHC. If their status is negative; they are split between 
those who are True Negative (TN) or False Positive (FP).  
Each endpoint in the tree represents a unique combination of events for invasive breast 
cancer patients; these are the true HER2 status, the final result given and the consequent 
treatment plan. Table 7-1 describes these. There are 6 possible scenarios regarding a 
patient’s HER2 pathway. For two of these (C and F); additional FISH testing is required, so 
while they are ultimately given the correct treatment, the additional test causes delay and 
adds an extra cost to the pathway.  For scenarios B and E incorrect treatment is prescribed; 
one where it is omitted (B) and the second where it is given in error (E). The introduction of 
183 
 
DP IA is anticipated to reduce the probability of these four combinations of events and 
increase the likelihood of the remaining ideal two scenarios (A and D) where breast cancer 
patients are given the correct diagnosis on the first round of testing and thus prescribed 
Herceptin appropriately.  
Figure 7-1 Illustration of the convention microscope arm of the decision tree 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7-1 Decision tree endpoints 
 End Point True Status IHC FISH Herceptin Care Plan 
A +NEQ TP Positive +3 ---- Yes Correct 
B +NEQ FN Positive 0/+1 ---- No Incorrect 
C +EQ Positive +2 Amplified Yes Correct 
D -NEQ TN Negative 0/+1 ---- No Correct 
E –NEQ FP Negative +3 ---- Yes Incorrect 
F -EQ Negative +2 Non-Amplified No Correct 
 
Probabilities are included following each chance node in the tree as well as costs and QALYs 
are added to the end points of each branch. While each arm of the decision tree model is 
identical on its structure, QALYs and costs, the attached probabilities differ between the two 
arms. Cost and QALY differences between the CM and DP IA were valued over the breast 
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cancer patient’s lifetime by using total lifetime QALY estimates per patient for Herceptin 
treatment estimated and reported by Clarke et al. (2017).  
The model assumes that all patients will receive a conclusive HER2 score by the end of the 
two-step testing process; in reality this is not always the case. For various reasons such as 
inadequate specimen submitted; a definite HER2 result may not be reached even post FISH 
and thus generally for these patients a recommendation is made to repeat the HER2 testing 
process on a second specimen. The model also assumes that all patients are treated with 
Herceptin if they are found to be HER2 positive; in reality this is also not the case. If age, co 
morbidities or patient preference are taken into account a fraction of breast cancers will not 
be treated with Herceptin even though they are HER2 positive. The model also does not 
differentiate between primary and metastatic cases and considers all invasive breast cancers 
a homogenous group.  
7.3.2 Model costs 
Costs are assigned at the endpoints of each branch of the decision tree. The cost 
effectiveness analysis took an NHS Perspective and as such only included costs to the NHS 
directly related to HER2 testing and Herceptin treatment process. For each branch a 
combination of costs are incorporated; these are the cost of (1) IHC Test (2) FISH Test, 
including both the cost of the test itself and delivery and (3) the cost of Herceptin Treatment. 
The decision tree model follows UHCW HER2 testing processes and current UK 
recommendations as outlined in figure 6-2 in chapter 6 and assumes all FISH testing is carried 
out off-site. The reference cost year was 2015-2016; adjusted using inflation indices from 
PSSRU (2016) where data was not available for this period.  
The cost of basic IHC slide preparation is the same for both the digital and the conventional 
arm and so this is not included as an input in the model. A business case was put together at 
UHCW to support the introduction of the digital system into their pathology labs and for its 
use across the trust. As part of this, the projected costs of digital pathology over a 7-year 
period were detailed, this does not include the cost of the HER2 image analysis algorithm. 
Based on UHCW data the annual figures for slides requested over the 7-year period could 
also be extrapolated. All histopathology slides were included since in reality digital pathology 
will be used across all diseases not just breast cancer cases. Based on this information, the 
system installation will cost an extra £0.64/slide. Due to the high throughput and consequent 
minimal cost/slide, the cost of digital pathology and image analysis were not included in the 
model at this stage of the analysis. The focus will be on measuring the changes in treatment 
costs and benefits as a result of accuracy implications with DP IA.  
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The cost of FISH testing is based on UHCW prices; this is currently £115 and includes both 
the cost of test and delivery. For the analysis, the Herceptin treatment duration is assumed 
to be 9 weeks and sensitivity analysis will explore the impact on INB if this was at the 
currently recommended 12 month treatment duration. Herceptin costs for both 9 weeks and 
12 months treatment are based on values from Clarke et al. (2017); their 2013/2014 costs 
are adjusted to 2015/2016 costs using PSSRU (2016), these are expressed and input into the 
model as normal distributions. The costs are identical for both arms of the decision tree since 
the cost of digital pathology image analysis is not included at this stage of the economic 
evaluation. Example mean cost values for each branch of the tree are given in table 7-3; these 
are based on the base case 9 weeks Herceptin treatment. 
Table 7-2 Cost of Herceptin treatment (Clarke et al., 2017) 
 
 
 
 
Table 7-3 Example 9 week mean model costs input 
 
 
 
 
 
 
 
 
7.3.3 Model QALYs 
In addition to costs; QALY values are assigned to the various decision tree endpoints. For the 
TP and FN arms; these are taken from Clarke et al. (2017). Their cost effectiveness analysis 
undertook a network meta-analysis where all trials recruited patients who were HER2 
positive.  The outcomes seen in the observation; zero Herceptin arm are assumed to be 
equivalent to those breast cancer cases with HER2 positive status but not given treatment 
due to error in reporting results i.e. they are FN. The consequent QALY outcomes for the 
9week and 12month treatment arms are used for TP status. TP and FN QALYs are expressed 
and input into the model as normal distributions, these are given in table 7-4.  
Duration Distribution Parameters 
9weeks Normal £7666 (95% CI: £6,831, £8,501) 
12months Normal £28,494 (95% CI: £25,064, £31,924) 
Branch Included Costs Total 
+NEQ TP Herceptin £7666 
+NEQ FN None £0 
+EQ Herceptin + FISH £7781 
-NEQ TN None £0 
-NEQ FP Herceptin £7666 
-EQ FISH £115 
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The QALYS for the TN and FP arms were estimated as these values were not available in the 
literature. Katzorke et al. (2013) compared outcomes in HER2 positive breast cancers treated 
with Herceptin to those HER2 negative cases. Overall survival is greater in the former 
compared to the latter; with a hazard ratio of 0.67 (95% CI: 0.48, 0.92) (Katzorke et al., 2013). 
The mean hazard value is used to calculate the TN QALY from the TP QALY distribution. 
FP patients are those whose true status is negative but receive Herceptin due to reporting 
errors; their QALY values are calculated by subtracting the disutility of 0.104 (95%CI: 0.084, 
0.0125) (Garrison et al., 2015) associated with cardio toxicity experienced when a patient is 
given Herceptin treatment. As with costs; base cases analysis was based on the 9 week 
treatment period and sensitivity analysis will explore changes in INB when 12 months of 
Herceptin is prescribed.  
Table 7-4 QALYs of Herceptin treatment 
 
 
 
 
For the +EQ branch the QALY will be identical to TP values and for the –EQ branch the QALY 
input will be equal to the TN values. The QALY values are the same for both the digital and 
conventional arms of the decision tree.  
7.3.4 UK prevalence 
The incidence of HER2 positivity is based on a 5 year UK national audit  estimating the overall 
HER2 positivity in invasive breast cancer patients at 14.5% (Rakha et al., 2014).  
7.3.5 Model probabilities 
The test effect was measured using odds ratios (OR). Estimates of the DP IA arm probabilities 
were derived by application of Log(OR) for the test effects to CM arm probabilities reported 
in the published literature as illustrated in the equation below: 
logit(p2x) = logit(p1x) + Log(ORx) 
Welton et al. (2012) 
p1 are the probabilities used to populate the CM arm of the model, p2 are the probabilities 
for the DP IA arm and x defines the probability of interest as listed, where x can be one of 
the following: 
Arm Distribution 
Parameters 
9 weeks 12months 
TP Normal 10 (95%CI: 8.62, 11.38) 9.2 (95%CI: 7.95, 10.45) 
FN Normal 8.6 (95%CI: 7.45, 9.75) 8.6 (95%CI: 7.45, 9.75) 
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1. +eq the probability of an equivocal score if HER2 positive 
2. –eq the probability of an equivocal score if HER2 negative 
3. Sens the probability of a TP result in the positive non-equivocal group 
4. FPR the probability of a FP result in the negative non-equivocal group 
There are four test effects to be estimated on the log scale to be applied in the above 
equation, these are listed in table 7-5.  
Table 7-5 List of test effects 
Log(ORx) Description 
Log(OR+eq) 
Odds of an equivocal result if HER2 status is positive in the DP IA arm 
relative to the odds of an equivocal result in the CM arm 
Log(OR-eq) 
Odds of an equivocal result if HER2 status is negative in the DP IA arm 
relative to the odds of an equivocal result in the CM arm 
Log(ORsens) 
Odds of a TP result in the DP IA arm relative to the odds of a TP result in 
the CM arm 
Log(ORFPR) 
Odds of a FP result in the DP IA arm relative to the odds of a FP result in 
the CM arm 
 
Distributions for p1x and Log(ORx) differ between base case and the sensitivity analysis 
scenarios. These are described under each.  
7.3.6 Base case scenario 
This analysis estimated p1x  and log(ORx) from studies that met the criteria for inclusion in 
the systematic review described in chapter six and adopted the 2013 thresholds for scoring. 
The OR for each of the four test effects from each study were pooled on the log scale using 
the metafor package in R, the mean and standard error (Se) of the Log(OR) are given in table 
7-6.  
Table 7-6 Estimates of Log(OR) 
 2013 data 2008 data 2013 single study data 
Log(ORx) mean Se mean Se mean Se 
Log(OR+eq) -1.1041 0.4487 -0.1199 0.3489 -0.5994 0.1771 
Log(OR-eq) -2.9553 0.7421 -0.4054 0.1921 0.1852 0.3725 
Log(ORsens) -0.8079 0.3692 0.0173 0.4766 -0.3127 0.2248 
Log(ORFPR) -0.3453 0.4719 -0.0601 0.8194 0.3453 1.5111 
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P1 probabilities are either based on the meta-analyses carried out in chapter 6 or are based 
on data extracted directly from the published literature. In the base case analysis p1+eq and 
p1-eq are from Mohammed et al. (2012), this is a good quality head-head study that adhered 
to the 2013 thresholds for scoring. p1+eq and p1-eq were expressed and input into the model 
as beta distributions in the CM arm of the model. The same distributions were transformed 
onto the logit scale and the log(OR+eq) applied to logit(p1+eq) and log(OR-eq) to logit(p1-eq) to 
estimate logit(p2+eq) and logit(p2-eq) respectively. The resultant distributions were back-
transformed to generate the probability distributions for p2+eq and p2-eq to be input as 
distributions into the DP IA arm of the model.  
p1sens and p1FPR were taken from the outputs of base case bivariate meta-analysis in chapter 
6. These were already expressed on the logit scale, log(ORsens) and log (ORFPR) were applied 
to these to generate logit(p2sens) and logit(p2FPR). All logit probabilities were back 
transformed and used to populate the model. Summary of the p1 probabilities that are used 
to populate the CM arm of the model are given in table 7-7.  
Table 7-7 BCA p1 distributions 
p1 Distribution Parameters Source 
p1+eq Beta α=18 β=62 
Mohammed et al. (2012) 
p1-eq Beta α=5 β=346 
logit(p1sens) Normal 2.652 (95% CI: 2.238, 3.066) Chapter 6: Bivariate meta-
analysis results  logit(p1FPR) Normal -2.735 (95% CI: -3.167, -2.303) 
 
The Costs and QALYS associated with the 9-week treatment period are used in the base case 
analysis due to its dominance over 12 month treatment. 
A deterministic version of the model is initially run by applying point estimates of the mean 
for all the model parameters, this is followed by probabilistic version of the model is run 
where all parameter inputs are based on the distributions outlined previously to generate a 
probability for cost-effectiveness. 
To further explore cost-effectiveness implications of DP IA and ascertain the robustness of 
decisions made, four further scenarios are explored as described below by making 
appropriate modifications to the model. Scenario analyses are all carried out using stochastic 
models to allow for random variation.  
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7.3.7 Scenario analysis 1: 2008 scoring thresholds 
Under this scenario the impacts on cost-effectiveness when the test effect estimates are 
based on the 2008 scoring thresholds are explored. Identical cost and QALY distributions to 
those in the BCA were used to populate the model. The model structure and methods for 
assessment of p2x are also identical. Rather than using data from the 2013 threshold studies, 
all log(ORx) are based on the 2008 threshold studies that were eligible for inclusion in the 
systematic review in chapter 6. Summary of the distributions are given in table 7-8.  
For p1x distributions, the same approach was taken as that for the base case. p1+eq and p1-eq 
were based on Minot et al. (2009), a good quality head-to-head study that adopts the 2008 
thresholds for scoring. For estimations of p1sens and p1FPR the outputs from the bivariate 
meta-analysis in chapter 6 for the 2008 studies was used. A summary of the p1 distributions 
as they are input into the model is given in table 7-8.  
Table 7-8 SA1 p1 distributions 
p1 Distribution Parameters Source 
p1+eq Beta α=7 β=10 
Minot et al. (2009) 
p1-eq Beta α=24 β=113 
logit(p1sens) Normal 1.064 (95% CI: 0.75, 1.378) Chapter 6: Bivariate 
meta-analysis results logit(p1FPR) Normal -4.507 (95% CI: -5.01, -4.004) 
 
7.3.8 Scenario analysis 2: 12 month treatment period 
Whilst published studies have shown the 9-week treatment period for Herceptin to dominate 
12 months, the latter still remains the recommended treatment length in the UK. This 
scenario explores cost-effectiveness outcomes using cost and QALYs associated with 12-
month treatment. These are listed in table 7-2 and table 7-4. Model probabilities are identical 
to those used in the base case model.  
7.3.9 Scenario analysis 3: Single study approach 
The third scenario explores the impact on cost-effectiveness when the probabilities and test 
effect are estimated using a good quality head-to-head study. The systematic review in 
chapter 6 identified Mohammed et al. (2012)  as a good quality head-to-head study; this was 
the only study adhering to the 2013 thresholds that scored positively on all the domains of 
the QUADAS-2 tool as illustrated in table 6-6. Data from this study was used to inform this 
scenario analysis. 
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 QALY and cost distributions are identical to those used in base case analysis however values 
for p1x are expressed and input into the model as beta distributions using data extracted 
from Mohammed et al. (2012) and log(ORx) are expressed as normal distributions and are 
also based on data extracted from Mohammed et al. (2012). p2x values are estimated using 
the same methods as described previously. Table 7-6 and 7-9 summarise estimates of 
log(ORx) and p1x respectively.  
Table 7-9 SA3 p1 distributions 
p1 Distribution Parameter Source 
p1+eq Beta α=18 β=62 
Mohammed 
et al. (2012) 
p1-eq Beta α=5 β=346 
p1sens Beta α=53 β=9 
p1FPR Beta α=2 β=344 
 
7.3.10 Cost-effectiveness analysis 
The model equations are designed to start at the decision tree end point, applying back 
calculations to determine the total QALYs and costs associated with each arm of the model. 
The incremental cost and QALY between the DP IA and CM arms are estimated using the 
following equations: 
Incremental QALY = DP IA QALY – CM QALY 
Incremental Cost = DP IA Cost – CM Cost 
50000 observations are generated from all model distributions. The model inc(cost) and 
inc(QALY) are plotted against each other on the cost-effectiveness plane for each scenario. 
These provide a visual representation of cost-effectiveness observing the distribution of the 
50000 simulated results on the quadrants of the plane.  
The probability of cost-effectiveness was estimated by using incremental INB values at each 
WTP threshold. The incremental QALY distributions generated under each scenario are 
converted into a distribution of monetary values through multiplication by the WTP 
threshold. These values are converted to INB as follows: 
INB = (Incremental QALY*WTP threshold) – Incremental Cost 
A positive INB indicates that the intervention is cost-effective whereas a negative INB does 
not favour the intervention. 50000 simulations of INB are generated at each WTP threshold. 
The total number of positive estimations is divided by 50000 to generate the probability of 
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cost-effectiveness at each WTP threshold. Each probability was plotted against its WTP 
threshold to generate a cost-effectiveness acceptability curve (CEAC) demonstrating how 
cost-effectiveness alters with WTP for each scenario.  
7.3.11 Value of Information Analysis  
The value of information (VOI) analysis quantifies the value of reducing uncertainty through 
further research (Wilson, 2015) to inform a decision problem. Two levels of VOI were carried 
out for each scenario. The expected value of perfect information (EVPI) is the difference 
between a decision being made based on perfect information where uncertainties around 
all parameters are eliminated, and the decision being made based on the existing imperfect 
information (Claxton and Sculpher, 2006). EVPI was estimated for each scenario at both the 
£20,000 and the £30,000 WTP threshold. The mean net benefit at the WTP thresholds is 
known, the 50000 simulated INB values are each compared against the mean net benefit. If 
the investment decision is altered with the individual INB value compared to the decision 
that was made with the mean INB the individual INBs are summed and averaged, this is the 
EVPI. The EVPI quantifies the value of eliminating uncertainty around all the model 
parameters.  
Further to patient level estimates, EVPI can also be quantified at the population level, this is 
a more appropriate value to compare to the costs of further research (Thorn et al., 2016). 
The incidence of invasive breast cancer cases over a suitable time horizon was multiplied by 
the patient EVPI to calculate a value for population EVPI. A discount rate of 3.5% was applied. 
Further research can be justified if the cost of investment falls below the population EVPI 
(Oostenbrink et al., 2008).  
The EVPI value alone is not sufficient on which to base research funding decisions (Thorn et 
al., 2016). The expected value of partial perfect information (EVPPI), quantifies the difference 
in expected INB when perfect information is available for each of the model parameters. 
Similarly to the methods for EVPI but an additional loop is added, for the model parameter 
of interest the value is fixed for each run of the model that generates 50000 estimations of 
INB. This loop is repeated for each of the 50000 values of the parameter of interest. The 
decision made using the mean INB for each loop is compared against the decision made prior 
to EVPPI analysis, where there is a change the mean INBs are summed and averaged to 
generate a value for the elimination of uncertainty around the parameter of interest. Each 
parameter is investigated independently defining where future research should focus.  EVPPI 
was carried out for the base case analysis and  
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7.4 Results 
7.4.1 Base case analysis results 
The decision tree model for base case analysis was initially run as a deterministic model to 
estimate the INB of DP IA compared to CM when scoring HER2 IHC. The INB was negative at 
both the £20,000 and the £30,000 WTP thresholds. A summary of these results is given in 
table 7-10 together with the incremental costs and QALYs when comparing DP IA to CM. 
Table 7-10 Deterministic model outputs 
 
 
 
 
 
The deterministic model outputs show DP IA as not cost-effective at both WTP thresholds 
because the monetary value of the QALY loss outweighs the cost-savings observed. The costs 
and QALY outputs of the decision tree would lie in the south-west quadrant on the cost-
effectiveness plane; as digitisation is predicted to be both cost saving and QALY reducing.  
Due to the QALY losses experienced when moving from conventional to digital techniques, a 
negative value is generated in the first part of the INB calculation. An increase in the WTP 
gives a greater monetary value to the QALY loss incurred and so an increase in the threshold 
is associated with a concurrent decrease in INB.  
The base case scenario model was run again with all the model parameters expressed as 
distributions rather than as point estimates.  50000 estimations of incremental cost and 
QALY were generated and are illustrated on the cost-effectiveness plane in figure 7-2. The 
two lines on the figure represent the NICE WTP thresholds, any points falling below these 
favour digitisation, contrarily points above the WTP thresholds favour conventional 
microscope techniques. 
On review of figure 7-2 it is obvious that judgements on the cost-effectiveness of digitisation 
are not so clear-cut. Unlike what is seen under the deterministic analysis, digitisation does 
not always generate a negative INB outcome. There is both evidence to support and to 
counter the cost-effectiveness of digitisation.  The results fall across all four quadrants 
however it appears that there may be a low probability of cost-effectiveness due to the 
position of the points in relation to the WTP thresholds with what appears to be more than 
50% lying above the lines.  
Strategy 
Model outputs INB results 
QALY Cost WTP £20000 WTP £30000 
CM 7.17 £1453.85 
-£108.52 -£258.62 DP IA 7.16 £1262.46 
Increment -0.01 -£191.38 
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To explore the level of uncertainty around the cost-effectiveness, the points on the plane in 
figure 7-2 are manipulated to form the cost-effectiveness acceptability curves (CEAC) in 
figure 7-3. The probability of cost-effectiveness is plotted against a series of WTP thresholds. 
At the £20,000 WTP threshold there is a probability of 0.41 of cost-effectiveness and at the 
£30,000 WTP threshold decrease to 0.35, probability cost effectiveness is reducing with the 
threshold, due to the higher value attached to the QALY losses observed.  
Figure 7-2 BCA cost-effectiveness plane 
 
Figure 7-3 BCA CEAC 
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7.4.2 Scenario analysis results 
Cost effectiveness planes and CEAC were generated for each scenario analysis, the cost 
effectiveness planes are given in figures 7-4, 7-5 and 7-6 for each scenario and the CEACs in 
figure 7-7. 
Figure 7-4 SA1 cost-effectiveness plane 
 
Figure 7-5 SA2 cost-effectiveness plane 
 
The scatter of points on the cost-effectiveness planes for the SA1 scenario, where ORs and 
probabilities are based on studies that use 2008 scoring thresholds and for the SA2 scenario 
where costs and QALYs are based on 12 months of Herceptin treatment are noticeably similar 
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to the base case cost-effectiveness plane. For the SA3 scenario the scatter of points obviously 
differ from the others. 
Figure 7-6 SA3 Cost-effectiveness plane 
 
Figure 7-7 CEAC for all scenarios 
 
The CEACs in figure 7-7 summarise the impact of uncertainty in the model parameters on the 
cost-effectiveness of digitisation. Rather than present a single INB value CEACs allow decision 
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makers to understand the likelihood of cost-effectiveness and so make better-informed 
decisions about the adoption of digitisation in pathology. Figure 7-7 shows the SA2 scenario, 
where costs and QALYs are based on 12months treatment, to consistently produce 
probabilities of cost-effectiveness that are superior to those for the other scenarios across 
all WTP thresholds. The SA3 scenario where model probability estimates are based on a 
single head-to-head study has a consistently lower probability of cost-effectiveness across 
all the WTP thresholds. NICE recommend a WTP of £20,000 to £30,000 per QALY, decision 
makers in the UK will in particular want to know the probability of cost-effectiveness at these 
WTP thresholds. These are summarised in table 7-11.  
Table 7-11 Probability of cost-effectiveness at NICE WTP thresholds 
Out of the four scenarios, three generate probabilities of 
cost-effectiveness at both WTP thresholds that are less 
than 0.5. Under BCA, SA1 and SA3 there is a greater 
likelihood of digitisation not being cost-effective. Under 
SA2, there is a greater than 70% chance of digitisation being 
cost-effective. 
 
7.4.3 Value of Information Analysis 
The VOI analysis provides evidence to support further research and identifies where this 
should be focused. Patient level EVPI for all scenarios and EVPPI for the base case and single 
study scenarios were carried out. 
7.4.3.1 EVPI results 
A graphical representation of the patient EVPI at a range of WTP thresholds is given in figure 
7-8. The value of further research is generally highest for the SA2 scenario where 12months 
of Herceptin treatment is given and lowest for the SA3 scenario where single study estimates 
of model probabilities are used. Table 7-12 summarises the EVPI values at both the NICE WTP 
thresholds for each scenario.  
At the £20,000 WTP threshold EVPI for the base case analysis is very close to that for SA2, 
however the gap widens as the threshold increases. The SA3 scenario remains associated 
with the lowest EVPI values. 
 
 
 WTP threshold 
£20,000 £30,000 
BCA 0.412 0.351 
SA1 0.473 0.474 
SA2 0.778 0.717 
SA3 0.334 0.299 
197 
 
0
100
200
300
400
500
600
700
800
900
0
4
0
0
0
8
0
0
0
1
2
0
0
0
1
6
0
0
0
2
0
0
0
0
2
4
0
0
0
2
8
0
0
0
3
2
0
0
0
3
6
0
0
0
4
0
0
0
0
4
4
0
0
0
4
8
0
0
0
5
2
0
0
0
5
6
0
0
0
6
0
0
0
0
6
4
0
0
0
6
8
0
0
0
7
2
0
0
0
7
6
0
0
0
8
0
0
0
0
8
4
0
0
0
8
8
0
0
0
9
2
0
0
0
9
6
0
0
0
1
.0
0
E+
0
5
EV
P
I
WTP threshold
BCA SA1 SA2 SA3
Table 7-12 EVPI at NICE WTP thresholds 
 
 
 
 
 
 
Figure 7-8 Patient level EVPI 
 
 
 
 
 
 
 
 
 
 
 
To achieve a meaningful value of EVPI that can be compared to the cost of further research, 
the population EVPI is calculated by multiplying the patient EVPI by the UK incidence rate of 
invasive breast cancer. The population EVPI was calculated for each scenario and at both 
thresholds over a three, five and ten year horizon for comparison purposes. 
CancerResearchUK (2018) determined an annual incidence of 54,751 in 2015 for invasive 
breast cancer cases in the UK. This was discounted by 3.5%. It was assumed that the HER2 
IHC test was carried out on all invasive breast cancer patients, in reality this is not the case 
due to the presence of age and comorbidity factors. Where clinicians know on outset that a 
recommendation for Herceptin treatment cannot be made regardless of the patient’s HER2 
 WTP threshold 
£20,000 £30,000 
BCA £120.36 £136.84 
SA1 £96.53 £146.66 
SA2 £121.09 £183.33 
SA3 £78.26 £74.32 
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status they do not expose them to the HER2 testing process. The results of the population 
EVPI are given in table 7-13. 
Table 7-13 Population level EVPI 
Model WTP 
Time Horizon 
3 years 5 years 10 years 
BCA 
£20,000 £25,052,883 £36,344,333 £61,396,662 
£30,000 £28,481,329  £41,317,996 £69,798,695 
SA1 
£20,000 £20,093,080  £29,149,123 £49,241,759 
£30,000 £30,526,064  £44,284,302 £74,809,691 
SA2 
£20,000 £25,205,117  £36,565,180 £61,769,740 
£30,000 £38,159,158  £55,357,667 £93,515,981 
SA3 
£20,000 £16,290,172  £23,632,228.31 £39,922,040 
£30,000 £15,469,277  £22,441,352.21 £37,910,287 
 
7.4.3.2 EVPPI 
The value of eliminating uncertainty around the model parameters in both the base case and 
SA3 scenarios is investigated with EVPPI.  This identifies where further research should be 
focused. EVPPI was investigated for five groups of parameters, the first valued the 
elimination of uncertainty in all the p1 (CM) probabilities, the second valued the elimination 
of uncertainty around test performance and the third and fourth investigated elimination of 
uncertainty around the QALY values for the TP and FN cases. The results of this analysis are 
given in table 7-14. 
Table 7-14 EVPPI results 
 
The greatest 
value in 
research 
under the 
SA3 
scenario is 
around test 
performance. The SA3 scenario measures these uses a single study, contrarily the EVPPI for 
test performance under the base case analysis were log(ORx) are based on meta-analysis is 
considerably lower. The base case EVPPI suggests the greatest value in research is around 
the QALY estimates that are used to populate the model.  
Model parameters 
BCA SA3 
WTP threshold WTP threshold 
£20,000 £30,000 £20,000 £30,000 
CM probabilities (p1x) £28.47 £10.91 £0.00 £0.00 
Test performance (LogORx) £3.08 £1.48 £65.30 £49.22 
TP QALYs  £68.56 £73.49 £0.00 £0.00 
FN QALYs £48.65 £50.22 £0.00 £0.00 £0 
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7.5 Discussion 
The aim of the economic evaluation was to explore the effects of pathology lab digitisation 
together with image analysis algorithms on the clinical and cost outcomes for invasive breast 
cancer patients when scoring HER2 IHC. A decision modelling approach to the economic 
evaluation was taken and a summary of the cost effectiveness probabilities is given in table 
7-11. The majority of results favour CM and do not support the adoption of DP IA. The 
probability of cost-effectiveness falls below 0.5 at the WTP thresholds for all the scenarios 
investigated except for SA2, where the costs and QALYs of Herceptin are based on the 12 
months treatment plan. This model includes the current recommended treatment duration. 
The cost of Herceptin under this scenario is much greater than at base case and the range of 
QALY estimates is lower. In the cost effectiveness plane for SA2 in figure 7-5, many of the 
estimates of incremental costs and QALYs fall in the bottom two quadrants where DP IA 
would be considered a cost saving intervention. Since the cost of Herceptin is higher under 
this scenario, the total cost saving across the model is much greater than that seen at base 
case. The cost saving is more likely to balance out the monetary value of the QALYs lost so 
that INB is greater than 0 and DP IA is more likely to be considered cost-effective. 
Due to the ethical implications it can be challenging to make cost-effectiveness decisions 
based on results that fall in the south-west quadrant, in these cases the intervention’s cost-
effectiveness is associated with a reduction in clinical effectiveness. DP IA will reduce the 
QALYs gained for some patients that would have otherwise gained under the CM scenario 
(Dowie et al., 2015). Discussion has taken place around this issue with methods suggested to 
determine the cost-effectiveness of interventions that fall in the south-west quadrant. One 
such proposal is the use of a different threshold. The compensation a patient is willing to 
accept (WTA) for a health loss is greater than the amount they would be willing to pay for 
the same health gain as demonstrated in the review by O'Brien et al. (2002). Eckermann 
(2015) suggest the use of what they refer to as a ‘kinked threshold’ that is based on WTA in 
the south west quadrant and WTP in the north east quadrant of the cost effectiveness plane. 
Under such an approach, interventions are less likely to be cost effective if they fall in the 
south west quadrant. However when taking a societal perspective the aim is to maximise 
total health benefits to society within a limited budget so that the opportunity cost of 
investing  in interventions that fall in the south west quadrant must be considered (Klok and 
Postma, 2004). 
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The increased probability of cost-effectiveness under SA2 compared to the other scenarios 
is driven by the Herceptin treatment regimen. There is no dispute around the value of 
Herceptin when given to the correct patients but there is much debate and ongoing research 
around the recommended length of treatment to reach full benefits with minimum 
cardiotoxicity. The HERA trial; a three arm randomised control trial compared no Herceptin 
treatment with Herceptin for 1 year and Herceptin for 2 years (ICR, 2017). Whilst the trial 
found an improvement in patient outcomes when patients were given 1 year of Herceptin vs 
no Herceptin; there was no benefit in increasing the duration of Herceptin treatment to two 
years and evidence indicated a higher possibility of cardio toxic events with 2 years of 
treatment (Goldhirsch et al., 2013). NICE guidelines recommend that Herceptin is given for 1 
year of treatment post chemotherapy (NICE, 2006b) and this is still considered the standard 
treatment pattern for HER2 positive breast cancers.  Research to determine if shorter periods 
of Herceptin treatment will produce results equivalent to one year are ongoing with 
investigations into both 6 months and 9 week treatment courses.  
There is not yet any full publication on the Persephone trial comparing 6 month to 12 month 
Herceptin treatment but early indications suggest the non-inferiority of 6 months, reducing 
both cardio-toxicity and the costs of treatment (Earl et al., 2018). Joensuu et al. (2009)’s trial 
comparing 9 weeks of adjuvant therapy with or without Herceptin presented evidence 
supporting the use of Herceptin. Whilst there are no head to head trials comparing 9 weeks 
to 1 year of Herceptin treatment; Clarke et al. (2017)’s Network Meta-Analysis suggested 
cost savings and QALY increases when comparing 12 months against 9 weeks of treatment; 
hence showing the 9 week period to dominate the 12 months.  Reducing the length of 
Herceptin treatment whilst maintaining the outcomes seen with 12 months of treatment will 
guard patients from cardio-toxic effects. These are only experienced during the treatment 
period; with risk of these events returning to normal levels once treatment ceases (Onitilo 
et al., 2014). A shorter period of treatment coupled with accuracy improvements will 
undoubtedly result in cost-savings to the NHS and allow patients to set on the path to 
remission sooner.  
A perceived limitation of the economic evaluations is the lack of suitable accuracy data to 
populate the model. The meta-analysis were limited in the number of studies that could be 
included due to the various criteria that had to be considered. There is undoubtedly a need 
for further research, particularly around the test performance of the techniques used for 
scoring. The population EVPI is an upper bound of what would be considered suitable funding 
for further research.  The population EVPI ranged from just 15 to 90 million depending on 
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the scenario, WTP threshold and time horizon used in the analysis. Certainly, the benefits of 
additional research will outweigh the cost of further research, as it is expected that the cost 
of further research will be a lot lower than these values. It is worth noting that all invasive 
breast cancer female patients will not be exposed to this test and the population EVPI 
analysis could have taken this into consideration. However based on data collected at UHCW 
these cases represent a small proportion of breast cancer patients and so is likely to have 
little impact on the calculated population EVPI. Breast cancer is the second most common 
cancer in the UK, investment in research that could bring benefits to this large group of 
patients should be supported. 
EVPI supports further research, decisions around where research funding should be focused 
were also determined. The EVPPI of four sets of model parameters were valued across the 
SA3 scenario based on a single study and the base case scenario. Interestingly the highest 
values for EVPPI under the SA3 scenario are around the test performance of DP IA compared 
to CM. These are largely diminished under the base case scenario, most likely because the 
test performance is based on synthesised studies. Whilst the number of eligible studies in 
the systematic review has been repeatedly highlighted as a limitation of the review, the 
EVPPI is low suggesting no further research is needed. Under the base case scenario the high 
EVPPI values are associated with QALY estimates for the TP and FN cases, these are taken 
from Clarke et al. (2017). They used a network meta-analysis to estimate the total QALYs per 
patient for each of the three arms of their cost-effectiveness analysis, no Herceptin 
treatment, 9 weeks treatment and 12months treatment. However they do highlight large 
uncertainties around the QALY values as a limitation of their study, explaining the EVPPI 
results. Further research on determining QALY values associated with Herceptin treatment 
are needed. In addition it was particularly challenging to find estimates in the literature of 
the QALY values for the TN and FP cases in the model.  
The evaluation did not consider the costs associated with the use of image analysis 
algorithms. To an extent the absence of a digital pathology cost deliberation is justifiable as 
the use of image analysis assumes digital systems are already in place with previous 
rationalisation and defence. In reality this is not the case; the cost of the introduction of 
image analysis algorithms for any biomarker or the cost effectiveness of digital pathology as 
a standalone system have not been studied elsewhere. 
This research shows promise and can be used to define the feasibility of transforming 
pathology labs through digitisation. Further research incorporating the test into a diagnostic 
202 
 
RCT and following patients through from diagnosis through to Herceptin treatment, 
capturing all costs and clinical outcomes is needed to make an informed judgement on 
digitisation from the perspective of the HER2 IHC test. Understandably this requires time and 
resources and so more interim robust head-to-head cohort studies are recommended from 
which accuracy estimates can be meta-analysed and results used to inform models. These 
are straightforward to carry out and less resource intense. The results from such a study can 
be compared to those from a diagnostic RCT when available, strengthening the position in 
favour or against digitisation.  
While the picture is not clear for this biomarker it is important to keep in mind that 
digitisation will not only be used for image analysis HER2 scoring but in most cases alone 
producing enhancements in system work flow practices and total throughput in pathology 
labs. In addition, it will be used alongside scoring algorithms for a vast array of biomarkers, 
across many diseases including cancers; here there may be potential for a more superior 
refinement of accuracy. Essentially digital pathology cannot be viewed solely from the HER2 
angle but as a system likely to have effects on a wide range of areas in healthcare. The cost-
effectiveness of this technology can be proved through many other avenues whether by 
focusing on digitisation alone or with the parallel use of image analysis algorithms; the 
research in this area is lacking. 
7.6 Conclusion 
In conclusion, it is not clear if HER2 IHC scoring using DP IA represents a cost-effective 
alternative to CM.  At the current UK guidelines for treatment and scoring thresholds, DP 
could possibly be cost-effective however the ethical implications of the QALY loss must be 
considered when a decision on investment is made. If the length of Herceptin treatment is 
reduced as the research currently indicates, DP cannot be considered a cost-effective 
intervention from the perspective of this particular biomarker.   
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Chapter 8: General discussion and conclusion 
8.1 Overview of thesis and main findings 
The work presented through this thesis attempted to begin to address the research gaps 
identified by the systematic review in chapter 2.  
The systematic review highlighted the paucity of published research around the economic 
evaluations of innovation within pathology practice. Whilst this was perhaps not the case for 
new cancer tests it was particularly clear that no economic analysis had been carried out to 
justify changes in systems and processes within pathology or to justify the introduction of 
new technologies designed to maximise efficiency, productivity  and enhance the accuracy 
of pathologists’ reporting. Even so the few studies that were eligible for inclusion were 
mainly related to testing, they were not specifically evaluations of new tests but the majority 
focused on the adaptation of existing testing strategies to improve accuracy. There were no 
economic evaluations of generic process pathology lab interventions that have a diffuse 
effect within and beyond the pathology lab. Based on the review findings in chapter 2, the 
thesis focused on identifying, measuring and valuing the costs and benefits of digital 
pathology when used within the breast cancer pathway.  
No published work has previously attempted to measure both the costs and benefits of 
digital pathology to the cancer patient.  
8.1.1 The breast cancer pathway 
To evaluate the impacts of pathology digitisation for breast cancer patients, an appreciation 
of the pathology activities, their position within the breast cancer pathway and how they 
interact with events taking place across other medical specialities that feed into patient 
outcomes had to first be gained. This was achieved by reviewing the published breast cancer 
guidelines and interviewing the full spectrum of clinicians involved in breast cancer 
management and treatment at UHCW. The resultant breast cancer pathway output is 
described in chapter 4. As there were no discrepancies between the recommended 
guidelines and clinical practice at UHCW, with information from the latter supplementing 
what is learnt from the former, the pathway represented what could be interpreted as good 
practice clinical care within a large teaching hospital. This pathway was used as a foundation 
for the construction of the DES model in chapter 5, and a section within it was the basis for 
the second decision model developed in chapter 7.  
In reality, the breast cancer pathway illustrated can be used as an information source on 
which to base future research. Researchers both within and outside of pathology, evaluating 
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interventions that have diffuse consequences across the breast cancer pathway can use the 
illustrated diagrams to gain an overview of the chain of events between the intervention 
they are evaluating and patient outcomes. This helps researchers understand the sections of 
the overall pathway that are relevant and should be considered in the evaluation to gain a 
holistic view of the gains or losses for breast cancer patients. This is particularly useful when 
evaluating system changes or complex interventions that have more than one impact on the 
pathway and thus several ways by which they can influence patient benefits. In reality the 
processes described in chapter 4 can be duplicated to depict pathways of good practice 
clinical care for all cancers or even across all disease areas to provide a readily available 
resource that can be used as a base in future economic evaluations.   
Chapter 3 summarises the published literature on the digital pathology impacts for the breast 
cancer patient. These varied and included both time savings and accuracy gains.  Nonetheless 
these were in many cases hypothetical discussions based on very limited evidence and a 
research gap was certainly identified. Other than studies that measured the concordance in 
reporting for some of the characteristics of breast cancer there were no good quality 
synthesis or head-to-head studies that explored the time implications of digitisation when 
compared to standard pathology practice.  
Through knowledge of both the impacts of digitisation for breast cancer patients learnt in 
chapter 3 and information understood about the pathway in chapter 4, it was possible to 
construct the process chain network of events for pathology digitisation that feeds into 
patient outcomes. Familiarity of this network of events was vital to constructing the DES 
model to ensure that pathology always remained at the centre of all modelling construction 
decisions.  
Beyond chapter 4 and the breast cancer pathway illustrated, the remaining chapters in the 
thesis were split between two economic evaluations of digital pathology. Firstly, chapter 5 
focused on the evaluation of digital pathology from a broad perspective as a generic process 
by taking a complete view of the breast cancer pathway. Chapters 6 to 7 evaluate the cost-
effectiveness of digital pathology from a narrower perspective as a targeted process, 
focusing on a single test used within the breast cancer pathway 
8.1.2 Economic evaluation using DES modelling 
Digital pathology is a technological intervention within the pathology workflow, introduced 
to enhance efficiency and productivity as well as contribute to improved accuracy by 
supporting pathologists to report disease characteristics. The published literature describe 
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many points of its influence within the breast cancer pathway as summarised in chapter 3. 
DES modelling allowed the simultaneous evaluation of the processes in the breast cancer 
pathway influenced by digitisation to gain a holistic view of the impacts of digital pathology 
for breast cancer patients rather than the impact on one chain of processes. The model was 
first developed conceptually based on the full breast pathway illustrated in chapter 4. The 
conceptual model is a summary of the more detailed pathway and is designed to reflect the 
processes that are influenced by digitisation and the chain of events that contribute to 
patient outcomes. 
Construction of the DES model is in itself an output of the thesis. The DES model has been 
designed to model pathology and all its interactions within the breast cancer pathway. It can 
be used as a tool for future evaluations of any pathological intervention introduced within 
the breast cancer pathway. One of the main limitations of the economic evaluation in 
chapter 5 is the lack of primary research investigating the impacts of digitisation so that the 
economic evaluation is based on a series of hypothetical scenarios rather than good quality 
research evidence. As research is published and becomes available the model can be 
updated to reflect the most recent findings in order to validate or refute the preliminary 
findings presented in chapter 5. Furthermore, in the same way as for digitisation, evaluations 
of other generic pathology processes that may influence the breast cancer pathway can be 
carried out using the DES model. The DES model is too complex and unnecessary for the 
evaluation of targeted pathology processes e.g. modifications in testing as stand-alone 
interventions, the cost-effectiveness of these can be explored independently using simpler 
modelling approaches as was done for the HER2 test in chapters 6 and 7. However the costs 
and effectiveness data related to targeted processes can be explored within the network of 
processes of an upper level generic pathology process.  
The motivation for the economic evaluation carried out in chapter 5 was largely exploratory 
for this reason a cost-consequence analysis was chosen. The evaluation starts to build a 
picture of the combined impacts of pathology digitisation on the breast cancer pathway. 
Several scenarios for digital pathology were explored, they reflected a series of hypothetical 
impacts of pathology digitisation.  They were all equal on changes observed in the test results 
reported for HER2 and grade but differed on the time savings they predicted. The first 
explored an overall 10% time saving across all pathology activities, the second explored 
consequences if 50% of CBs are reported on in 1 day and the third scenario, if 100% are 
reported on in 6 hours.  
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Evidence of time savings in the pathway were observed for all breast cancer patients under 
each of the DP scenarios when compared to CM. Time savings undoubtedly contribute to 
achieving government cancer waiting time targets however it was difficult to map the time 
savings in the pathway to the specific government targets. Cancer waiting time targets start 
from referral in primary care, this phase of the patients’ care pathway is not incorporated 
into the DES model as it is not relevant to evaluations of pathology.  Nonetheless there is 
evidence of an overall time saving in the breast pathway due to the combined impact of the 
various effects of pathology digitisation. However this needs to be explored further by using 
model parameters and estimations of time savings that are based on good quality research 
rather than clinician estimations as is currently the case. 
MDT outputs of the DES model in chapter 5 showed evidence of a decrease in the number 
of MDT discussions per breast cancer case across all of the DP scenarios when compared to 
CM. This may not in particular be caused by enhanced efficiency within the MDT meeting 
itself but a consequence of enhanced efficiency within the pathology lab, demonstrating how 
pathology modernisation can have positive benefits beyond the lab. Test results are available 
sooner and breast cases can be discussed in a single MDT meeting rather than going back on 
forth between MDT and the pathology lab due to test results not being available. Even 
though it was beyond the scope of the model to be measured, fewer MDT discussions per 
case, frees up clinician time for the discussion of more complex cases in the meeting or even 
could possibly shorten the overall length of the meeting itself, freeing up clinicians time for 
other activities. Modernisation in pathology can have far reaching impacts beyond those 
outlined in the process chain networks in figure 4-15.  
The model also extrapolated the impacts of pathology digitisation on test results accuracy to 
the treatment packages prescribed. The model was able to measure the joint impact of 
changes in accuracy for both HER2 scoring and the grade determined since these are both 
considered when recommending chemotherapy. There was an evident decrease in the 
number of patients prescribed combined chemotherapy and Herceptin and an increase in 
the number of patients prescribed chemotherapy alone. These are preliminary findings and 
further exploration of the time outputs are needed as primary research becomes available 
that compares CM and DP accuracy. 
Across all three DP scenarios there was evidence of cost savings with pathology digitisation 
when compared to the use of conventional microscopes.  Modifications in treatment 
packages, reductions in the number of MDT discussions per case and a decrease in the 
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number of HER2 FISH tests requested, all contribute to the cost savings observed. 
Modernising pathology labs through digitisation is evidence of a cost-saving intervention.  
A limitation of the DES model is that it didn’t go as far as mapping changes in clinical 
processes such as the treatment prescribed to patient outcomes or value time savings to the 
patient. However it presented an example of how DES modelling can be used in the 
evaluation of a systems intervention such as pathology digitisation. The model is available 
and can be used as tool in future evaluations of pathology interventions within the breast 
cancer pathway.  
8.1.3 HER2 IHC accuracy with digital pathology 
The dearth of primary research that compares CM to DP was highlighted in chapter 5, this 
motivated the comparison of HER2 IHC accuracy that was carried out in chapter 6. Accuracy 
estimates of sensitivity and specificity for each of CM and DP when scoring HER2 IHC were 
measured using a bivariate meta-analysis and compared against each other in ROC space.  
A strength of the systematic review that was carried out is the inclusion of head-head studies 
only that compare the two tests directly in the same sample reducing the risk of bias due to 
confounding. However this limited the number of studies that were eligible for inclusion in 
the review especially when studies were grouped according to the underlying thresholds 
used for scoring in each study.  
Using bivariate meta-analyses techniques rather than univariate meta-analysis was a 
strength of this review. Bivariate meta-analyses preserve the underlying relationship 
between sensitivity and specificity when pooling results and provide better estimations of 
these accuracy estimates than the use of univariate meta-analyses. A challenge within this 
study was the presence of the equivocal score within the HER2 category, this group was 
simply excluded from 2x2 tables when estimating sensitivity and specificity and pooled 
separately. This is a limitation of the analysis, since the relationship between the probability 
of an equivocal score and sensitivity or specificity was not considered.  
The evidence generated by the meta-analyses did not necessarily support the superiority of 
digitisation over conventional microscope approaches. Using the 2013 threshold data it is 
possible to conclude that digitisation can potentially signify a more precise approach to 
scoring HER2 IHC than conventional microscopes, first through the reduction of equivocal 
scores and secondly by reducing the confidence region around the mean. However it cannot 
be established that there are improvements in accuracy of IHC scoring with digitisation when 
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compared to conventional microscopes. For the 2008 threshold data there was no difference 
in sensitivity and specificity between CM and DP.  
The value of IA for scoring HER2 IHC can be disputed based on the meta-analysis results. The 
evidence does not support the hypothesis that DP IA results in superior accuracy when 
scoring HER2 IHC. All the studies that were include in the systematic review specifically had 
to include IA as part of their estimation of HER2 scores in the DP arm. Further analysis could 
include studies that used DP alone without IA to support scoring. In this situation DP is 
identical to CM except the pathologist is viewing computer slides rather than glass slides.  
The intention is not to dismiss IA, but its value for this particular biomarker is questionable. 
However IA algorithms can be generated for all sorts of biomarkers beyond breast cancer. 
The value of IA could be greater when being used to support the pathologist in scoring a 
disease characteristic such as grade where there is known be wide inter- and intra- observer 
variability. Meta-analysis can only be carried out when the primary research becomes 
available, it was evident, for breast cancer at least that this information is lacking.  
Sensitivity and specificity outputs of the bivariate meta-analysis model that were based on 
the 2008 and 2013 thresholds were compared. The 2008 threshold data showed sensitivity 
to be lower than that at the 2013 threshold but specificity to be higher under the 2008 
threshold demonstrating the ability of the 2013 thresholds at better identifying positive 
HER2 cases. This supports the continual research around cut-off thresholds to improve 
accuracy. Since this study the ASCO/CAP guidelines have once more been updated however 
it would not have been possible to estimate test performance based on these since 
undoubtedly the published research is still very early in development. 
8.1.4 Economic evaluation of digital pathology for HER2 scoring  
Measuring changes in accuracy are of little value if not measured directly to the patient. In 
this economic evaluation the targeted pathology process i.e. HER2 IHC test was mapped onto 
the clinical process i.e. Herceptin treatment to measure the outcomes of digitisation to the 
patient. Test performance was used to inform a decision tree model comparing the costs and 
benefits of digital pathology image analysis to the use of conventional microscopes when 
scoring HER2 IHC. DP IA for scoring HER2 IHC compared to CM is not a cost-effective 
alternative, this is largely due to the QALY losses experienced with DP. These results support 
those generated in the previous chapter, DP IA greatest influence is not likely to be on the 
HER2 biomarker. 
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The study confirms that the benefit of digitisation will come from efficiency and productivity 
improvements and not necessarily from accuracy. However these results need only be 
interpreted from the breast cancer perspective. In reality different results may be observed 
when considering other cancers or disease areas that digitisation pf pathology is expected to 
influence.   
8.2 Strengths and limitations of research 
There are several strengths to the research undertaken. Firstly, the use of DES modelling for 
the evaluation of complex health interventions was demonstrated and the model can be 
used for future research. The use of bivariate rather than univariate meta-analysis for 
estimations of sensitivity and specificity, however a limitation was the omission of equivocal 
scoring group from these analyses. A third strength is the level of detail that was gathered 
around the cancer pathway through guidelines and clinician interviews so that the models 
developed accurately represent the breast cancer pathway. 
The main limitation of the research and this is particularly the case for the DES model is the 
hypothetical nature of the scenarios that were drawn up. Whilst the evaluations suggest DP 
is cost and time savings, these are hypothetical conclusions only and are not robust enough 
on which to base investment decisions.  
8.3 Recommendations for policy 
Digitisation has been at the centre of plans to transform the NHS since 2013, digital 
pathology is part of this wider plan of modernisation. Pathology departments have 
repeatedly cited access to funding and high upfront costs as a barrier to the introduction of 
digitisation (Williams et al., 2018b). When evaluating the impact of DP for HER2 accuracy 
there was evidence of cost savings (albeit QALY losses) and costs savings were also identified 
from the evaluation of DP as a whole. These are just cost savings from the breast cancer 
perspective, if similar evidence is presented for other cancers, the cost saving implications 
of DP could be immense. Based on the UHCW business case the cost of digital pathology per 
slide is less than £0.50, if all disease areas that are impacted by digitisation in pathology are 
considered, there will certainly be evidence that the cost savings as a result of digitisation 
will outweigh the cost of investment.  
There is certainly a case for the introduction of digital pathology systems based on this 
impact alone, since in reality DP without IA is expected to at least be equivalent to CM, as 
they are both simply different mediums for viewing the same slide. It is IA that will really 
make the difference to accuracy and impact patient outcomes.  
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8.4 Recommendations for research 
Primary research data around the effectiveness of digital pathology for each of the processes 
within the breast cancer pathway it is expected to influence was very limited. This research 
is preliminary to any undertaking that evaluates digital pathology as a whole system 
intervention to gain a full picture of its implications.  While accuracy is important efficiency 
is overlooked in many cases in the published literature. Further research should focus on 
exploring time implications and how these translate into patient benefits since the study 
undertaken suggests that the greatest value of digitisation will be through time savings. The 
value of reducing time to diagnosis for cancer patients has not previously been measured 
and this could be considered in future research. Time savings contribute to early cancer 
diagnosis and are expected to improve survival outcomes, however these were not 
measured in the study and further research is needed to confirm that the few days saved in 
the pathway will in fact have this consequence which is the motivation behind government 
cancer waiting time targets. 
DES modelling has been used for the evaluation of pathology services within a cancer 
pathway. DES modelling can be considered for the evaluation of activities within the 
pathology lab to gain a granular understanding of the impacts of DP on workflow and the 
challenge of understaffing.  
Whilst the focus of this thesis has been on the effects of digitisation to patients, there are 
benefits beyond those to pathology staff. Since workforce constraints have been highlighted 
as a major challenge for the future of pathology, future research could focus on the 
implications of digitisation in compensating for staff shortages and overcoming the burden 
of increased demand for services.  
8.5 Conclusions 
The thesis presented an example of an economic evaluation of a generic process whose 
impacts crosses multiple disease pathways. Innovation in pathology is expected to have 
positive benefits for cancer patients. The preliminary research undertaken has shown 
evidence of time savings for breast cancer patients and cost savings to the NHS as a direct 
result of pathology digitisation.  
However when evaluating the impact of digitisation specifically on the accuracy of the HER2 
biomarker, the cost-effectiveness analysis did not support digital pathology adoption.  
Further primary research is needed to measure and value the impact of pathology 
digitisation on time in the pathway and the accuracy of other cancer biomarkers.   
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Appendices 
Appendix A: Search strategies-systematic review of economic 
evaluations 
Medline 
1. exp Economics/  
2. Economic*.mp.  
3. Decision Tree.mp.  
4. Markov*.mp.  
5. Model*.mp.  
6. Simulat*.mp.  
7. 5 and 6  
8. Cost.mp.  
9. *"costs and cost analysis"/ or *"cost allocation"/ or *cost-benefit analysis/ or *"cost 
control"/ or *"cost savings"/ or *"cost of illness"/ or *health care costs/ or *direct service 
costs/ or *drug costs/ or *employer health costs/ or *hospital costs/ or *health 
expenditures/  
10. *Decision Trees/  
11. *models, statistical/ or *models, economic/ or *models, econometric/  
12. 1 or 2 or 3 or 4 or 7 or 8 or 9 or 10 or 11  
13. Tumor.mp.  
14. Tumour.mp. 
15. *Neoplasms/  
16. Malignan*.mp.  
17. *Carcinoma/  
18. Cancer*.mp.  
19. *"Early Detection of Cancer"/  
20. 13 or 14 or 15 or 16 or 17 or 18 or 19  
21. *pathology/ or *pathology, clinical/ or *pathology, molecular/ or *pathology, surgical/ 
or *telepathology/  
22. Pathologist.mp.  
23. Histopathology.mp.  
24. Digital Pathology.mp.  
25. Telepathology.mp.  
26. 21 or 22 or 23 or 24 or 25  
27. 12 and 20 and 26  
28. limit 27 to english language ;l 
29. limit 28 to yr="2000 -Current" 
 
Embase 
1. exp economics/  
2. exp health economics/  
3. Economic*.mp.  
4. exp economic evaluation/  
5. exp "cost utility analysis"/ or exp "cost benefit analysis"/ or exp "cost minimization 
analysis"/ or exp "cost effectiveness analysis"/  
6. exp "health care cost"/  
7. Cost*.mp.  
8. *model/  
9. exp statistical model/  
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10. *"decision tree"/  
11. Decision Tree.mp.  
12. Markov.mp.  
13. *neoplasm/ or *metastasis/ or *"precancer and cancer-in-situ"/  
14. Malignan*.mp.  
15. Tumour.mp. 
16. *carcinoma/  
17. "Cancer*".m_titl.  
18. "Tumor*".m_titl.  
19. *pathology/  
20. *pathologist/  
21. *histopathology/  
22. *telepathology/  
23. Digital Pathology.mp.  
24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12  
25. 13 or 14 or 15 or 16 or 17 or 18  
26. 19 or 20 or 21 or 22 or 23  
27. 24 and 25 and 26  
28. limit 27 to english language  
29. limit 28 to yr="2000 -Current" 
 
Econlit 
This strategy did not include search terms related to economic evaluations as this is a subject 
specific database.  
               Query 
S11 S6 AND S9 
S10 S6 AND S9 
S9 S7 OR S8 
S8 pathologist 
S7 pathology 
S6 S1 OR S2 OR S3 OR S4 OR S5 
S5 oncology 
S4 Malignan* 
S3 tumours or cancer or neoplasms 
S2 Carcinoma* 
S1 Cancer* 
 
Web of Science   
# 7 #5 AND #4 AND #3 
Refined by: LANGUAGES: ( ENGLISH ) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 6 #5 AND #4 AND #3 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 5 TS=(Tumour* OR Tumor* OR Cancer* OR Malignan* OR Carcinoma OR Neoplasm) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 4 TS=*Patholog* 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 3 #2 OR #1 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
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# 2 TI=Cost* 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 1 TI=Economic* 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
 
CRD Database 
NHSEED 
1 MeSH DESCRIPTOR Early Detection of Cancer EXPLODE ALL TREES 
2 (Cancer*) IN NHSEED 
3 (Tumor*) IN NHSEED 
4 (Tumour*) IN NHSEED 
5 (Neoplasm*) IN NHSEED 
6 (Carcinoma*) IN NHSEED 
7 (Malignan*) IN NHSEED 
8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 
9 (Patholog*) IN NHSEED 
10 (Histopatholog*) IN NHSEED 
11 MeSH DESCRIPTOR Pathology EXPLODE ALL TREES 
12 #9 OR #10 OR #11 
13 #8 AND #12 
 
HTA 
Line Search 
1 MeSH DESCRIPTOR Health Care Economics and Organizations EXPLODE ALL TREES 
2 MeSH DESCRIPTOR Models, Economic EXPLODE ALL TREES 
3 MeSH DESCRIPTOR Value of Life EXPLODE ALL TREES 
4 (Cost Utility) IN HTA 
5 (Cost Benefit) IN HTA 
6 (Cost Effectiveness) IN HTA 
7 MeSH DESCRIPTOR Decision Trees EXPLODE ALL TREES 
8 (Decision Tree) IN HTA 
9 (Markov*) IN HTA 
10 (Economic Evaluation) IN HTA 
11 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 
12 MeSH DESCRIPTOR Early Detection of Cancer EXPLODE ALL TREES 
13 (Cancer*) IN HTA 
14 (Tumor*) IN HTA 
15 (Tumour*) IN HTA 
16 (Neoplasm*) IN HTA 
17 (Carcinoma*) IN HTA 
18 (Malignan*) IN HTA 
19 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 
20 MeSH DESCRIPTOR Pathology EXPLODE ALL TREES 
21 (Patholog*) IN HTA 
22 (Histopatholog*) IN HTA 
23 #20 OR #21 OR #22 
24 #11 AND #19 AND #23 
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DARE 
Line  Search 
1 MeSH DESCRIPTOR Health Care Economics and Organizations EXPLODE ALL TREES 
2 MeSH DESCRIPTOR Value of Life EXPLODE ALL TREES 
3 MeSH DESCRIPTOR Models, Economic EXPLODE ALL TREES 
4 (Cost Utility) IN DARE 
5 (Cost Benefit) IN DARE 
6 (Cost Effectiveness) IN DARE 
7 MeSH DESCRIPTOR Decision Trees EXPLODE ALL TREES 
8 (Decision Tree) IN DARE 
9 (Markov*) IN DARE 
10 (Economic Evaluation) IN DARE 
11 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 
12 MeSH DESCRIPTOR Early Detection of Cancer EXPLODE ALL TREES 
13 (Cancer*) IN DARE 
14 (Tumor*) IN DARE 
15 (Tumour*) IN DARE 
16 (Neoplasm*) IN DARE 
17 (Carcinoma*) IN DARE 
18 (Malignan*) IN DARE 
19 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 
20 MeSH DESCRIPTOR Pathology EXPLODE ALL TREES 
21 (Patholog*) IN DARE 
22 (Histopatholog*) IN DARE 
23 #20 OR #21 OR #22 
24 #11 AND #19 AND #23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
235 
 
Appendix B: Data extraction form - systematic review of economic 
evaluations 
Name:                                                                                            For completion by the reviewer 
Notes  
Bibliographic 
details 
Author  
Year  
Journal  
Publication Type  
Additional Comments 
 
General 
details  
Country  
Study site(s)  
Additional comments 
 
Target 
population 
Cancer type  
Sample size  
Additional comments 
 
Pathology Intervention details  
Comparator details  
Additional comments 
 
Economic 
evaluation 
 
Perspective(s)?  
Approach  
Design  
Time horizon  
Additional comments 
 
Outcome(s) measured Methods 
 
Sources 
Total intervention outcome  
Total comparator outcome  
Additional Comments 
 
Unit cost(s) Methods 
 
Sources 
 
Resource Use Methods 
 
Sources 
Currency  
Financial year  
Discounting   
Total intervention costs  
Total comparator costs  
Additional Comments 
 
Uncertainty analysis  
Decision rule  
Cost-effectiveness results  
Additional comments  
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Appendix C: Simul8 building blocks 
 
Building Block Description Image 
Activity An entity has something done to it here 
 
Batching 
Method in which we can split one entity so that 
it moves through 2 or more activities 
simultaneously e.g. a case has both ER and 
HER2 testing simultaneously 
 
End Where the entity leaves the model 
 
Entity 
The work item in the system, here these are 
suspected breast cancer cases 
 
Labels 
These are used to attach attributes such as test 
results to an entity which are used to control 
how it moves through the model 
NA 
Queues An entity waits here to be processed   
Routing 
These rules tell simul8 where the entity should 
go 
NA 
Start Where an entity enters the model 
 
Visual logic 
Is the Simul8 language allowing detailed codes 
to be built into the model to control how it 
behaves 
NA 
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Appendix D: List of search terms 
Key words listed in the five published papers 
-Breast Cancer   -Breast Neoplasms 
-HER-2    -Fluorescence in Situ Hybridization 
-Herceptest   -HER2 
-Reproducibility   -Targeted Therapy 
-Subjective Analysis  -Image Analysis 
-Digital Image Analysis  -IHC 
-FISH    -Virtual Slides 
-ACIS    -Automated IHC Method 
-Immunohistochemistry  -HER2 FISH test 
-Automation   -Primary Invasive Breast Cancer 
-Trastuzumab   -Survival 
-Herceptin   -Visual IHC Method 
 
Key words identified through screening the titles and abstracts of the five published 
papers 
-Immunohistochemical Staining  -Comparison   -Misinterpreted 
-Concordance/Concordant  -Visual    -Standardise 
-HER-2 targeted therapy  -Assessment   -Interpretation 
-Manual    -Impact    -Diagnostic tool 
-Inter observer reproducibility  -Outcome   -Determination 
-Accurate    -Computerized Image Analysis -Variability 
-Automated    -Agreement    -Uncertainty 
-Imaging system   -Visual Scoring   -Reliability 
-Correlation/Correlated   -Algorithm   -Consistent 
-Performance    -Evaluation   -Classify 
-Positive predictive value  -Results   -Computer Aided 
-Quality    -Biomarker   -Quantitative  
-Subjective    -Conventional Testing  -Reference  
-Expression    -HER2 protein expression   
-Scoring/scored/score   -Semi-quantitative 
-Inter observer    -Digital Images 
-Discrepancies    -Evaluation 
-Comparable/Compare    -Correlation 
-Performance    -Kappa 
-Consensus    -Visual Evaluation 
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Appendix E: Search terms used in initial phase search strategy 
 Keyword Related Terms Truncations 
Population 
 
Breast 
Breast Cancer 
Breast Neoplasms 
Primary Invasive Breast Cancer 
 
HER2 
HER-2                                         
Biomarker  
HER2 protein expression 
 
IHC 
Herceptest 
Immunohistochemistry 
Immunohistochemical staining 
 
Intervention IHC DP IA 
Digital                                    Image Analysis 
Imaging system                   Computerised  
Digital Images                      Virtual Slides  
Algorithm                             Computer                                    
Automation/Automated   Aided 
Automated IHC method    Quantitative 
Imag* 
Automat* 
Computer* 
Comparator IHC  CM 
Subjective Analysis 
Visual IHC method 
Visual  
Manual 
Subjective 
Conventional Testing  
Semi-quantitative 
 
Reference 
Standard 
FISH 
Fluorescence in situ hybridisation 
Reference 
 
Outcome 
 
Accuracy 
Kappa                                    Consistent 
Accurate                               Reliable 
Uncertainty                          Performance                            
Variability 
Agreement             
Sensitivity  
Specificity 
Discrepancies                                
Comparable/Compare/Comparison 
Reproducibility                             
Misinterpreted 
Correlation/Correlated             
Positive predictive value            
Scoring/scored/score  
Inter observer                              
Concordan* 
Correlat* 
Scor*
Compar* 
Accura* 
Herceptin 
Trastuzumab 
Targeted Therapy 
HER-2 targeted therapy 
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Appendix F: Search strategies - systematic review of HER2 accuracy 
Medline 
1 exp Breast Neoplasms/ 
2 Breast Neoplasm.mp. 
3 Breast Cancer.mp. 
4 1 or 2 or 3 
5 exp Receptor, ErbB-2/ 
6 exp Receptor, Epidermal Growth Factor/ 
7 HER2.mp. 
8 HER-2.mp. 
9 5 or 6 or 7 or 8 
10 exp Immunohistochemistry/ 
11 IHC.mp. 
12 Immunohistochemi*.mp. 
13 10 or 11 or 12 
14 exp Image Processing, Computer-Assisted/ 
15 exp Image Interpretation, Computer-Assisted/ 
16 exp Algorithms/ 
17 Digital.mp. 
18 exp Automation/ 
19 Automat*.mp. 
20 Virtual.mp. 
21 Algorithm.mp. 
22 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
23 exp In Situ Hybridization, Fluorescence/ 
24 Fluorescence in situ hybridisation.mp. 
25 FISH.mp. 
26 23 or 24 or 25 
27 4 and 9 and 13 and 22 and 26 
 
Embase 
1 exp breast tumor/ 
2 Breast Cancer.mp. 
3 Breast Neoplasm.mp. 
4 1 or 2 or 3 
5 HER2.mp. 
6 *epidermal growth factor receptor 2/ 
7 HER-2.mp. 
8 5 or 6 or 7 
9 exp immunohistochemistry/ 
10 IHC.mp. 
11 immunohistochemistry.mp. 
12 9 or 10 or 11 
13 *computer assisted diagnosis/ 
14 *computer analysis/ 
15 exp laboratory automation/ 
16 exp digital imaging/ 
17 exp digital microscope/ 
18 exp digital slide scanner/ 
19 image processing/ 
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20 exp image analysis/ 
21 exp imaging system/ 
22 imaging system.mp. 
23 exp microscope image/ 
24 exp quantitative diagnosis/ 
25 exp quantitative histochemistry/ 
26 virtual slides.mp. 
27 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 
28 FISH.mp. 
29 exp fluorescence in situ hybridization/ 
30 Fluorescence in situ hybridisation.mp. 
31 28 or 29 or 30 
32 4 and 8 and 12 and 27 and 31 
 
Web of Science 
# 20 #19 AND #16 AND #13 AND #7 AND #4 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 19 #18 AND #17 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 18 TOPIC: (Cancer) OR TOPIC: (Neoplasm) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 17 TOPIC: (Breast*) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 16 #15 OR #14 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 15 TOPIC: (FISH) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 14 TOPIC: (Fluorescence in situ hybridisation) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 13 #12 OR #11 OR #10 OR #9 OR #8 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 12 TS=(automation) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 11 TS=(quantitative diagnosis) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 10 TS=(virtual slide) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 9 TS=(Image analysis) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 8 TS=(Digital Pathology) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 7 #6 OR #5 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 6 TOPIC: (IHC) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 5 TS=(immunohistochemistry) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 4 #3 OR #2 OR #1 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 3 TOPIC: (Epidermal growth factor receptor 2) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
241 
 
# 2 TOPIC: (HER-2) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
# 1 TOPIC: (HER2) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
 
PubMed 
#10 ((((((FISH) OR Fluorescence in situ hybridisation)) AND ((((Digital Pathology) OR 
Image Analysis) OR automat*) OR Virtual Slides)) AND ((Immunohistochemi*) OR IHC)) AND 
(((HER2) OR HER-2) OR Human Epidermal Growth Factor Receptor 2)) AND ((Breast) AND 
((Neoplasm) OR Cancer)) 
#9 (FISH) OR Fluorescence in situ hybridisation 
#8 (((Digital Pathology) OR Image Analysis) OR automat*) OR Virtual Slides 
#7 (Immunohistochemi*) OR IHC 
#6 ((HER2) OR HER-2) OR Human Epidermal Growth Factor Receptor 2 
#5 (Breast) AND ((Neoplasm) OR Cancer) 
#4 (Neoplasm) OR Cancer 
#3 Breast 
#2 Neoplasm 
#1 Cancer 
 
Cochrane Library  
#1 Breast Cancer   
#2 MeSH descriptor: [Breast Neoplasms] this term only 
#3 #1 or #2   
#4 Her-2   
#5 HER2   
#6 Human epidermal growth factor receptor 2   
#7 MeSH descriptor: [Genes, erbB-2] this term only  
#8 #4 or #5 or #6 or #7   
#9 IHC   
#10 immunohistochem*   
#11 #9 or #10   
#12 FISH   
#13 Fluorescence in situ hybridisation  
#14 MeSH descriptor: [In Situ Hybridization, Fluorescence] explode all trees  
#15 #12 or #13 or #14   
#16 Imag*   
#17 Digital   
#18 MeSH descriptor: [Image Interpretation, Computer-Assisted] explode all trees
 8722 
#19 algorithm  
#20 automat*   
#21 MeSH descriptor: [Algorithms] this term only 
#22 MeSH descriptor: [Automation, Laboratory] explode all trees 
#23 quantitative   
#24 MeSH descriptor: [Diagnosis, Computer-Assisted] explode all trees 
#25 #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24  
#26 #3 and #8 and #11 and #15 and #25  
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Appendix G: Data extraction form - systematic review of HER2 accuracy 
 For completion by the reviewer 
Notes  
 
Name of reviewer  
Bibliographic 
Details 
Title  
Author  
Year  
Journal  
Publication Type  
Additional Comments 
 
Sample Size  
IHC CM Assay  
Threshold 0  
1+  
2+  
3+  
Additional Comments  
 
IHC DP Scanner  
Algorithm   
Measurement  
Additional Comments  
 
243 
 
FISH  Assay   
Threshold -ve  
Equi  
+ve   
Additional Comments  
 
2x2 Tables 
Fish 
IHC CM IHC DP 
-ve Equi +ve -ve  Equi +ve 
-ve       
Equi        
+ve        
 
 Additional Comments  
 
Outcomes IHC CM 
Sensitivity  
Specificity  
%2+  
Additional Comments 
 
IHC DP 
Sensitivity  
Specificity  
%2+  
Additional Comments 
 
